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Introduction 

1 Why Pharmacovïgilance? 
The final test of the safety of a drug is in fact 
its release for general use 
L. Witts (1964)™ 
Before reading about the objectives of this thesis, the reader may need some back-
ground information concerning pharmacovigilance. The development of a medical 
treatment proceeds in several phases (see table 1). The process involves a step-wise accu-
mulation of knowledge about the treatment, e.g. its practicability, mechanism (phar-
macology), efficacy, safety, adverse effects,"' and often also about the pathology and 
epidemiology of the disorder treated. Other treatments may become available in due 
course. Treatment should be re-evaluated in the light of new developments, e.g. new 
adverse effects or alternative treatments. 
An important point in these developments is the moment of approval and introduc-
tion, when the experimental treatment is transformed into an established one. 
Table 1 — The development of a medical treatment 
Experimental 
1. Discovery / invention 
2. Realisation 
3. Testing (animal pharmacology and toxicology; clinical pharmacology 
phases I—III) 
Approval and introduction 
Established 
4. Increase in experience 
5. Refinements (e.g. dose, regimen, delivery form, indications) 
6. Re-evaluation of balance of benefit and risk, and comparison with other 
treatments 
*) In this thesis the words 'side effect', adverse effect' and adverse reaction' are used as synonyms; adverse event' 
refers to the event only, irrespective of its cause The precise meanings of these notions have been reviewed by 
Mwards et al ' : 
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Table 2 — Examples of important -1 e serious, frequent or unexpected - drug-induced di-
seases m a 100-year period11 
Yearb 
1880 
1923 
1925 
1933 
1938 
1942 
1946 
1950 
1952 
1953 
1954 
1958 
1961 
1962 
1963 
1964 
1965 
1966 
1967 
1968 
1969 
1970 
1971 
1972 
1973 
Drug 
Chloroform 
Onchophen 
Bismuth compounds 
Ammophenazone 
Sulphanilamide (in 
diethylene glycol) 
Bismuth compounds 
Streptomycin 
Thorium dioxide 
Chloramphenicol 
Phenacetin 
Stalinon 
Isonia/id 
1 halidomidc 
Procainamide 
Ajmaline 
Arsenic containing drugs 
Gold salts 
Chloroqume 
Phenylbutazone and 
related drugs 
Aspirin and other NSAlDs 
Antithyroid agents 
Sulphonamidcs 
Reserpme 
MAO inhibitors 
(tranylcypromine) 
Barbiturates 
Oral contraceptives 
Methyldopa 
Inhalation of 
sympathicomnnttics 
Mercurial diuretics 
(mersalyl) 
Aminorex 
Clioquinol 
Nitrofurantoin 
Phenacetin 
Isonia/id/ 
nfampicin 
Diethylstilbestrol 
Bismuth compounds 
Erythromycin 
(estuiate) 
Amiodaronc 
Neuroleptics 
Co tnnioxa/ole 
Adverse effect 
Cardiac arrest 
Hepatitis 
Embolia cutis medicamentosa 
(Nicolau syndrome) 
Agranulocytosis 
batal poisoning 
Hepatitis, 
Renal failure 
Deafness 
Rcval failure 
Malignant disorders 
Aplastic anaemia 
Nephropathy 
Tatal poisoning 
Hepatitis 
Phocomelia 
Systemic lupus erythematosus 
Cholestatic hepatitis 
Carcinogenesis (e g skin, lung) 
Blood dyscrasias 
Retinopathy 
Aplastic anaemia, 
Agranulocytosis 
Gastrointestinal ulcers and 
bleedings 
Agranulocytosis 
Agranylocvtosis 
Depression 
Hypertensive crises 
(food or drug interactions) 
Addiction 
Thromboembolic disease 
Haemolytic anaemia 
Increased asthma mortality 
Nephrotic syndrome 
Pulmonary hypertension 
Myelo-optic neuropathy 
Polyneuropathy, 
Pneumonitis 
Urinary tract carcinoma 
I lver injury 
Vaginal carcinoma, 
Urogenital malformations 
Encephalopathy 
Cholestatic hepatitis 
Hypo- or hyperthyroidism 
Iardive dyskinesia, 
Stevens Johnson syndrome and other serious 
hypersensitivity reactions 
1974 Practolol 
1975 
1976 
1977 
1978 
1979 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1988 
1989 
1990 
1991 
1994 
1995 
1996 
1997 
Clindamycin/ 
lincomycin 
Perhexilinc 
Clozapine 
Venopyronum 
Glafeninc 
Influenza vaccine 
(swinc) 
Perhexihne 
Triazolam 
I lelenic aud 
Ticlopidine 
Penicillamine 
Fenfluramine 
Kttocona/olc 
Benoxaprofen 
Phen\ Ipropanolamine 
Zimeldine 
Osmosin 
(Indometacin) 
/omepiuc 
Valproate sodium 
Cianidanol 
Mianserin 
Isoxicam 
Nomifensine 
Pyrimethamine/ 
sulfadoxine 
Almetrine 
Suprofen 
Ofloxacin 
Ceftriaxone 
Inhalation of 
42 agonists 
Pirprofen 
I-lryptophane 
Deferoxamine 
Fluoroquinolones 
(pefloxacin) 
Tiaprofenic acid 
Felbamate 
Mefloquine 
Indinavir 
Sclerosing peritonitis 
(oculomucocutaneous syndrome) 
Pseudomembranous colitis 
Hepatitis 
Agranulocytosis 
SI F syndrome 
Anaphylactic shock 
Polyradiculoneuritis 
(Guillain-Barrd) 
Polyneuropathy, 
Hepatitis 
Psychosis, 
Behavioural abnormalities, 
Anterograde amnesia 
I iver and kidney injury 
\granuloc) tosis 
Induction of autoimmune 
diseases 
Pulmonary hypertension 
Hepatitis 
Photodermatitis 
H)pertension 
Polyradiculoneuritis 
Distal intestinal ulcers 
Anaphylactic shock 
Spina bifida 
Hepatitis, 
Haemolysis 
Agranulocytosis 
Toxic epidermal necrolysis 
lever 
Hepatitis, 
Hacmolvtic anaemia 
Stevens Johnson syndrome 
Polyneuropathy 
Renal pain syndrome 
Psychosis 
Hypersensitivity reactions 
Biliary lithiasis 
Increased asthma mortality 
Hepatitis 
Eosmophilia-mialgia syndrome 
Opportunistic infections 
(Yersinia, mucormycosis) 
Achilles tendinitis & rupture 
Cystitis 
Aplastic anaemia 
Central nervous system side effects 
Haemolytic anaemia 
a Cytotoxic drugs excluded 
b The years are only indicative, с g refer to the date of publication of a major paper on the adverse reaction or 
to the period measures were taken 
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Far reaching changes take place after approval, involving medical, scientific, ethical, 
legal and commercial aspects (see chapter 3 for more information). 
Medicines differ in several respects from other treatments. Medicines are both power­
ful health care instruments and profitable commercial products. Potential conflicts of 
interest following from this dualism are noticeable anywhere in the processes or drug 
regulation. There is special legislation regulating governmental control of their devel­
opment, introduction and evaluation. Ал important feature of medicines is that they 
are, for a period of time, protected by patent. With regard to surgical treatments, for 
example, this would in many countries be considered unethical. 
Obviously, the array of drugs now available has dramatically improved the prognosis 
and quality of life of patients suffering from a great variety of diseases. The action of 
most drugs, however, is not purely selective. In addition to the therapeutic effect they 
exert a variety of additional effects on the body, that are potential causes of adverse 
responses. In spite of the principle 'first of all do no harm' in the medical oath intro­
duced by Hippocrates from Kos about 2400 years ago, drug safety has for most of the 
time been a secondary concern in medicine. The desperate need for effective treatments 
often made the safety issue seem a luxury. Through the ages, the objective demonstra­
tion of therapeutic efficacy and the explanation of the effects of medical drugs has been 
notoriously difficult. It was only after the Second World War that the methodology of 
the clinical trial came to full development. The assessment of adverse effects and the 
quantitative measurement of the safety of drugs faces even greater problems, in scien­
tific, ethical and financial respects, and is still in a developmental phase. 
In our time the names of Leopold Meyler, Owen Wade, David Finney, William Inman 
and several others are attached to the issue of drug safety. The first volume of Mcylcr's 
Side Effects of Drugs appeared in 1952 and was followed with a continuing series of 
subsequent volumes, since 1975 edited by Graham Dukes. In the USA the occurrence 
of drug-induced haematological diseases such as agranulocytosis and aplastic anaemia 
led in 1953 to the development of a Blood Dyscrasia Registry by the Council on Drugs 
of the American Medical Association. In 1960 the USA Food and Drug Administration 
began to collect case reports of adverse drug reactions of any kind. The tragic epidemic 
in the early sixties of malformed babies, induced by the hypnotic thalidomide, in many 
countries acted as a catalyst in the establishment of drug regulation and drug safety 
monitoring. The latter is nowadays often referred to as pharmacovigilance (see para­
graph 3 of the Introduction). 
Although extremely serious, the thalidomide case was only one in a series of more or 
less important drug-related problems, ranging from chloroform-induced cardiac arrest 
in 1880 to haemolytic anaemia and other adverse effects of drugs used in the treatment 
of HIV infections in 1997 (sec table 2). Interestingly, this list has not come to a halt 
after the introduction of drug regulation. This observation does not indicate a failure 
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in drug regulation, however, but is influenced by the situation that in the past 30 years 
an unprecedented number of new drugs have been introduced in medicine. 
New drugs often first seem safer than they really are, and their adverse effects must be 
monitored. Experience has shown that rare but serious adverse effects may have far-
reaching consequences, even when they occur in fewer than one in a thousand patients. 
No drug can be developed without the co-operation of patients. The gold standard for 
studying an experimental drug in patients is the - randomised, controlled - clinical 
trial.'3' Rules for Good Clinical Trial Practice (GCP) have been arrived at in order to 
ensure the ethical and scientific quality of trials.'4' A number of limitations, inherent in 
the design of clinical trials and of other pre-approval studies can explain this situation. 
Clinical trials are primarily intended for the objective demonstration of efficacy. 
Efficacy is expected in the majority of patients and its parameters are well described. 
Adverse effects, on the other hand, often develop in only a minority of patients and 
may be entirely unexpected. From the point of view of demonstrating safety, the num-
ber of patients in a trial is small and trial duration short. Conditions in a trial may differ 
from those encountered in 'real-life' use of the drug. Since there is selection of patients 
(the elderly, children, pregnant women and patients with concomitant illness arc often 
excluded), the trial findings may not reflect results for the population at large and risk 
factors and drug interactions may be overlooked. A clinical trial has only a limited capa-
city for providing information on safety and adverse effects. 
Table 3 — Topics of interest in the study of medicines after approval 
1. Fine-tuning of dosage recommendations 
2. Reappraisal of indications (extension or restriction) 
3. Drug use and drug users studies 
4. Assessment of long-term efficacy (e.g. in the case of surrogate endpoints) 
5. Assessment of side-effects: 
5.1. Detection of unexpected side-effects and interactions 
5.2. Identification of risk factors 
5.3. Quantitative measurement of (un)safety 
5.4. Long term safety/toxicity. 
5.5. Study of potential risk groups (children, the elderly, pregnancy) 
5.6. Detection of unexpected beneficial effects 
6. Further pharmacological and mechanistic studies 
7. Detection of pharmaceutical defects and counterfeit drugs 
8. Dangers of misuse (intentional and accidental intoxication, dependence) 
9. Quality of life and utility assessment 
10. Collection of data needed for cost assessment and comparison 
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In the Netherlands, pharmacovigilance started as early as 1963, with a call by the 
Dutch Medical Association to physicians to report suspected adverse reactions.'^' A year 
later the new centre - 'Bureau Bijwerkingen Geneesmiddelen' - moved to the govern-
ment's Pharmaceutical Inspectorate. The years from 1960 to 1980 saw pharmacovigi-
lance systems introduced in developed countries, usually as part of the drug regulatory 
authority. The World Health Organization (WHO) contributed much to this deve-
lopment. The WHO Research Project for International Drug Monitoring was estab-
lished in 1968, and started a collaboration between existing national centres. This pro-
ject evolved into the present WHO Collaborating Centre for International Drug 
Monitoring in Uppsala, with participation by more than 45 national centres from 
around the world.'6' In two revealing documents - Drug monitoring, the role of the 
hospital'7' and Drug monitoring, the role of national centres,'8' - the WHO dissemin-
ated information concerning the principles and background of pharmacovigilance and 
organisational aspects of'spontaneous reporting'. 
In addition to adverse effects, several more issues remain to be studied after the intro-
duction of medicines (see table 3). 
There are now several methods for the study of marketed medicines. A summary fol-
lows (table 4). 
Table 4 — Examples of methods for studying marketed medicines 
Spontaneous reporting in its various forms 
Intensive hospital monitoring 
Prescription event monitoring 
Case control studies; case control surveillance 
Follow-up studies 
Monitored release programs 
Large data resources on morbidity and drug use, including record linkage 
The study of medicines after approval is quite different from a clinical trial. It is more 
complex and difficult, ethically, scientifically and logistically. The methods it involves 
are still in a developmental phase. The state of the art has been reviewed in several 
handbooks, e.g. as edited by Inman,'9' Stephens'10' and Strom.'11' Although much 
progress has been made, pharmacovigilance is still not perfect. Adverse effects need to 
be detected earlier, uncertainty as to scientific validity may hinder prompt regulatory 
decisions, and important questions can often not be answered. If the introduction is to 
be made safer and the comprehensive information needed for a rational and safe use of 
medicines is to be provided, existing methods need to be improved and new strategies 
need to be designed and tested. 
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2 Objective and outline of the thesis 
When spontaneous reporting was introduced, in the aftermath of the thalidomide dis-
aster, it was the only conceivable approach for dealing with an urgent problem. At the 
time it was something new; there was only very limited experience worldwide. It was 
obviously not a perfect or ideal method, and its scientific principles and logistic chal-
lenges were only partly understood. Spontaneous reporting has now, however, become 
routine in governmental drug regulation around the world. 
This thesis aims at increasing our understanding of the scientific basis of pharmacovi-
gilance. The experiences with pharmacovigilance in the Netherlands are reviewed in an 
attempt to see what can be learned from the past and applied for the further develop-
ment and improvement of pharmacovigilance. A thorough understanding of the state 
of the art of pharmacovigilance, of its strong and its weak sides, may allow the deve-
lopment of more effective systems, make available better information for prescribers, 
pharmacists and patients, and promote rational and safer use of drugs. 
In the first part of the Introduction, background information is presented that descri-
bes why pharmacovigilance is needed. Next, the objectives are reviewed and an outline 
of the thesis is provided. The Introduction is completed with a description of the prin-
ciples and procedures of 'spontaneous reporting' currently the basic instrument of 
pharmacovigilance. 
The first section of the thesis is concerned with the primary aim of pharmacovigilance, 
the detection of hitherto unknown adverse effects of drugs. It addresses a basic question 
in pharmacovigilance: can the drug cause the adverse event? Chapter 1.1 comprises the 
evaluation of past experiences with pharmacovigilance in the Netherlands; of the na-
ture of the topics concerned (mainly adverse effects) and of the composition of the 
information produced. Then in chapter 1.2, the principles are reviewed that generally 
play a role in the detection of adverse effects of drugs: how arc adverse effects detected, 
which are the sources of signals, and which arguments play a role in the question as to 
whether or not suspicions regarding an adverse effect are likely to be justified. 
Spontaneous reporting is based on reports of suspected adverse effects of drugs. Time 
and again this inherent uncertainty in many case reports has been a cause of ambigui-
ty or confusion. The second section of the thesis therefore discusses in some detail the 
issue of case causality assessment, often referred to in the literature as 'imputation'. In 
other words, the section addresses another characteristic question in pharmacovigi-
lance: has the drug caused the adverse event in a given patient or case report? In chapter 2.1 
information is presented on the various causality assessment systems used at pharma-
covigilance centres in countries in and outside the European Union. Also the approach 
to harmonisation as proposed by the European Pharmacovigilance Working Party is 
described. The role of case causality assessment in pharmacovigilance in general is then 
reviewed in chapter 2.2. Pharmacovigilance and clinical trials have in common that the 
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data are derived from observations in real patients and the ensuing ethical restrictions 
need to be faced. In the third section of the thesis the needs for Good Practice in phar-
macovigilance (GPP) are discussed and a number of recommendations are made. 
Section 4 reviews the achievements and limitations of pharmacovigilance in the per-
spective of current and future needs and developments. 
3 The spontaneous reporting system of adverse effects of drugs 
Introduction 
Although a variety of other methods have been developed, 'spontaneous reporting' -
the country-wide system for reporting of suspected adverse effects of drugs - is so far 
the major routine source of information in pharmacovigilance, in addition to findings 
published in the literature."2·13·14' Since this thesis is largely based on experiences with 
spontaneous reporting, the present chapter reviews the 'ins and outs' of the method in 
some detail. Wc gratefully acknowledge the use, in the preparation of this review, of a 
draft of the Guidelines for Setting Up and Running of a Pharmacovigilance Centre, 
soon to be published by the World Health Organization.'4' 
Aims and definitions 
The WHO guidelines define pharmacovigilance as 'the detection, assessment and 
prevention of adverse drug effects in humans'.'15' Major aims of pharmacovigilance are: 
1. Early detection of hitherto unknown adverse effects and interactions. 
2. Detection of increases in frequency of (known) adverse effects. 
3. Identification of risk factors and mechanisms underlying adverse effects. 
4. Quantitative aspects of risks. 
5. Analysis and dissemination of information needed for drug prescribing and 
regulation. 
Since the ultimate goal of pharmacovigilance is described as 'the rational and safe use 
of medicines and the weighing of the risks and benefits of all drugs on the market' all 
issues listed in table 3 on page 7 could play a role in pharmacovigilance. 
National pharmacovigilance centres currently rely mainly upon spontaneous reporting. 
Spontaneous reporting refers to a structured countrywide reporting system for suspec-
ted adverse effects of drugs. Spontaneous reporting is in the first place an early warning 
system for unexpected adverse effects and other possible drug-related problems that 
occur in medical practice. 
An adverse drug effect (or reaction) is defined as 'any response to a drug which is harm-
ful and unintended and occurs at doses normally used in man'.'16' This definition 
implies that the term 'adverse effect' includes all sorts of direct and indirect responses 
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to the administtation of drugs, including interactions, irrespective of the - pharmaco-
logical or pathological - mechanism. Pseudomembranous colitis, for example, is caused 
by a toxin-producing bacterium. When an antibiotic has indirectly promoted the 
growth of the particular (resistant) micro-organism, the colitis is at the same time an 
adverse effect. 
A case report can be defined as 'a notification relating to a patient with a medical event 
or laboratory test abnormality, suspected of being drug-induced'. Case reports are 
characteristically spontaneous, i.e. not specifically requested. In addition, case reports 
usually are confidential. The identities of all persons (patients, physicians, reporters) 
and institutes involved are as a rule kept secret (see page 16). 
Reporting by whom? 
Professionals working in health care are the preferred source of case reports, e.g. fami-
ly practitioners, medical specialists, and pharmacists. Dentists, midwives, nurses and 
other health workers also may prescribe or administer drugs and should report relevant 
experiences. In addition, pharmacists and nurses can play an important role in the 
stimulation of reporting and in the provision of additional information (e.g. on co-
medication and previous drug use). 
If patients or their relatives report adverse effects, it is useful to consider the possibility 
of communicating with their physicians for data verification and additional informa-
tion. Reporting is voluntary in many countries, but the number of countries where 
health care professionals are legally obliged to report is increasing. 
A mandatory report may nevertheless be spontaneous, i.e. not specifically invited. 
In many countries it is mandatory that pharmaceutical companies report to the com-
petent authority any cases of suspected adverse effects that they know of (go-between 
function). 
What to report? 
Referring to the aims of pharmacovigilance a number of adverse effect categories can 
be recognised that particularly need to be reported: 
1. Effects of new drugs 
2. Unknown or unexpected effects 
3. Serious effects 
4. Proof-positive observations (e.g. a positive rechallenge) 
5. Experiences with educational or scientific value 
6. Unexpected therapeutic effects 
It should be emphasised that the reporting is requested of suspected effects and that 
uncertainty of the relationship should not be a reason for not reporting! 
The reporting of known effects that are not serious is usually only requested for new 
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drugs, e.g. within 3 or 5 years after their approval. With regard to established drugs the 
reporting is particularly needed of serious or unusual suspected adverse effects, where-
as minor and known effects (mentioned in the product information sheet) are of less 
interest. It is also a reason for reporting if an increased occurrence of a given adverse 
effect is suspected. 
Although pharmacovigilance is primarily concerned with approved medicines (inclu-
ding radiological contrast media, vaccines and diagnostics), adverse effects associated 
with medications used in traditional medicine (e.g. herbal remedies) and drug abuse 
should also be considered. Effects of drugs used in pregnancy (teratogenicity) and lac-
tation are specific fields of interest. 
It is recommended that, in addition to adverse medical events and laboratory test 
abnormalities, pharmaceutical defects and of lack of efficacy be reported. This applies 
especially when there is a possibility of manufacturing problems, counterfeit phar-
maceuticals or the development of resistance (e.g. antibiotics). 
The distinction between adverse effects and poisoning is somewhat artificial. 
Problems relating to (accidental or intentional) overdose may cast doubt on the safety 
of a medicine and also be relevant to pharmacovigilance. 
How to report? 
Reporting should be made as easy and cheap as possible. Special freepost reporting 
forms are usually disseminated countrywide to health cate professionals. It may be 
effective to include (freepost) reporting forms in the national formulary, drug bulletin, 
professional journals and prescription pads. It can demand the yearly distribution of 
hundreds of thousands of forms to yield only some hundreds of case reports. 
Telephone, facsimile transmission and electronic mail may also be easy means of repor-
ting. 
A case report should - as a minimum aim - contain information on the following ele-
ments: 
1. The patient: age, sex, and a brief medical history. In some countries ethnic origin 
may need to be specified, e.g. because of possible metabolic differences. 
2. Adverse event: description (nature, localisation, severity, characteristics), results of 
investigations and tests, start date, course and outcome. 
3. Suspected drug(s): name (brand or ingredient name, manufacturer), dose, route, 
start/stop dates, indication for use. (With particular drugs, e.g. vaccines or blood 
products, a lot number is important.) 
4. All other drugs used (including self-medication): names, dose, route, start/stop 
dates. 
5. Risk factors (e.g. impaired renal function, previous exposure to suspected drug, pre-
vious allergies, social drug use) 
6. Name and address of reporter (confidential; only to be used for data verification, 
completion and case follow-up). 
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Stimubtion of reporting 
Reporting of adverse effects needs to be stimulated continuously. It is important that 
health care professionals should develop a positive attitude towards pharmacovigilance 
and that the reporting of adverse effects of drugs becomes a routine both accepted and 
appreciated in medical practice. In summary, reporting can be encouraged by the fol­
lowing: 
- Easy access to prepaid reporting forms and other means of reporting; attractive 
reporting form 
- Receipt of a case report acknowledged by a personal letter (individual feed-back) 
- Increase general awareness by feedback to reporters in the form of articles in jour­
nals, adverse reaction bulletin or newsletter 
- Participation in pre- and postgraduate education and scientific meetings 
- Collaboration with local drug, or pharmacovigilance committees 
- Collaboration with professional associations 
- Support for general developmenr of clinical pharmacy and clinical pharmacology 
Data processing 
A computerised system for the processing and retrieval of case reports, according to sus­
pected drugs and adverse effects, shoud be available at pharmacovigilance centres. The 
computer system used should include a hierarchical drug file allowing drugs to be 
recorded according to product name, generic name, therapeutic category and dose. 
Similarly a hierarchical adverse effects terminology should be employed. Hierarchical 
systems for recording of drugs and adverse effects are necessary to allow for specific 
recording of detailed case information and still allow the retrieval of information on 
higher levels. Internationally recognised terminologies should be used as much as pos­
sible, to facilitate international exchange and comparison of data. Adverse effects can 
be coded according to the WHO Adverse Reaction Terminology (WHOART, availa­
ble in English, French, Spanish and Japanese) or another internationally recognised ter­
minology. Drug names should be registered in a systematic way, for example by using 
the WHO Drug Dictionary, which is based on the INN and АТС classifications.'61 
Special care should be taken to attain compatibility with the reporting requirements of 
the WHO Drug Monitoring Programme. It is normally not cost effective to design a 
computer system for pharmacovigilance 'from scratch'. Commercial programmes are 
available which have been appropriately tested and which can be customised to meet 
local needs, including local languages. Detailed instructions on how to organise com­
puterised data for submission to the WHO database may be obtained from the WHO 
Collaborating Centre in Uppsala. 
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Data assessment 
The data collected in a spontaneous reporting system are diverse and heterogeneous 
and influenced in a complex way influenced by uncertainty and reporting bias. 
Interpretation is often difficult. A pharmacovigilance centre has as tasks both to 
stimulate the use of the collected data by the health care professionals, and to ensure 
that the heterogeneous and largely unprovcn data are used in a careful and scientifical-
ly responsible way. It may be helpful to form a multidisciplinary advisory committee, 
as support for the pharmacovigilance centre, with regard to the quality of the procedu-
res for data collection and assessment, the interpretation of the data, and the publica-
tion of information. An advisory committee could represent the following disciplines 
and groups: clinical medicine, pharmacy, pharmacology, toxicology, epidemiology, 
pathology, drug regulation and quality assurance, and drug information. It is also help-
ful to have a network of experienced advisors in various medical specialties. When the 
centre is located in a hospital, specialised expertise is usually within easy reach. 
Assessment of individual case reports 
The assessment of case reports in spontaneous reporting takes place in two steps. First 
a routine case by case assessment of reports on arrival, and second the interpretation of 
aggregated data. Assessment of individual case reports may involve the following crite-
ria. 
The relevance of the report in the light of the aims of pharmacovigilance: is the effect 
known (i.e. mentioned in the literature or in the summary of product characteristics) 
or unknown, serious or not serious, or otherwise of scientific or educational interest? 
Quality of documentation (e.g. completeness and verification of data, quality of diag-
nosis, co-medication, follow-up). This criterion can be applied by using the automated 
documentation grading system of the Uppsala Monitoring Centre.'1'' 
Causality assessment or imputation. With few exceptions, case reports describe suspected 
adverse drug reactions. Various approaches have been developed for the standardised 
determination of the likelihood of a causal relationship between drug exposure and 
adverse events, for example by the WHO Collaborating Centre for International Drug 
Monitoring, the European Commission, or the French national pharmacovigilance 
program (see Section 2). 
Identification of duplicate reports 
Certain characteristics of a case (e.g. sex, age or date of birth, dates of drug exposure, 
concomitant drugs) can be used to identify duplicate reporting. 
Aggregated analysis of the data and interpretation 
The principle underlying spontaneous reporting is that, in spite of the uncertainty in 
individual cases, the aggregated assessment of series of case reports may yield meaning-
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ful and valuable information, e.g. for signal detection, regulatory measures, or publi-
cations. Searching for combinations of case reports of possible interest is a characteris-
tic challenge of spontaneous reporting. The data can be approached in several different 
ways. Examples of the many approaches are: 
1. Studies of selected case reports of possible interest, e.g. of new and unexpected asso-
ciations ('signals'). 
2. Studies of relatively large series of case reports of a given drug-adverse effect combi-
nation, e.g. for studying the clinicopathological characteristics. 
3. Drug profile studies: review of the pattern of adverse effects reported with a drug or 
a drug group, or comparison of different drugs as to adverse effects. 
4. Adverse effect profiles: review of the various drugs reported to have a particular 
adverse effect or group of effects (e.g. a review of anaphylactic reactions). 
5. Studies of differences or changes in reporting frequencies, between drugs or 'within' 
drugs. Differences may for example be studied in the course of time, in relation to 
drug utilisation, and between different drugs. Statistical disproportionality in repor-
ting rates may lead to signals regarding unknown adverse effects. 
Use of the data 
Data collected through spontaneous reporting can be used in a variety of ways. A rough 
distinction can be made between three fields of interest but there is a considerable over-
lap: 
Early warning 
Hypothesis generation as an early warning system is a primary function of spontane-
ous reporting. As a rule, a hypothesis is merely a suspicion and needs to be tested (for 
confirmation or refutation) and explained. Hypotheses may be tested in pharmacoepi-
demiological studies or (sometimes) in pharmacological experiments. When a signal is 
acute or serious, the regulatory authority, the pharmaceutical company and the medi-
cal-pharmaceutical community may need to be informed forthwith. 
Information, education and patient care 
When there is sufficient evidence in the case reports, the data may, once it has been 
carefully evaluated, be presented for publication in bulletins or professional journals. 
In addition, the spontaneous reporting system can be used as part of the under- and 
postgraduate education of health care professionals. Involvement of pharmacovigilan-
ce in training curricula is an excellent way of generating awareness and stimulating 
future participation in pharmacovigilance. 
Patients sometimes present with problems that cannot be solved readily with the infor-
mation available in for example data sheets and handbooks. In such situations, the file 
of unpublished experiences collected through pharmacovigilance can be a useful and 
rapid source of reference to the benefit of the patient. 
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Regulation and risk management 
Under current legislation, medicines need a marketing authorisation and must be 
monitored after their introduction. The spontaneous reporting system is a major 
instrument for the competent authority in post-registration regulatory decision making 
and risk management. It plays an important role in the functioning of the regulatory 
authority, e.g. for the amendment of data sheets and, occasionally, in decisions to take 
extreme measures such as the withdrawal of a marketing authorisation. 
Limitations of spontaneous reporting 
Spontaneous reporting — although an effective way of obtaining data, with minimal 
delay and at low costt - is not a perfect method. It is dependent upon the ability of phy-
sicians to recognise unknown drug-adverse effect associations. Reporting may be 
influenced by all sorts of bias. The interpretation of pharmacovigilance data may be dif-
ficult. Case reports are usually only suspicions: the causal involvement of the suspected 
drugs is uncertain. Spontaneous reporting should be seen as an eatly warning system 
for possible unknown adverse effects. Signals are often unsubstantiated and require 
further study, whether for confirmation or refutation (hypothesis testing) and for 
assessment of the reaction frequency. 
Underreporting is prevalent and is common to all countries. Correcting for underre-
porting is difficult, however, because the extent of underreporting is unknown and very 
variable. The proportion of serious reactions reported may not be more than 10%, even 
at established centres. Several countries, long since participants in the international 
programme of the Uppsala Monitoring Centre, report 200 or more adverse reactions 
per million inhabitants yearly and these reports come from about 10% of the physi-
cians. In many other countries, however, the reporting rates are much lower. 
Underreporting may delay signal detection and cause undetestimation of the size of a 
problem. Appropriate data for drug consumption are not available in a number of 
countries. Spontaneous reporting does not usually yield exact information about fre-
quencies of adverse effects. 
Detailed reporting of medical histories, and the use of such reports are subject to regu-
lations pertaining to privacy and medical secrecy. Case reports are confidential in most 
countries. Confidentiality primarily concerns the identities of all individuals (patient, 
reporter, physicians) and institutions (hospital) involved. The complex of details in a 
patient's history may be as personal as a fingerprint and is a potential identifier. Case 
report summaries are not considered confidential in many countries. It is advisable that 
a pharmacovigilance centre should set up data management regulations, identifying 
legitimate data users and describing which data elements are available to whom and for 
which purpose, and which uses are not appropriate. 
A pharmacovigilance centre has, on the one hand, as task to stimulate the use of the 
collected data by health care professionals and, on the other hand, the duty to ensure 
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that the heterogeneous and largely unproven data are used in a careful and scientifical-
ly responsible way. 
Spontaneous reporting is part of the commitment of health care practitioners and 
patients together to make information available for the improvement of the safe use of 
medicines. If pharmacovigilance data were to be used against the wish of those report-
ing, the entire system might collapse. 
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Section 1 
Signal detection: 
Can the drug cause the adverse event? 
In the first paragraph of the Introduction to this thesis, it is explained why pharmaco-
vigilance is needed, what its aims are and which tools are available. In the thord para-
graph a more detailed review is given of spontaneous reporting — i.e. the countrywide 
system for the reporting of suspected adverse effects of drugs - which is so far the most 
important method used routinely in pharmacovigilance worldwide. 
Since the thalidomide disaster, the early detection of signals pointing to possible ad-
verse reactions, unknown at the time of approval, has been the primary purpose of 
pharmacovigilance. Section I is concerned with this process of signal detection. 
Chapter 1.1 reviews the information published in an 18-year period by, or in collabo-
ration with, the former national pharmacovigilance centre in the Netherlands and con-
taining data derived from spontaneous reporting. Several aspects of the various topics 
are analysed, e.g. the subjects, the drugs involved, the type of publication, and num-
bers of case reports involved. The intention of the study was to use what is learned from 
the past for the further development of pharmacovigilance in this country, now a task 
of the Netherlands Pharmacovigilance Foundation, LAREB. 
While chapter 1.1 is concerned with concrete facts and findings, chapter 1.2 explores 
the scientific background of the detection of unknown and unexpected connections 
between drugs and events, and the mechanisms and considerations involved in the pro-
cess. 
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SUMMARY 
A retrospective analysis was made of the nature and composition of 107 consecutive topics 
presented in publications by or in collaboration with the nationalpharmacovigilance centre 
in The Netherhnds, containing data obtained through 'spontaneous reporting. These topics 
were published in various national and international professional journah or special bulle­
tins or as 'dear doctor letters'. The topics constituted a wide variety of events and disorders. 
There was, however, a predominance of concrete, characteristic and often serious diseases, 
notably specific hypersensitivity reactions (43%, e.g. anaphylaxis, blooddyscrasias and liver 
injury), toxic manifestations or syndromes (30%, especially involving the nervous system), 
and drug interactions (13%). Most topics presented predominantly qualitative information. 
62%> of topics concernedtype B, 33% type A and3% type С adverse drug effects. The topics 
often referred to small numbers of case reports: 10 or less in 70% of the 107 topics. 46% of 
the topics concerned new information. There was some predominance of established (56%) 
over new drugs. Five pharmacotherapeutic groups accounted for 74% of topics. Of the 72 
approved drugs or drug groups, 12 (17%>) have been removed from the market. These fin­
dings increase our understanding of the functioning of pharmacovigilance and may enable 
further improvement of the methods and strategies involved. 
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1.1.1 Introduction 
Spontaneous reporting (i.e. the countrywide reporting system for suspected adverse 
drug reactions, currently often referred to as pharmacovigilance) was first started in The 
Netherlands in 1963.'11 The first 10 years of The Netherlands national pharmacovigi-
lance centre (Pharmaceutical Inspection, Ministry of Health) were characterised by 
experimentation and change. During that period results of the system were only rarely 
used publicly. The next 18 years (1973 to 1990) were a period of relative stability and 
consolidation of procedures. During these years, the first author of this paper was direc-
tor of the centre. The major aims of pharmacovigilance are the early detection of new 
adverse effects, identification of risk factors and mechanisms, quantitative risk assess-
ment, and analysis and dissemination of information. Pharmacovigilance is still under 
development, and improvements may yet be needed. 
We retrospectively analysed the nature and composition of the topics addressed during 
the period 1973 to 1990 in publications by or in collaboration with the pharmacovi-
gilance centre in The Netherlands, containing data from original case reports. The pur-
pose was to find out whether certain characteristics and patterns can be recognised that 
may be of value for further improvements in pharmacovigilance. The contributions of 
pharmacovigilance to the drug regulatory authority (the Medicines Evaluation Board), 
e.g. changes in the product information sheets or withdrawals, were not studied becau-
se of the secrecy observed by this Board. 
1.1.2 Materials and methods 
1.1.2.1 Methods 
The pharmacovigilance system in The Netherlands is based on countrywide 'sponta-
neous reporting' by physicians and, less frequently, by pharmacists and dentists of cases 
of suspected adverse drug effects. ''' All published information that had been issued by 
or in collaboration with The Netherlands national pharmacovigilance centre was col-
lected during the period 1973 to 1990, e.g. in professional bulletins ot journals or as 
'dear doctor letters'. These communications were screened for the presence of topics 
(i.e. information concerning a specific adverse event or other problem in relation to one 
or more drugs) referring to case reports received through spontaneous reporting, with 
or without data from other sources. 
Drug-related events and problems are extremely varied, ranging from simple com-
plaints or abnormal laboratory values to full-blown and serious diseases. In order to 
identify characteristics and patterns, the topics were grouped using a classification 
based on event nature, clinicopathological and pharmacological determinants, and 
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relevance, as shown in figures 1 and 2. The various drug-induced diseases and syndro­
mes (item 2.3) were subdivided as in figure 2. 
Adverse effects were classified according to established categories: type А, В and С 
effects.·2'4' Type A effects ('drug actions') are those resulting from exaggerated phar­
macological actions or from interactions between drugs. Type A effects tend to be fair­
ly common, dose related, and may be avoided by using doses that are appropriate to 
the individual patient. Such effects can usually be reproduced and studied experimen­
tally, and are often already identified before marketing. Type В effects ('patient reac­
tions') characteristically occur only in a minority of patients and include immunoaller-
gic and 'idiosyncratic' reactions, and intolerance due to abnormal metabolism. Type В 
effects may display little or no dose relationship, but often there is a suggestive time 
relationship between drug intake and onset and course. They generally are unpredicta­
ble, may be serious, and are notoriously difficult to study experimentally. 
Type С effects refer to situations where the use of a drug may (often for unknown rea­
sons) increase the frequency of a 'spontaneous' disease. Type С effects may be both 
serious and relatively common (and include malignant tumours), and may have pro­
nounced effects on public health. These events may be coincidental and frequently 
involve long term effects; there often is no suggestive time relationship and the con­
nection may be very difficult to prove. 
1. Pharmaceutical defects 
2. Various types of adverse drug effects and interactions: 
2.1 Laboratory findings 
2.2 Complaints and symptoms of vaiying specificity 
2.3 Diseases and syndromes (pharmacologically or phenomenologically definitive) 
2.4 Drug interactions 
3. Drug profiles (review of reported adverse effects) 
4. Therapeutic failure 
5. Unexpected therapeutic effects 
Fig. 1 — Topics in pharmacovigiUnce. 
1. Immunoallcrgic hypersensitivity 
1.1 Nonspecific reactions (e.g. rashes) 
1.2 Specific hypersensitivity (e.g. anaphylaxis, hepatitis, blood dyscrasias) 
2. Manifestations of drug toxicity (e.g. organ toxicity, hormonal effects, 
embryoroxiciry) 
Fig. 2 — Classification of drug-induced diseases and syndromes. 
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Λ 1.2.2 Classification According to Group and 'Age' 
The suspected drugs in the topics were classified according to pharmacotherapeutic 
group and 'age'. A drug was considered 'new' when the interval between the introduc­
tion of the drug (as mentioned in the Informatorium Medicamentorum of the Royal 
Dutch Society for the Advancement of Pharmacy'5' ) and the year of publication of the 
communication was 6 years or less, and 'established' when the interval was 7 or more 
years. 
The limit of 6 years was chosen because regulations in the European Union require 
intensified pharmacovigilance for 5 years after the registration of a drug, whereas there 
may be a delay of about 1 year between the reporting of an adverse drug effect and the 
publication of the information. For example, the mean delay between the diagnosis of 
adverse drug reactions and their publication in medical journals was found to be about 
63 weeks (for first reports).'6- For drug interactions, the age of only one of the drugs 
was considered, either that of the acting drug or that of the affected drug. 
1.1.2.3 Assessment of New Adverse Effects 
An assessment was made of whether the adverse effects were new or not. A topic was 
considered 'new' when in the publication no reference was made to relevant informa­
tion in the data sheet or in the literature (i.e. previously described case histories). When 
similar cases had been published in the same year, the topic was nevertheless considered 
new (unless the topic appeared as a reaction to the earlier report). When a topic was 
addressed for a second time it was no longer considered new. The topics were studied 
in a quantitative way by counting the numbers of case reports involved. 
- New topic? 
- Number of case reports involved 
- Source of case reports (national or international) 
- Withdrawal from the market? 
Fig. 3 — Further pharmacovigiL·nce topics assessment items. 
With regard to sources of the reports, the topics were divided into 2 groups: referring 
only to case reports in The Netherlands or to reports in one or more additional coun­
tries. Finally, drugs that have been removed from the market after the topic was publis­
hed were identified. However, because of the secrecy in drug regulation, the question 
of whether the adverse effect had caused or contributed to withdrawal could not be 
addressed. These assessment items are summarised in figure 3. 
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1.1.3 Results 
In the study period (1973 to 1990), a total of 107 topics were presented in a variety of 
different publications by or in collaboration with the pharmacovigilance centre in The 
Netherlands. These publications contained information derived from original case 
reports (tables 1 to 5). 
Several publications concerned more than one topic and several topics were addressed 
in more than one publication. There were 81 articles or letters in national or interna­
tional professional journals. A special Adverse Reactions Bulletin (Bulletin Bijwer­
kingen) was produced by the pharmacovigilance centre in 3 volumes (1985 to 1987), 
and was distributed to all doctors and pharmacists in the country. Two articles were 
published in the Drugs Bulletin (Geneesmiddelenbulletin) issued by the Ministry of 
Health. Three letters were sent directly to medical practitioners and pharmacists ('dear 
doctor letters'). 12 topics were presented in Tromnibus, a periodical issued by the 
Federation of Dutch Thrombosis Services. 
In our survey, duplicate publications of topics referring to the same case reports (e.g. in 
a foreign language) were not counted separately, although the references are added to 
table 1. (A few identical and simultaneous publications in a second journal were not 
included.) Topics that were addressed for a second time and contained additional infor­
mation (e.g. follow-up reports or international studies), on the other hand, were 
regarded as separate topics. 
The 107 topics are reviewed in table I, specifying the nature of the adverse events (in 
summary), suspected drugs, references to the publications, types of adverse effects, 
numbers of case reports, 'age' of the drugs, and whether or not the topics were new. 66 
(62%) topics were classified as type В effects and 35 (33%) as type A effects, including 
13 of the 14 drug interactions. Three topics concerned type С effects (3%). Three 
topics did not refer to an adverse effect, but to a pharmaceutical defect, a therapeutic 
failure and a drug review, respectively. 
Seventy five (70%) of the 107 topics referred to 10 or less case reports, including single 
cases in 27 topics (table 2). In 15 (14%) topics the number of case reports was between 
11 and 50, whereas in 13 (12%) topics more than 50 case reports were involved. In 4 
topics the numbers of cases were not precisely specified. 42 (39%) topics concerned 
new medicines, whereas 60 (57%) referred to established products. 49 (46%) topics 
were considered new; 54 (51 %) had been described previously. In the reviews of ana­
phylactic reactions, agranulocytosis and oesophageal injury, the question of whether 
drug and topic were new was not addressed; in the review of nitrofurantoin, the lattet 
question only was thought not to be relevant. Furthermore, for 2 unapproved drugs the 
age question was considered inappropriate. 
In 92 (86%) topics the data were limited to Dutch case histories; 15 (14%) case reports 
from one or more other countries were also included. The reviews of anaphylactic reac-
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Table 1 — Review of 107 pharmacovigiUnce topics 
Topic summary sSuspected drug Ref' 
no 
ADR New No of Age of 
type topic' cases drugb 
Pharmaceutical defects 
Fragmentation of inhalation 
capsules 
Cromogl) cate and salbutamol 1 
Laboratory findings 
Hyperammonemia (in adults) Sodium valproate 
Complaints and symptoms 
( ough 
Testicular and perineal pain 
ACE inhibitors 
(captopril/enalapnl) 
Mazmdol 
Yes 
Yes 
No 
No 
No 
4 ' 19/18 
4 C 11 
21= 5/1 
8 d 8 
4 l 10 
Diseases and syndromes 
Immunoallergic hypersensitivity 
Nonspecific reactions 
(mainly rashes) 
Contact dermatitis 
Specific hypersensitivity 
Anaphylaxis and acute 
hypersensitivity 
Camazepam c 
Coumann derivatives 
Indapamide 
Mebendazole 
Placebo capsules containing 
quinine (capsulae albochin) 
Terfenadine 
1 iclopidine ς 
Udder ointment (human use 
of veterinary product) 
Cinoxacin 
rioctafcmnc 
Glafenine c 
Yes I V 
Isoflurane 
Ketoconazole 
Mebhydrolin 
Paracetamol 
Polidocanol 
Promethazine 
Review of reports of anaphylactic 
reactions, high reporting rate of glafenine l 
liver 
Hepatitis 
Cholestatic hepatitis 
Diclofenac 
Glafenine z 
Halothane 
Ketoconazole 
Nomifensine 
Phenprocoumon 
Pirprofen 
Amoxicillin-clavulanic acid 
7 
8 
9 
10 
11 
12 
В 
В 
в 
в 
в 
в 
No 
Yes 
Yes 
No 
Yes 
No 
16 l 
204 J 
8C 
1 
108 J 
1' 
>20 
13 
14 
>20 
3 
3 
13 
20 
24 
25,17 
26 
27 
28 
29 
30,31 
32 
343 
No 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Β 
В 
В 
в 
в 
в 
в 
в 
в 
в 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
26 л 
1 3 l 
32 ^ 
1161 
1 L 
2C 
3 C 
55 J 
3C 
2 l 
5 
11 
9 
12 
4 
2 
>20 
>20 
>20 
>20 
No 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
229 ' 
I e 
•=>' 
1 c 
5 C 
7 d 
1 c 
4 d 
I e 
10 
12 
15 
2 
3 
>20 
5 
6 
7 
27 
Table 1 — Continued 
"Iopic summary -Suspected drug Ref' ADR New No or Age of 
no tvpc topic' cases drug1' 
Hepatitis, serial 
climcopathological studies 
Blood 
Granulocytopenia 
Review of agranulocytosis reports
: 
of руга/olinone derivatives c 
Demonstration of drug-
dependent antibodies against 
hematopoieticprecursor cells in 
agranulocytosis 
riutamide 
Allopurinol 
Glafenine 
Ketoconazole 
Nitrofurantom/nifurtoinol 
Apnndme 
Mianserin 
Pirenzcpine 
Spironolactone 
Ticlopidinc c 
, high reporting rate 
Propylthiouracil 
34 
35 
36,31 
37,31 
38,31 
39,40 
41 
42 
43,44 
12 
45,46 
47 
В 
В 
В 
в 
в 
в 
в 
в 
в 
в 
в 
в 
Yes 
No 
No 
No 
No 
Yes 
No 
Yes 
Yes 
No 
Yes 
1' 
6 J 
38° 
55 е 
5 2 е 
8 l 
4 е 
l f 
l r 
l b 
90 l 
1 ς 
0 
>20 
19 
5 
19/22 
2 
4 
3 
>20 
3 
>20 
I hrombocytopenia 
Other organs and systems 
bever 
Pancreatitis 
Parotitis 
Interstitial nephritis 
Sclerosing peritonitis 
Photosensitivity 
Mianserin (drug-( 
antibodies) 
Nalidixic acid 
Pirenzcpine 
Jeper 
ndopidme (drug-depi 
antibodies)6 
Labetolol 
Nomifensine 
Pyrazinamide 
Methyldopa 
Nitrofurantoin 
Cimetidine 
Glafeninec 
Practolol l 
Azapropazone 
ident 
indent 
48,41 
49,50 
42 
12,51 
52,53 
28 
54 
55 
56,57 
58 
17 
59,60 
61 
62 
В 
В 
В 
В 
В 
в 
в 
в 
в 
в 
в 
в 
в 
в 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
No 
l l 
(,·-
I e 
I e 
2 ' 
22 J 
1 ' 
1 ' 
2° 
l l 
N S l 
5 ' 
5 L 
190 d 
3 
>20 
3 
3 
8 
3 
>20 
19 
13 
3 
12 
4 
13 
13 
Drug toxicity (e g organ toxicity, 
hormonal effects, embryotoxicity) 
Sterile meningitis Metrizamide v 
Optic neuropathy Amiodarone 
Erhambutol/isomazid 
Psychiatric complications (depression, 
anxiery, mania, depersonalisation, 
withdrawal reactions) Fenfluramine 
Peculiar visual and psychic 
disturbances Ben7ydamine ' 
Hallucinations in children Oxolamine ' 
Acute extrapyramidal 
dvstonic reactions Dompendone 
63 
64 
65 
66 
67 
68 
69 
70 
71 
В 
В 
в 
A 
A 
A 
A 
A 
A 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
No 
No 
N S l 
1 3 d 
2 ' 
13 е 
1 0 l 
4 c 
20 J 
9 C 
-11-1 
4 
18 
>20 
>20 
6 
15 
9 
10 
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Table I — Continued 
Topic summary 
Psychic agitation 
Depression and dyskinesia 
Psychosis, amnesia, behavioural 
disturbances 
Paradoxical motion sickness-like 
syndrome after withdrawal 
Prolonged postoperative apnoea 
Apnoea after epidural 
administration 
Sudden unexpected death in 
asthma patitnts 
Bodytemperature elevation 
Gvnaecomastia 
Interruption of menstruation 
Acute renal failure 
Oesophageal ulcers 
Hyperthyroidism 
Review of reports of 
oesophagus in|ury 
Nicolau syndrome 
(muscle and skin necrosis) 
Biliary concrements and colic 
Phlebitis 
Tace malformations 
Spina bifida 
Drug interactions 
Potentiation of coumarms 
Inhibition of coumarms 
Inhibition of oral contraceptives 
Alcohol intolerance 
Potentiation of amantadine 
Suspected drug 
Budesomde 
Flunarizine 
Triazolam ' 
Scopolamine TTS 
Keramine 
Sufentanil 
Ref' 
no 
72 
73 
74 
75 
76 
77,78 
79 
80 
ßn-sympathomimetic aerosols 81 
Oral contraceptives 
Captopril 
Naproxen 
Fumarie acid-esters 
Doxvcychne/ 
tetracycline capsules 
Kelp (hucus vesiculous) 
Doxycychne tablets 
Pinavenum bromide 
Pyrazolmone derivatives ' 
Ceftriaxone 
brgoramine 
Coumann derivatives 
Sodium valproate 
Amiodaronc 
A«ipropa/one 
Flurbiprofen 
Oxolamine ' 
Cotrimoxazole 
Acetylcysteine 
Colestyramine 
82 
83 
84 
86,87 
88 
85 
89 
90 
91 
92 
93,94 
95 
96,97 
98 
99,100 
ADR 
type 
В 
С 
С 
В 
В 
В 
А 
А 
С 
А 
В 
А 
А 
А 
А 
А 
А 
А 
В 
А 
А 
А 
А 
А 
101,102 A 
103Л04А 
105 
106 
107 
108 
Unexpected en/yme induction 
caused by barbiturates in 
hypnotics, e g Bellanoxc 
Modifast 
Anticonvulsants 
Griseofulvin 
Minocycline 
Ketoconazole 
Hydroi hlorothiazide/ 
amilonde 
obsolete 
109 
110 
111 
112 
113 
114 
115 
Л 
А 
А 
А 
А 
Л 
А 
А 
А 
В 
А 
New 
topic' 
Yes 
Yes 
No 
Yes 
No 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
Yes 
Yes 
Yes 
No 
Yes 
No 
No 
Yes 
Yes 
Yes 
Yes 
No 
No 
No of 
cases 
2 C 
8 ' 
2 2 l 
>100 e 
1000 í 
3 e 
1 ' 
A' 
2 6 l 
1 l 
1 ' 
2 1 
4 ' 
1 ' 
1 ^ 
2 C 
5 ' 
57 l 
3° 
2 l 
7 C 
3 ' 
10^ 
7 ' 
N S l 
2 C 
2 ' 
3 C 
1 l 
5^ 
A' 
N S C 
3 l 
22 i 
1 L 
1 ' 
1 ' 
Age of 
drug11 
5 
3 
3 
1 
11 
1 
15 
New 
ca 14 
>20 
7 
6 
Old 
>20 
16 
2 
>20 
5 
>20 
>20 
13 
12 f 
I f 
К 
5 f 
6 f 
I f 
2 f 
18 f 
2 f 
12* 
>20s 
17 
8 1 
8P 
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Table 1 — Continued 
Topic summary Suspected drug RefJ ADR New No of Age of 
no type topic' cases drug1. 
Drug profile Nitrofurantoin 116 2 1 8 ' 13 
Review of reported suspected adverse effects, no increase in reporting 
Therapeutic failure 
Insufficient analgesia and 
decreased efficacy of subsequent 
morphine in cancer patients Buprenorphine (sublingual) 117 Yes 2' New 
a References to the publications in this table are published in the appendix. 
b Age of drug - year of publication of communication minus year of introduction, as mentioned in the 
Informatonum Medicamentorum of the Royal Dutch Society for the Advancement of Pharmacy 
с Dutch case reports only 
d Case reports from 2 or more countries 
e Withdrawn from the market 
f Age ofacting drug 
g Age of affected drug 
Abbreinatwns ADR = adverse drug reaction, NS = not specified 
tions, agranulocytosis and oesophageal injury referred to many different drugs and are 
not included in this figure. 72 different approved drugs or drug groups and 6 unoffi­
cial drugs were involved in the topics (tables 1 and 3). Of the 72 approved drugs, 12 
(17%) have been withdrawn from the market (table 4). The 5 pharmacotherapeutic 
drug groups most frequently involved are listed in table 5. 
1.1.4 Discussion 
From the start, the use of data reported to The Netherlands pharmacovigilance centre 
in publications has been limited by confidentiality and uncertainty with regard to the 
role of the suspected drugs. During the study period there was, however, an obvious 
tendency to use the data to their best advantage in publications for the medical/phar­
maceutical community. The choice of the topics was influenced by the interests and 
concerns of the pharmacovigilance centre and its Advisory Committee. Case reports 
may attract attention for several reasons, e.g. because the drug is new, the adverse event 
is unexpected, serious or little known, or because of the scientific value of the data. In 
other cases a request for information from outside (e.g. someone preparing an article) 
may lead to the inclusion of case reports in a publication. 
There were different types of publications: warning letters, brief communications, ori­
ginal journal articles, or additions to articles by others. 
As table I shows, there was a remarkable pluriformity of topics encountered in phar­
macovigilance in The Netherlands, illustrating the diversity and heterogeneity of 
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adverse drug effects. At the same time, however, there appeared to be a predominance 
of concrete, characteristic and often serious diseases, notably specific hypersensitivity 
reactions (n = 46; 43%), e.g. anaphylaxis (n = 11; 10%), blood dyscrasias (n = 11; 10%) 
and liver injury (n = 14; 13%), toxic manifestations or syndromes (n = 32; 30%) espe­
cially involving the nervous system (n = 17; 16%), and drug interactions (n= 14; 13%); 
altogether 86% of topics. This pattern resembles that in the study of drug withdrawals 
by Spriet-Pourra and Auriche.'7' In that study, of 66 products withdrawn because of 
Table 2 — Characteristics of '107' pharmacovigilance topics 
No of topics % 
No of case reports 
1 
2-10 
11-50 
51-100 
> 100 
Not specified 
27 
48 
15 
5 
8 
4 
25 
45 
14 
5 
7 
4 
Source of case reports 
Netherlands only 92 86 
Netherlands and one or more 
other countries 15 14 
33 
62 
3 
3 
39 
56 
5 
46 
51 
4 
Type of adverse effects 
Type A effects 
Type В effects 
Type С effects 
Not applicable 
New or established drugs? 
New drug·1 
Established drugb 
Not applicable 
New topic? 
Yes 
No 
Not applicable 
35 
66 
3 
3 
41 
60 
5 
49 
54 
4 
a Registered 6 or less years before publication of topic 
b Registered 7 or more years before publication of topic 
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clinical adverse effects, 14 (21%) were associated with liver injury, 12 (18%) with blood 
dyscrasias, and 9 (14%) with neurological disorders, together accounting for 33 (50%) 
withdrawals. 
The majority of topics (62%) concerned type В adverse effects. This is likely to reflect 
the situation that type В effects are a primary concern of pharmacovigilance in the first 
place. However, type A adverse effects occur with relatively high frequency and in great 
Table 3 — Unapproved drugs in 6 topics 
Fumarie acid esters (used in psoriasis) 
Capsulae albochin Formularium Nederlandse Apothekers (FNA), 
placebo capsules containing quinine for bitter taste 
Kelpasan, a kelp (Fucus vesiculosis) product containing iodine 
Modifast, a slimming product containing vitamin К and sold only 
in pharmacies 
Sufentanil for epidural anaesthesia (at that time not yet approved) 
Veterinary udder ointment containing phenoles and citronellal 
used for selfmedication in humans 
Table 4 — Withdrawn drugs 
Hypnotics containing barbiturates (e.g. secobarbital/ 
brallobarbital/amobarbital in Bellanox) 
Benzydamine (oral use) 
Camazepam 
Glafenine 
Metrizamide 
Nomifensine 
Oxolamine 
Pirprofen 
Practolol 
Pyrazolinone derivatives (e.g. Baralgin, Buscopan comp, 
Butazolidine, Irgapyrine, Tanderil, Tomanol) 
Ticlopidine 
Triazolama 
1
 Τι lazolam wa¿ withdrawn in 1979 and reintroduced in 1990. 
32 
Table 5 — Pharmacotherapeutk drug categories in 107 pharmacovigiL·nce topics (more 
than one category per topic possible) 
Category 
Drugs acting on the central nervous system 
Anti-infective agents 
Analgesic and antirheumatic drugs 
Anticoagulants 
Cardiovascular drugs 
Other 
No. of 
topics 
22 
20 
19 
16 
12 
32 
% 
18 
17 
16 
13 
10 
26 
variety, and this finding also suggests that spontaneous reporting is especially effective 
in detecting type В effects. Of the 35 topics classified as type A effects, 13 were drug 
interactions. The 9 interactions with coumarin derivatives were reported with the aid 
of a reporting project in collaboration with the countrywide organisation of 69 region­
al outpatient anticoagulant monitoring centres (Dutch Federation of Thrombosis 
Services).18' 
Only 3 topics were considered to relate to type С effects. Depression and parkinsonism 
in association with flunarizinc were categorised as type С effects because of the possi­
bility of coincidence (2 different publications). The inquiry on sudden and unexpected 
death during the use of 2 sympathomimetic aerosols (the other type С effect) was per­
formed after receiving a few spontaneous case reports. The results confirmed the exis­
tence of the association, but a cause-effect relationship remained uncertain. 
In the light of the historical thalidomide tragedy, it is worth mentioning that 2 topics 
(2%) concerned congenital malformations (coumarins and valproic acid). Mebhy-
drolin-induced anaphylaxis, one of the many associations in the review of anaphylactic 
reactions, was included as a separate topic because it had not been published previous­
ly. For one drug (nitrofurantoin), a profile of the reported suspected adverse effects was 
included in a review article. 
One single topic referred to a pharmaceutical defect, i.e. fragmentation during admi­
nistration of capsules containing powder for inhalation (cromoglycate or salbutamol). 
Therapeutic failure was reported only once (buprenorphine in cancer patients), but it 
should be added that in the 7 topics on inhibition of oral contraceptives or coumarins, 
lack of effect was of course the major issue. There were no unexpected therapeutic 
effects. 
With regard to suspected drug involvement, it is noteworthy that there was a predo­
minance of established (56%) over new drugs (39%) ['not appropriate' in 5%]. Of the 
49 topics classified as new, 20 (41%) concerned established drugs. These findings em-
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phasise that pharmacovigilance should not be restricted to new medicines only. It also 
shows the relativity of the rule recently introduced in the European Union, that 5 years 
after registration of a medicine pharmacovigilance is considerably relaxed. 
Less than half of the topics (46%) were considered new. Many more topics, however, 
had an obvious news value, e.g. because the adverse effects were only recently detected 
or were little known in the medical community. Original observations concerning 
adverse effects that have only once or twice been reported in the distant past may be of 
considerable value. In addition, the various review articles and clinicopathological 
studies, although not classified as new topics, presented many new pieces of informa­
tion. 
An interesting finding was that many of the pharmacovigilance topics referred to fair­
ly small numbers of case reports (table 2). In 70% of the topics, 10 or fewer case reports 
were involved. In the 49 topics classified as new, a similar pattern was found: in 37 
(76%) the number of case reports was 10 or fewer. This is in accordance with a recent 
study in the UK. Of 46 problems naming one drug and one serious (type of) reaction, 
published in Current Problems, 24 (52%) were concerned with 10 or fewer yellow card 
reports, and of these 12 (26%) with only 4 or fewer cases. '9' These findings are in keep­
ing with the view of the WHO Collaborating Centre for International Drug 
Monitoring that in the signalling of type В adverse effects, a minimum of some 3 to 9 
case reports is often needed."0·11' 
The situation that there is a minimal number of reports needed to provide sufficient 
evidence for the detection of an adverse effect suggests that the time needed for detec­
tion is directly dependent upon the rate of reporting. The smaller the proportion of 
doctors reporting, the smaller the monitored population of drug users, and the longer 
it takes before the required minimal number of adverse reaction patients have accu­
mulated. 
In 13 topics, on the other hand, more than 50 case reports were involved. Two of these 
were serial studies of clinicopathological patterns: hepatic injury with ketoconazole and 
nitrofurantoin, respectively. Only in these 2 studies was an estimation of the frequen­
cy of the adverse effect made. For 5 other drugs the numbers of reports were thought 
to reflect relatively frequent adverse reactions, without further specification, i.e. aza-
propazone (photosensitivity), glafenine (anaphylactic reactions), Indapamide (rashes), 
pyrazolinone derivatives (agranulocytosis), and triazolam (psychic disturbances). 
Triazolam (which received an unusually large number of reports in 1979), was a special 
case that has been reviewed in detail elsewhere."2' 
In the review article on nitrofurantoin it was concluded that there were no indications 
for an increase in reporting, relative to the consumption of the drug. Four of the topics 
referring to more than 50 case reports were cumulative international studies (i.e. on 
azapropazone, Indapamide, paracetamol and terfenadine). 
Five pharmacotherapeutic groups accounted for a total of 74% of the topics: dtugs 
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acting on the central nervous system, antiinfective agents, analgesic and antirheumatic 
drugs, anticoagulants, and cardiovascular drugs (table 5). Many of these drugs are 
known causes of relatively frequent and/or serious adverse effects. The emergence of 
anticoagulants to some extent reflects the above mentioned special interaction report­
ing project. The absence of cytotoxic drugs, on the other hand, undoubtedly reflects 
selective underreporting. 
The majority of topics (n = 101; 94%) concerned approved drugs. In addition, 2 topics 
concerned unapproved remedies, one topic concerned the human use of a veterinary 
product, one involved a warning for the presence of quinine in a placebo (capsulae 
albochin), one concerned the unapproved use of a registered drug, and one referred to 
a pharmacy-only slimming product interacting with coumarin anticoagulants (table 3). 
1.1.5 Clinical Implications 
Pharmacovigilance is a complex process of data collection, assessment and distribution, 
aiming at the safe use of medicines and the prevention of adverse effects. A better 
understanding of the mechanisms and procedures involved and their scientific, logistic 
and educational aspects may enable further improvements. The experiences with phar­
macovigilance in The Netherlands lend support to the following observations: 
1. Pharmacovigilance must continuously hold an open mind for the new, the unusu­
al and the unexpected. The routines involved should enable the precise recording 
of case histories and not lead to simplification or distortion of adverse events. 
2. Spontaneous reporting is particularly useful in the detection of type В adverse 
effects and of type A effects that were not identified during clinical testing (includ­
ing drug interactions), but is of less value in the study of type С effects. 
3. A limited number of adverse effects are responsible for the majority of the more 
serious problems encountered in pharmacovigilance. Pharmacovigilance may be 
improved by intensified monitoring of these effects. 
4. Information derived from only small numbers of case reports may already provide 
valuable information and lead to the detection of new adverse effects. 
5. The provision of first reports (i.e. on new adverse effects) is a major role of phar­
macovigilance. 
6. In addition, the dissemination to healthcare practitioners of all sorts of informa­
tion relevant to the knowledge of adverse effects and the appropriate use of medi­
cines (including reminders of previously reported adverse effects) is an important 
function of pharmacovigilance. 
7. Pharmacovigilance should cover all drugs on the market, new and established, 
approved and non-orthodox. 
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8. Pharmacovigilance topics often concern predominantly qualitative information. 
For precise quantitative information (e.g. frequency), additional studies are often 
needed. 
9. Signal detection speed is directly dependent on the si7e of the monitored popula­
tion of drug users and therefore on the proportion of doctors contributing to the 
reporting system. Underreporting delays the detection of rare adverse effects. In 
addition, the capacity of spontaneous reporting to provide clues with regard to the 
frequency of adverse effects (important for regulatory decision making) also 
depends on the proportion of reporting doctors. 
10. The integration of national and international pharmacovigilance may require fur­
ther development. 
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SUMMARY 
Adverse drug effects are manifold and heterogeneous. Many situations may hamper the sig­
nalling (i.e. the detection of early warning signs) of adverse effects and new signah often 
differ from previous experiences. 
Signals have qualitative and quantitative aspects. Different categories of adverse effects need 
different methods for detection. Current pharmacovigihnce is predominantly basedon spon­
taneous reporting and is mainly helpful in detecting type В effects (those effects that are often 
allergic or idiosyncratic reactions, characteristically occurring in only a minority of patients 
and usually unreUted to dosage and that are serious, unexpected and unpredictable) and 
unusual type A effects (those effects that are reUted to the pharmacological effects of the drug 
and are dosage-reUted). Examples of other sources of signah are prescription event monito­
ring, Urge automated data resources on morbidity and drug use (including record linkage), 
case-control surveilUnce and follow-up studies. Type С effects (those effects reUted to an 
increased frequency of spontaneous' disease) are difficult to study, however, and continue to 
pose a pharmacoepidemiological challenge. 
Seven basic considerations can be identified that determine the evidence contained in a sig­
nal: quantitative strength of the association, consistency of the data, exposure response rela­
tionship, biological phusibility, experimental findings, possible analogies and the nature 
and quality of the data. A proposal is made for a standard signal management procedure at 
pharmacovigiL·nce centres, including the following steps: signal delineation, literature 
search, preliminary inventory of data, collection of additional information, consultation 
with the World Health Organization Centre for International Drug Monitoring and the 
relevant drug companies, aggregated data assessment and a report in writing. A better 
understanding of the conditions and mechanisms involved in the detection of adverse drug 
effects may further improve strategies for pharmacovigilance. 
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1.2.1 Introduction 
Since its beginning, in the wake of the thalidomide tragedy in the early 1960s, the pri-
mary function of pharmacovigilance - or 'drug monitoring' as it was formerly called -
is the provision of early warnings (signals) with regard to previously unknown adverse 
effects of medicines.'11 Originally, the primary problem was where to find such signals. 
However, spontaneous-reporting systems have now developed around the world. The 
number of case reports received at the World Health Organization (WHO) Collab-
orating Centre for International Drug Monitoring in Uppsala, Sweden is continuous-
ly rising and now numbers almost 200 000 per year. In addition, progress in automa-
tion technology has enabled the development, in many countries, of comprehensive 
databases covering large populations. These huge data reservoirs contain a multitude of 
potential signals, and pharmacovigilance now concentrates on the question of how to 
identify early, relevant signals. 
The discovery of an adverse drug effect is a stepwise process, consisting of: (i) hypo-
thesis generation; (ii) hypothesis strengthening and preliminary assessment of the avail-
able data; and (iii) signal testing, evaluation and explanation.'2' In pharmacovigilance, 
signal detection refers primarily to the first 2 steps: the generation and preliminary 
assessment of hypotheses. 
Clinical trials are inherently limited in their ability to produce data regarding adverse 
effects, especially when these are rare and unexpected. Therefore, at the time of mar-
keting of a drug, the knowledge of its tolerability is inevitably incomplete. During the 
years following the launch of a drug, this knowledge usually increases, for example, 
with regard to pharmacology, clinical use and adverse effects. Although pharmacovigi-
lance is especially concerned with adverse effects, a signal is more broadly defined as a 
set of data constituting a hypothesis that is relevant to the rational and safe use of a drug 
in humans. Such data are usually clinical, pharmacological, pathological or epidemio-
logical in nature. A signal consists of a hypothesis, together with data and arguments. 
In this article, we review the principles and mechanisms underlying signal detection 
and the conditions that may promote or inhibit signal detection. A better understand-
ing of signal detection may enable further improvements in pharmacovigilance and 
drug regulation. 
1.2.2 Signal Generation 
Since the huge expansion in the recognition of diseases and syndromes during the nine-
teenth century and the first half of the twentieth century, new disease entities are now 
rarely encountered. If a new disease is found, its cause is often a chemical substance (e.g. 
medicines, food additives, or occupational and environmental pollutants) or an infec-
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Table 1 — Situations favouring signal detection 
Clustering of a clinical event or syndrome with one or more of the following features: 
- a (very) low natural frequency 
- characteristic or unusual (combinations of) signs and symptoms 
- occurring in groups of similar patients (e.g. same age, region, disease history, 
drug use) known to be frequently drug-induced (e.g. anaphylaxis, agranulocytosis, 
Stevens-Johnson syndrome) 
High frequency of exposure to the drug 
Adverse effects with one or more of the following features: 
- high frequency 
- suggestive time (immediate reaction, positive rcchallenge) or dose relationship 
- plausible pharmacopathological mechanism 
tious agent. Recent examples of such diseases include (in chronological order) congen-
ital rubella syndrome, thalidomide-induced phocomelia, diethylstilbestrol induced 
vaginal carcinoma, practolol-induced oculomucocutaneous syndrome, legionnaires 
disease (Legionella pneumophila), AIDS and tryptophan-induced eosinophilia-myal-
gia syndrome. With these examples in mind, it can be seen that the detection of adver-
se effects of drugs may be enhanced by a number of situations (table 1). 
Unfortunately, the connection between a drug and an adverse effect is often difficult to 
detect. The discovery of a new adverse effect may be hindered and delayed by a variety 
of circumstances, for example, when: (i) the frequency of the adverse effect is low (as is 
often the case); (ii) the background frequency of the effect involved is (relatively) high; 
(iii) the frequency of exposure to the drug is low; or (iv) there is no suggestive time or 
dose relationship. 
Although there are countless causes of disease, the symptoms produced are limited.131 
Many adverse drug effects are not new clinical entities, but imitations of established 
disorders, ranging from trivial complaints to specific and serious diseases; a signal in 
pharmacovigilance often concerns a new cause for an old disease. The 'Five Realities' 
which inferred the establishment of a causal relationship between a given virus and a 
given respiratory disorder, as first described by Evans in 1967, in many respects also 
apply to pharmacovigilance (table 2).^ 
1.2.3 Sources of Signals 
Signals in pharmacovigilance are usually derived from observations in individual 
patients or in populations, or from experimental studies, and have a qualitative and a 
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Table 2 — The 'Five Realities' ofEvanJ^ as applied to pharmacovigihnce 
1. The same clinical syndrome may be produced by a great variety of drugs and by non-
drug causes 
2. The same drug may produce a variety of clinical events or syndromes 
3. The predominating drug in a given adverse effect may vary according to the type of 
population (e.g. age group, geographical location, indication, prescribing habits) 
4. In individual patients, it is often impossible to prove the causal role of the suspected 
drug 
5. The aetiology, frequency and pathology of many common complaints and disorders 
are still uncertain 
quantitative dimension. Various possible sources of signals are listed in table 3. In the 
context of this article, we do not distinguish between methods and systems. 
At present, spontaneous reporting (in all its varieties'1,2'), and anecdotal reports in pro­
fessional journals, play a major role in the detection of adverse drug effects. Although 
the methods used in analytical epidemiology (such as case control and follow-up stud­
ies) are primarily used in signal evaluation, they may also serve in signal generation. 
Any disproportionate difference in the occurrence of an event in the population of 
users of a given drug (or class of drugs), or any difference in the rate of reporting of an 
event in association with a drug relative to other drugs, may constitute a signal. 
Of the epidemiological approaches, prescription event monitoring (РЕМ), case-control 
surveillance and record linkage are especially useful in signal detection. РЕМ is perfor­
med at the Southampton Drug Surveillance Unit in the UK.'6' Large cohorts of users 
(often larger than 10 000 individuals) of various drugs are identified via the Pre­
scription Pricing Authority, and their doctors are requested to provide information on 
any events that have occurred during or after the use of those drugs, irrespective of 
whether there is a possibility that the drug was the cause. Large comprehensive popu­
lation databases, such as have recently been developed by health insurance systems, 
open new possibilities for the record linkage approach.'2' 
Experimental toxicology traditionally has a screening function before marketing, but is 
rarely used after marketing. New or refined techniques in experiments and in in vitro 
tests may, however, increase their future role in postmarketing signal detection. 
The examples in table 3 (and in sections 3 and 5) are not exhaustive; other approaches 
have, or may, become available. For further information, the reader is referred to hand­
books, such as those edited by Inman'1' and Strom.'2' 
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Table 3 - Sources of signals 
Observations in patients (qualitative signals) 
Spontaneous-reporting systems 
Anecdotal literature reporting 
Intensive hospital monitoring 
Prescription event monitoring 
Follow-up studies 
Monitored release programmes 
Observations in populations (quantitative signals) 
Large data resources on morbidity and drug use (including 
record linkage) 
Case-control studies; case-control surveillance 
Follow-up studies 
Prescription event monitoring 
Intensive hospital monitoring 
Large spontaneous reporting systems (e.g. World Health 
Organization, US Food and Drug Administration) 
Experimental findings 
Clinical trials 
In vitro experiments 
Animal toxicology 
1.2.4 Types of Adverse Effects and Their Detection 
Adverse drug effects are manifold and heterogeneous, and are often unexpected, unu­
sual and unpredictable. New signals often differ from previous experiences. Different 
types of adverse effects — particularly with regard to frequency, manifestations or 
mechanism — may need different methods of detection.'6,7i In accordance with previous 
proposals,'1,81 adverse effects may, somewhat artificially, be distinguished into types A, 
В and C. The characteristics of these 3 types of adverse effects, the reasons why they 
may be difficult to detect, and the most useful methods of detection for each type, are 
shown in table 4. 
Type A effects are often 'sufficient' or 'necessary'causes. Type В effects are often 'neces­
sary' causes. Type С effects are often 'contributory' causes. For explanations, see page 
52. 
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Table 4 — Characteristics of different types of adverse effects, reasons why they may be dif­
ficult to detect, and suitable methods of detection for each type 
Type A lypeB Type С 
Characteristics 
Relatively frequent Occur in a minority 
(usually >1 in 100) of users (often <1 in 1000) 
More frequent and severe Pre-e\istent (often unidentified) 
with higher dosages predisposing factors 
Probable pharmacological mechanism I ow background frequency 
Time relationship may or 
may not be suggestive 
May or may not be specific 
May or may not be serious 
G m be studied experimentally 
May be predictable 
Mechanism often unknown 
Often suggestive time relationship 
Specific, characteristic 
Often serious, but reversible 
Reasons why they may be difficult to detect 
May seem coincidental Rare or ver) rare 
(c g nausea, dizziness) 
Infrequent with low/moderate doses Unexpected, unpredictable 
No suggestive time relationship 
Occurs in special situations 
(excluded in trials) 
Interactions 
Mechanism unclear 
Lxpenmental study may be difficulta 
Multiple drug use ь 
Suitable methods of detection 
Clinical trials (phase III and IV) 
Follow-up studies 
Prescription event monitoring 
Spontaneous or anecdotal reporting 
No suggestive relationship 
with dosage 
Often no diagnostic test 
May not be experimentally 
reproducible 
Multiple drug use 
Increased frequency of 
'spontaneous' disease 
Occurs at random interval 
or after long induction time 
Often characteristic, serious, 
persistent 
Mechanism uncertain 
Drug-induced fraction of the disease 
may be small 
Unexpected, unpredictable 
Often (relatively) high background 
frequency 
No suggestive time relationship 
(delayed effects) 
May not be experimentally 
reproducible 
Multiple causal factors 
Multiple and incomplete drug history 
Absence of adequate comparison 
(untreated patients) 
High potential for confounding 
Spontaneous or anecdotal reporting Case-control studies 
Prescription event monitoring 
Case-control studies and 
case-control surveillance 
Diagnosis (episode) registrations 
Experimental studies (e g in animals) Large data resources on morbidity 
and drug use, and record linkage 
Long term follow-up studies 
I*arge data resources on morbidity 
and drug use, and record linkage 
Long interval prescription 
event monitoring 
a Such as headache in animals 
b Problems iclating to multiple drug use do not usually occur in clinical trials 
1.2.4.1 Type A Adverse Effects 
Type A adverse effects are those related to the (exaggerated) pharmacological effects of 
the drug, and tend to be fairly common, dosage-related (more frequent or severe with 
higher dosages) and may often be avoided by using dosages that are appropriate for the 
47 
individual patient. Many adverse drug reactions can be classified as type A effects, such 
as morphine-induced constipation. 
Type A effects can usually be reproduced and studied experimentally, and are often al­
ready identified before marketing. However, problems may arise for many reasons, such 
as: (i) when the effect is only manifest in a minority of the users; (ii) when there is not 
a strong relationship with dosage; (iii) when the phenomenon is trivial, and may seem 
coincidental, or is difficult to reproduce in experiments; or (iv) when the mechanism is 
unclear. An example is cough associated with Captopril and other ACE inhibitors. This 
type A effect was not recognised during the original clinical trials, but was detected by 
means of spontaneous reporting only after marketing. With type A effects of low spe­
cificity, quantitative and controlled assessment may be needed in order to confirm the 
relationship and measure the frequency. 
1.2.4.2 Type В Adverse Effects 
Type В adverse effects ('patient reactions') are often allergic or idiosyncratic reactions 
and characteristically occur in only a minority of patients (e.g. less than 1 per 1000) 
and are usually unexpected and unpredictable. Type В effects are often serious, may 
show little or no relationship with dosage and, for several reasons, may be difficult to 
detect. In type В effects, the relationship with time and a low background frequency 
are often major reasons to suspect the drug. 
Type В effects are either immunological or non-immunological and occur in patients 
with, often unidentified, predisposing conditions. Immunologic reactions may range 
from rashes, anaphylaxis, vasculitis and inflammatory organ injury, to highly specific 
autoimmune syndromes. Also, non-immunologic type В effects occur in a minority of 
predisposed patients who are 'intolerant' to the drug, possibly because of an inborn 
error of metabolism or acquired deficiency in a certain enzyme (resulting in an abnor­
mal metabolic pathway, or accumulation of a toxic metabolite). Characteristic examp­
les of type В effects are haemolytic anaemia induced by methyldopa, and hepatitis 
induced by isoniazid. 
1.2.4.3 Type С Adverse Effects 
The past 50 years has seen the development of many powerful drugs that substantially 
improve life expectancy and quality of life of patients with a variety of serious and 
chronic diseases. In some diseases, such as diabetes mellitus and myasthenia gravis, the 
course has changed dramatically, and late disease complications (e.g. diabetic micro­
angiopathy) now determine wellbeing and prognosis of the patients. In other words, 
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effective treatments may change the clinical picture of these diseases. At the same time, 
medicines may - especially when taken long term - introduce new morbidity, or change 
the frequency of natural diseases that may occur in a lifetime. 
Type С effects may be both serious and (relatively) common and have pronounced 
effects on public health. Tardive disease manifestations may be difficult to distinguish 
from chronic drug toxicity, and in individual patients, causation and coincidence may 
be inextricable. There is often no helpful time relationship and the connection may be 
difficult to prove (or refute). When the drug is widely used, the absolute number of 
affected patients may be substantial, even if the drug-induced fraction of the disease in 
question is only small. Examples of the problems encountered with type С effects are 
those relating to the possible influence of oral contraceptives on the incidence of breast 
tumours, or the relative frequency of thromboembolic complications with different 
oral contraceptives. 
The assessment of the long term benefit and damage caused by the treatment of chron­
ic diseases remains a major challenge, not only to pharmacovigilance, but to medical 
science as a whole. 
1.2.5 Frequency of Adverse Effects 
From the point of view of assessment methodology, a major difference between thera­
peutic and adverse effects is that the therapeutic effect is the rule (occurring in most, if 
not all, patients), whereas the adverse effect is the exception (occurring in only a minor­
ity of users of the drug). Because of the dominating role in signal detection, the impli­
cations of the low frequency of adverse effects are discussed separately here. In order to 
discover an adverse effect with a frequency of, for example, 1 in 2000 users and a low 
background frequency of only 1 in 100 000, a study population of about 16 000 drug 
users would be needed, while for a frequency of 1 in 10 000, the cohort size needed 
would exceed 100 000. ^  With higher background frequencies, the required size of the 
study population again considerably increases. It may take a long time before data on 
so many patients have been collected and studied, so the detection of an adverse effect 
may be delayed. 
With spontaneous reporting, a minimal number of case reports - in the range of about 
3 to 9 - is usually needed for a signal (page 34).[9' The speed with which the minimal 
number of cases is collected depends upon the number of users, the frequency of the 
adverse effect and the reporting rate. The smaller the number of users of a new drug, 
the longer it may take before an adverse effect is discovered. Likewise, the lower the rate 
of reporting, the larger the user population needs to be, and the longer the detection of 
the effect will be delayed. In other words, signal detection speed depends on the pro­
portion of doctors contributing to the reporting system. 
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Table 5 — Suitable methods for detecting adverse drug effects, according to the frequency of 
the adverse effects. For detection methods, see Inman1'1and Strom,Q! 
Detection method Frequency of adverse effete 
>1/10 
Spontaneous reporting 
(llátlOllil) — 
International reporting1* 
Intensive monironng 
(New Zealand0, in hoipitald) -
Prescription event monitoring — 
Case control surveillance -
Large data resources 
(and record linkage) 
Follow up studies — 
Monitored release -
Clinical trials ++ 
1/10 to 
1/100 
+ 
-
+ 
+ 
-
+ 
+ 
++ 
1/100 to 
1/1000 
++ 
+ 
+ + 
++ 
+ 
++ 
++ 
+ 
+ 
1/1000 to 1/5000 to 1/10000 to <1/50000J 
1/5000 1/10000 1/50000 
++ 
++ 
++ 
a May be undetectable or not relevant at this frequency 
b As conducied by the World Health Organization (WHO) Collaborating Centre for International Drug 
Monitoring in Uppsala, Sweden, and international pharmaceutical companies The W H O Collaborating 
Centre collects data derived from national spontaneous reporting systems throughout the world ' " '2 | This has 
the advantage of creating che largest possible data file, and also creates possibilities for comparing drugs in dif-
ferent countries and at different times 
с In addition to a high reporting rate of adverse effects, the intensive monitoring programme developed in New 
Zealand , 0 ' enables the identification of first users cohorts of selected new drugs (comparable to 'recorded re­
lease') which can be used for rapid signal testing and quantitative data collection 
d Intensive monitoring in hospitals " 
Symbols - = of little or no use, + = may be helpful, ++ = preferable 
In table 5, various methods are reviewed, in order of appropriateness, in relation to the 
detection of adverse effects with different frequencies. However, this is only intended 
as an example, since other factors may also play a role, such as specificity of the event 
(or the lack of it), background frequency and delayed onset. Future improvement of a 
method may increase its capacities. 
1.2.6 Signal Assessment 
1.2.6.1 Qualitative versus Quantitative 
Signals derived from observations in patients (e.g. spontaneous reporting) often refer 
to fairly small numbers of cases - in the range of about 3 to 9 — and are predominant­
ly qualitative in nature.'913"15' In exceptional cases, a single good report (e.g. with a 
positive rechallenge) may be a valid signal. The number of case reports needed to pro­
vide sufficient evidence for a signal may differ, depending upon the nature of the effect, 
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the quality of the reports and possible evidence from other sources (e.g. pharmacolo­
gy). Such predominantly qualitative signals mainly concern type В adverse effects.'и' 
On the other hand, signals can be primarily quantitative. The strength of a quantita­
tive association can in its simplest form be calculated in a cross table (fig. 1), using 
standard formulae to estimate the relative risk (either directly or via the odds ratio).'1 6 1 
The higher the relative risk, the stronger the signal. Since the precision of this estimate 
is determined by its confidence interval, the number of case patients needed in a sta­
tistical signal may be considerably higher than in a 'qualitative' signal. However, since 
the relative risk is only calculated to detect disproportionality, statistical significance is 
of less importance in signal generation than in analytical epidemiological studies that 
address causality (i.e. in signal testing). In the signal detection phase, it may be very dif­
ficult to rule out chance, selection or confounding. 
Quantitative signals often concern type В or С adverse effects and may be found in 
population databases, large spontaneous-reporting systems [e.g. those of the W H O 
Collaborating Centre' 1 1 · 1 2 ' or the US Food and Drug Administration (FDA) 1 1 7 1], 
РЕМ'
5
' and follow-up or case-control studies.'1·2' For signal detection, the pharmaco-
vigilance centre of the FDA compares the frequency of reports for a drug, relative to 
those received for the same drug in previous time periods (within-drug comparison), 
and with the frequency of reports for other drugs (between-drug comparison).'1 7 ' 
Differences or changes in reporting that are in excess of a certain level can be automat­
ically detected. 
Experience at the Southampton Drug Surveillance Research Unit, which has a large 
РЕМ database, has shown that when the rate ratio T l : T 2 exceeds 3 : 1 , the event is 
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likely to be an effect of the drug (or a sign or symptom of the disorder being treated).'5' 
In this context, T l is the rate of an event during the first month of treatment with a 
test drug and T2 is the average rate of the same event during the subsequent follow-up 
period, irrespective of whether or not treatment is continued. Rate ratios may be cal­
culated in several different ways, for example, by comparing different drugs. 
Clinical trials (phase III and IV) are especially effective in providing information on 
type A adverse effects. Characteristically, they combine qualitative with quantitative 
data, but their use is inherently restricted to effects with a high frequency and a short 
induction time. Examples of other, highly structured, methods that have the potential 
to simultaneously provide qualitative and quantitative information are follow-up stud­
ies, intensive hospital monitoring and РЕМ, but their applicability may also be limited 
(e.g. because of low detection sensitivity or high costs) [table 5]. 
1.2.6.2 Aetiology 
When a signal is detected, the central question ¡s whether it is true or not that the drug 
can cause the event concerned. This question is not restricted to medicinal drugs, but 
also applies to causes of disease in general, such as environmental or biological agents. 
At the end of last century, under pressure from a medical establishment that did not 
believe in the aetiological role of micro-organisms, in the Henle-Koch postulates strict 
conditions were put forward for attributing causation'4' These were: (i) demonstration 
of the suspected agent in affected tissues in all individuals; (ii) absence of the agent in 
unaffected individuals; and (iii) experimental reproduction of the disease by the agent 
(in animals). These can be seen as criteria for the (preliminary) assessment of the sus-
picion that a micro-organism may cause a given disease, preceding a comprehensive 
epidemiological study. Relaxation of these strict Henle-Koch criteria was needed, 
however, in order to accept other agents, such as viruses and chemicals, as causes of 
human disease.'4' 
Diseases are often the result of a complex process involving many subsequent or inter-
acting events and conditions. There are 3 different categories of disease aetiology,'18,19' 
all of which may be encountered in pharmacovigilance. 
1. Sufficient causes. On exposure to a sufficient cause, the disease will inevitably follow. 
Type A adverse effects (e.g. sedation with hypnosedatives, alopecia with cytotoxic 
drugs) are often sufficient causes. 
2. Necessary causes. Although exclusion of a necessary cause inevitably prevents the dis-
ease, exposure to this type of cause is not invariably followed by development of the 
disease. This is characteristically the case with type В adverse effects, which develop 
in only a minority of exposures. 
3. Contributory causes. These factors increase the risk of a given disease. The exclusion 
52 
of a contributory cause in a population leads to a reduction in the frequency of the 
disease, but not to eradication. In an individual patient, the role of a contributory 
cause may remain obscure. Type С adverse effects fit into this category. 
1.2.6.3 Attributing Causality 
Although related, the causality question addressed in signal detection (i.e. whether it is 
possible for the drug to have caused the event) differs from the other important 
question in pharmacovigilance: 'Has the drug actually caused the event (in a given 
patient)?' The latter question - systematic case-causality assessment or 'imputation' — 
is addressed elsewhere. '2 0 ' 
Since the time of Henle and Koch, progress has been made in the attribution of diseas­
es to aetiological agents. Bradford Hill'21' reviewed 9 basic criteria for differentiating 
between association and causation in occupational medicine, and emphasised the 
importance of issues such as time- and dose-response relationships, the specificity of 
the disorder, and the consistency and biological plausibility of the data. 
In 1976, Evans proposed a unified concept of 10 criteria for accepting causation, appli­
cable to both acute and chronic diseases.'^ He pointed out, among other things, that: 
(i) the frequency of the disease should be significantly higher in individuals who were 
exposed to the putative cause than in those who were not exposed; (ii) exposure to the 
putative cause should be more common in individuals with the disease than in those 
without it, when all other risk factors were held constant; and (iii) the elimination of 
the putative cause (or of the vector carrying it) should reduce the incidence of the dis­
ease. Evans pointed out that experimental findings - the basis of the Henle-Koch con­
cept - can contribute much to the evidence for causation. In 1983, Venning'22' de­
scribed 11 criteria for accepting or rejecting a relationship between a drug and a 
suspected adverse effect. He divided these criteria into 3 different categories, providing 
either 'convincing', 'strong' or 'weak' evidence regarding causality. 
Against this background, we propose that signals in pharmacovigilance require the 
careful and aggregated assessment of all available data from different sources, which 
includes controlled and uncontrolled interventional and observational data, as well as 
spontaneous reports, both published and unpublished. Table 6 shows a framework for 
the assessment of a pharmacovigilance signal. In addition, a signal may be much stron­
ger if similar observations have been reported in other countries or studies. 
At national pharmacovigilance centres, many signals are derived from spontaneous 
reporting systems. To enable the assessment of a signal in the way suggested above, the 
data need to be appropriately collected and processed. Therefore, we propose a practi­
cal procedure in 8 steps for the management of signals at pharmacovigilance centres. 
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1. Selection of the relevant data (case reports) and delineation of the signal (hypothe-
sis). 
2. Literature search. 
3. Survey of available data and identification of missing data and unanswered 
questions. 
4. Gathering of missing data (follow-up of cases, structured enquiry). 
5. Consultation with the WHO Collaborating Centre for International Drug Moni-
toring (Uppsala, Sweden). 
6. Contact with the pharmaceutical company; study of the data in the registration file. 
7. Assessment or reassessment of all available data (including complete case reports), 
according to the criteria in table 6. 
8. Writing a report containing: (i) a summary of the signal; (ii) a presentation of orig-
inal data; (iii)a presentation of additional information; (iv) a discussion, with ref-
erence to positive and negative arguments; (v) a conclusion (even if preliminary); 
and (vi) suggestions for further study. 
Table 6 — Criteria for signal assessment in pharmacovigilance 
Criterion Explanation 
Quantitative 
Strength of the association 
Qualitative 
Consistency of the data 
Exposure-response relationship 
Biological plausibility of the 
hypothesis 
Experimental findings 
Analogy 
Nature and quality of the data 
The number of case reports (in relation to 
exposure to the drug), statistical 
disproportionaliry and significance 
The general presence of a characteristic feature 
or pattern, and absence or rarity of 
converse findings 
Site, timing, dosage-response relationship, 
reversibility 
Pharmacological and pathological mechanisms 
Rechallenge, drug-dependent antibodies, 
high blood or tissue drug concentrations, 
abnormal metabolites, diagnostic markers 
Previous experience with related drugs; 
event known to frequently be drug-induced 
Characteristic nature and objectivity of 
the event, accuracy and validity of 
documentation, case causality assessment 
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The report may serve as a basis for decision-making by the competent authority and 
the pharmaceutical company, and may be used for the preparation of information for 
practitioners and in the published literature. 
1.2.7 Discussion 
Previously unknown diseases are rarely encountered nowadays. Procedures for data col-
lection, which are needed to assist in the detection of adverse drug effects (and other 
new and unexpected disorders), have not usually been established in routine medical 
practice. 
In modern medicine, there is a continuous turnover of drugs. New products are often 
modifications of established drugs (e.g. in chemical structure, composition or phar-
maceutical formulation). Less frequently, a drug is a genuine new chemical entity or has 
a novel pharmacological action. In all situations, however, the new drug may be an 
unexpected cause of a serious adverse reaction. Adverse effects constitute a wide range 
of complaints, symptoms, disorders and syndromes. Many different effects and mecha-
nisms may be involved, encompassing the entire clinicopathological spectrum. A sing-
le approach to the detection of all adverse drug effects is, therefore, impractical. 
20 years ago, Jick1"' recognised 5 different categories of adverse effects, purely on the 
basis of adverse effect frequency, relative to background frequency. He was probably the 
first to propose a comprehensive strategy for the detection of adverse drug effects, 
which was restricted, however, to clinical trials, case-control and cohort studies. 
The connection between a drug and a disorder is often difficult to make. Many disor-
ders develop as a result of the interaction of various factors and cofactors. Coincidence 
may imitate a time relationship, while pathological findings may be an epiphenomenon 
and erroneously be suggestive of a causal factor or mechanism. Since the possibility of 
performing toxicological experiments on humans is very limited or nonexistent, the 
demonstration of a causal relationship between an agent and a disease is notoriously 
difficult. Compared with many other environmental causes of disease, pharmaceutical 
agents are often new or have been in existence for a relatively short period of time, so 
experience may be of too short a duration to provide scientific proof of causality. 
For many accepted adverse drug reactions, as mentioned in bulletins, journals, text-
book or data sheets, the evidence of causation is only circumstantial and often incon-
clusive. Despite such uncertainty, in drug regulation prescribing-policy decisions have 
to be made and measures taken. 
Different types of adverse effects require different methods for signal generation, and 
the arguments in favour of, or against, causation may differ in nature and in weight. A 
good understanding of the logic and mechanisms involved - however diverse, complex 
or confusing - may accelerate signal detection and may rationalise the subsequent 
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assessment of the evidence. Careful testing, using appropriate scientific methods, is the 
natural response to a signal. Not infrequently, however, comprehensive signal evalu­
ation may not take place, because of shortage of time and money, or because of scien­
tific or ethical constraints. The use of appropriate methods in signal detection and the 
use of the 7 criteria proposed above for the assessment of signals (see table 6), may 
improve rational decision making in pharmacovigilance, whenever the final answer to 
a problem is not (yet) available. 
The existing pharmacovigilance systems are especially effective in detecting type A and 
type В adverse effects, but of limited value with regard to type С effects.'15' Since type 
С effects may have a great impact upon public health, improvement of the monitoring 
of type С effects is a priority in the further development of pharmacovigilance. 
In this article, we have focused on the first 2 steps in the discovery of adverse drug 
effects: the generation and preliminary assessment of signals. Subsequent phases — test­
ing of the signal, measuring adverse effect frequency, and solving remaining questions, 
or filling gaps in knowledge - usually take time. Analytical epidemiological and exper­
imental studies may be needed to exclude bias, chance and confounding factors, to elu­
cidate the mechanism and to identify risk factors. A thorough knowledge of the adverse 
effects of a drug should mean that it can be safely administered, for example, by using 
preventive measures or providing additional instructions for use. 
1.2.8 Conclusion 
Different adverse effects need different methods of detection. Signals in pharmacovigi­
lance have a variety of sources. Pharmacovigilance may not rely upon one single 
method but needs a strategy of complementary activities. Signals are essentially suspi­
cions. We propose a series of basic criteria (see table 6) for assessing the credibility of 
signals in pharmacovigilance. For the testing of signals further studies are often needed. 
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Section 2 
Causality assessment: 
Has the drug caused the adverse event? 
Whereas section 1 covered the attribution in general of adverse events to medical drugs, 
section 2 addresses another important problem often encountered in pharmacovigi-
lance: the attribution of events to drugs in individual patients or in case reports. 
Chapter 2.1 reviews the systems for standardised causality assessment that are used at 
national pharmacovigilance centres in the European Union and in some countries out-
side the Union. The next chapter, 2.2, is a discussion of the scientific basis of case-
causality assessment in general. The various advantages and limitations are reviewed 
and some recommendations are then made for the future use of causality assessment in 
pharmacovigilance. 
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CHAPTER 2.1 
Causality Classification at Pharmacovigilance 
Centres in the European Community 
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SUMMARY 
The assessment and classifications of the likelihood of a causal relationship between a drug 
and a suspected adverse reaction, imputation, is an important element in pharmacovigi-
hnce. A comparison of the procedures currently tun use at national pharmacovigilance cent-
res in the countries of the European Community (EC) and three countries outside the com-
munity (Sweden, Australia and Canada) showed that causality assessment has developed 
somewhat differently in different countries. In spite of the differences, the procedures in most 
EC countries have much in common and three major causality categories could be recog-
nized, covering the vast majority of case reports. As a step towards harmonization in the EC, 
and in order to facilitate international data processing and drug regulation the use of three 
categories has recently been adopted by the Committee for Proprietary Medicinal Products 
(CPMP). The scientific basis ofpharmacovigiUnce is still in development and the strategies 
for causality assessment may change in the future. The establishment of European drug regu-
btion and increasing world-wide collaboration require further harmonization of causality 
assessment and other procedures in pharmacovigilance. 
62 
2.1.1 Introduction 
Observations in individual patients experiencing adverse events in temporal association 
with the use of a medicine play an important role in the discovery of hitherto unknown 
adverse reactions and the study of the clinical and pathological characteristics of such 
reactions. Suspected adverse drug reactions (ADRs) may be published in single case 
reports or as a small series in the scientific journals, notably in the correspondence 
colums, or be reported to special registers maintained by governmental, industrial or 
professional organizations, i.e. pharmacovigilance centres - a procedure which is often 
referred to as 'spontaneous monitoring' or 'voluntary reporting'.'1,2' 
It was the pioneering work of the pathologist Irey which first emphasÌ7ed the impor-
tance and logic of standardized assessment of the relationship between the use of a drug 
and a possibly associated adverse event.'''4' The subsequent work of Karch and 
Lasagna,5j Kramer et al/ '7 ' and Vcnulet et al/ '9 ' raised more generally the interest of 
the medico-pharmaceutical community in this issue, and several additional proposals 
for a systematic causality assessment have been put forward for clinical, regulatory or 
scientific use.'810,1 ' 26' On the other hand, it has been found that even with standarized 
procedures agreement between different observers may be difficult to reach.'',2' 
About 10 years ago the WHO Collaborating Centre introduced a set of six causality 
terms on its reporting form, viz. 'certain', 'propable', 'possible', 'unlikely', 'unclassified', 
'unclassibiablc'; however, no explanation of the meaning of these terms was given. In 
the past decade national governmental pharmacovigilance centres in the European 
Community (EC) have developed various strategies for causality assessment. In only 
one country, France, has the national system been described in detail in the litera-
ture.'11' The intention of this article is to describe the practices as used until now in the 
EC and to present a model for harmonization, enabling a cumulative assessment of the 
internationally collected data, which has recently been developed by the Pharma-
covigilance Working Party of the Committee for Proprietary Medicinal Products 
(CPMP). 
Table 1 — Review of causality terms and their meaning as used in the countries of the 
European Community 
Belgium 
I he Belgian Centre has a choice of seven causality terms. 
— Certain 
- I ime relationship with the administration of the suspected drug is well-established 
- Suspected drug is a know cause or the adverse reaction, 
- Reaction confirmed by rechallenge. 
- Probable 
- Time relationship with the administration of the suspected drug is well-established 
- Suspected drug is a known cause of the adverse reaction. 
- Reaction confirmed by dechallcnge. 
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- Possible 
- Time relationship with the administration of che suspected drug is reasonably well established, 
but less evident, 
Suspected drug is known to cause the adverse reaction 
- Unlikely 
- Time relationship with the administration of the suspected drug is reasonably well established, 
but less evident, 
- But the drug is not known to cause the adverse reaction 
- Unclassified 
- Because of lack of data 
- Unclassifiable 
- Imputation impossible 
Deleted 
- Excluded from pharmacovigilance 
Denmark 
In Denmark five causality terms are used Definite, Probable, Possible, Unclassified and Unlikely These terms have 
no further descriptions or definitions and there is no special procedure for allocating the terms 
France and Luxembourg 
In 1 uxembourg a monitoring system is not operational, but this small country of the h C is technically associated 
with one of the regional centres in France The French regional pharmacovigilance centres, pharmaceutical firms 
and medicines authority all use the assessment system as described in the literature n This system is noteworthy 
m that it is very well developed and tested in practice It takes into account, on the one hand, the arguments for 
a causal relation as present in the case observations (c g time association, likelihood of other causes) e e intrinsic 
imputation, and on the other hand the evidence available in the literature (extrinsic imputation) I he two consul 
erations are measured in points and the outcomes together result into one of the following caregones Verv Likely 
(14), L ikely (13), Plausible (12) Possible/dubious (11), Unlikely (appears excluded, 10) bor more information on 
the interesting French system the reader may consult Bcgaud et al (1985) ' " 
Germany 
The situation in Germany has also been described in the literature ' 2 " There are considerable differences in com 
panson with other comunes Τ here is only one positive category - 'Possible', two categories express uncertainty -
'Not Evaluated' and 'Unclassifiable', and one is negative - 'Unlikely' There is no special algorithm for allocating 
a term 
Greece 
The meanings of the causality terms as used in Greece are specified as follows 
С Certain 
(a) A reaction in reasonable temporal relationship with administration of the suspected drug 
(b) Positive rechallenge 
(c) С onfirmation by measuring drug level in body fluids or tissue 
(Sub b is considered to be critical ) 
Ρ Probable 
(a) A reaction in reasonable temporal relationship with administration of the suspected drug 
(b) Positive dcchallcngc 
S Possible 
A reaction is reasonable temporal relationship with administration of the suspected drug 
N Not possible or unlikely 
Any reaction not meeting the above criteria 
U Unclassified 
Insufficient data for classification 
X There is an additional category X, used when subsequent information reveals that the reaction is 
unlikely to be drug-induced 
Ireland 
The Lausahiy terms used for determining causality in the drug-reaction relationship in Ireland have the following 
definitions 
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- Certain This term is used when sufficient information has been supplied and validated (including laborato­
ry data, ι e biopsy reports, post-mortem results, details of rechallenge, etc ) which confirms the existence of 
a drug-reaction relationship I his evidence mav also be supported bv details of other reports on the data hank 
(national or international) and the predictability of the reaction according to its pharmacological activity 
- Probable 1 his term is used when sufficient information is supplied and validated shich suggests the likeli­
hood of an ad\erse reaction, particularly one which has been well recognized and documentated 
- Possible The term is used when a report suggests the possibility of a drug-reaction relationship via the infor­
mation supplied and validated and the pharmacological activity of the drug, even if not previously recogni/ed 
- Unlikely The term is used when a report suggests the possibility of an adverse reaction, but the pharmacolo­
gical activity of the drug coupled with a dearth of other reports and data to back this up deem this possibili­
ty remote 
- Unclassified No attempt to classify a relationship has been made This term is used in case of clinical trial 
event reports 
- Unclassibiable It is not possible to classify a relationship due to lack of data 
Italy 
Causality categories used in Ttalv 
- Certain Time-relation appropriale, known reaction, positive dechallenge, when available positive rechallenge 
- Probable Appropriate time-relationship, positive dechallenge, no other causes 
- Possible Other causes may contribute 
- Doubtdul Other causes more likely 
The Netherhnds 
1 he procedure in The Netherlands is somewhat different from other countries It is based on a note of guidance, 
of which a summary has been published previously ' 4 ' 
- Unclassified Incomplete or conflicting data Iemporal relationship not helpful A malignancy or malforma­
tion is only classified when there are strong reasons to suspect the drug 
- Unlikely Relationship not excluded Time relation seems inappropriate Another cause more likely (but not 
proven) 
Only when the time relation seems appropriate can one of the following categories be chosen 
- Possible Relationship not impossible or unlikclv A trivial event which ma) be a coincidence An objective 
event which is unknown or seems inexplicable as a reaction to the suspected drug An immunologic reaction 
to a rarely sensitizing drug Another drug or cause is equally suspected As 'Probable (below) but fewer details 
- Probable Relationship plausible Consistent with a reaction to the suspected drug Good reasons for assu­
ming causality but no proof No likely alternative Strong association (place contact reaction time imme­
diate reaction) An objective or characteristic event, known or explicable as a reaction to the drug Outcome 
as expected An immunologic reaction to a frequently sensitinng drug or a characteristic reaction to the drug 
A subjective event with a positive rechallenge As 'Certain (below), but fewer details 
- Certain Convincing evidence Well-documented case All evidence implicates the drug Outcome as expec­
ted Alici native ruled out An objective event v. uh low spontaneous frequency and a knov, η or explicable reac­
tion to the drug A convincing rechallenge 
Portugal 
In this country the ADR system was introduced only in 1991 It has been agreed to use four causality terms 
- Probable 
- Sufficient information has been supplied and validated 
- I ime relationship with the administration of the suspected drug is well established 
- Reaction confirmed by dechallenge 
- Reaction confirmed by rechallenge 
- Possible 
- Sufficient information has been supplied and validated 
- Time relationship with the administration of the suspected drug is well-established 
- Suspected drug is a known cause of the adverse reaction 
- Reaction confirmed by dechallenge 
- Unlikely 
- Sufficient information has been supplied and validated 
- Relationship is not excluded 
- Time relationship with the administration of the suspected drug is not evident or well established 
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- 1 he drug suspected is not vet a known cause of the adverse reaction and its pharmacological activity 
deems this possibility remote 
- Unclassified (unclassified + unclassifiahle) 
Because or lack of data 
- Conflicting data 
- Imputation impossible (malignancy or malformation) 
Spam 
As in trance, the pharmacovigilance centre in Spain uses a quantitative imputation system, based on a list of dif-
ferent questions resulting in a score 
Score 
Timing of events 
1 Compatible 
2 Compatible but not coherent 
3 No information 
4 Incompatible 
5 ADR due to drug withdrawal 
Previous knowledge 
1 Well-known ADR 
2 Known from anecdotal reports 
3 Unknown 
4 Information against the relationship 
Dechallenge 
1 ARD improves 
2 ADR docs not improve 
3 Drug not ceased, ADR does not improve 
4 Drug not ceased, ADR improves 
5 No information 
6 Not assessable due to irrevetsible ADR 
7 ADR improves (suspected drug tolerance) 
Rechallenge 
1 Positive ADR reappeared 
2 Negative 
3 No information 
4 Not assessable due to irreversible ADR 
Alternative enologie candidates 
1 Strong alternative 
2 Weak alternative 
3 No information 
4 No alternative 
Favouring factors (illness) 
Favouring evidences (drug levels) 
Converting to imputability categories 
I Improbable 
2 Conditional 
3 Possible 
4. Probable 
5 Definite 
2 
1 
0 
- 1 
2 
2 
1 
0 
-1 
2 
- 2 
1 
1 
0 
0 
1 
3 
- 1 
0 
0 
- 3 
-1 
0 
1 
1 
1 
0 or less 
1-3 
4-5 
6-7 
8 or more 
United Kingdom 
The terms used in the UK are Probable (A), Possible (B), Unlikely (C), Insufficient information for assessment 
(D) and Unassessable (U, e g carcinogenic and teratogenic effects) These terms art selected b> experienced 
experts but there are no special definitions or algorithms in current use 
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2.1.2 Materials and methods 
A questionnaire was sent to the national pharmacovigilance centres in the EC, asking 
for details with regard to causality assessment of case reports of suspected adverse reac-
tions and the procedures for the classification of case reports into different causality 
categories. Replies were received from all countries. The results are presented in Table 
1. For comparison the same questionnaire was also sent to three non-EC countries with 
populations of comparable sizes, viz. Australia, Canada and Sweden (see table 2). 
Table 2 — Causality terms and their meaning as used in some countries not belonging to 
the European Community 
Australia 
In Australia four broad categories are employed for routine assessment of the case reporrs: Certain, Probable, 
Possible and Unlikely. For selection of terms the following system is used: 
Certain 
(a) Confirmed bv rechallenge; and/or 
(b) Confirmed by laboratory data; and/or 
(c) Reaction onset immediately followed drug administration (within 5 minutes if injection 
was the method of administration). 
— Probable 
(a) Temporal or spatial (e.g. skin) correlation with administration; and/or 
(b) Recovery on withdrawal of drug if no other drug is withdrawn and no therapy given; and/or 
(c) Uncommon clinical phenomenon associated with the administration of the drug in rhe absence of other 
factors. 
— Possible 
(a) A possible alternative explanation exists; and/or 
(b) More than one drug is suspected; and/or 
(c) Data are incomplete; and/or 
(d) Recovery follows withdrawal of more than one drug; and/or 
(e) Time relationship is not clear; and/or 
(f) Outcome of the reaction is not recorded; and/or 
(g) Recovery follows therapy in addition to withdrawal of drug. 
— Unlikely 
This classification is accorded where a clinical event may well be explained as arising from factors related to 
underlying disease, or orher non-drug aetiology Reports listed as unlikely are not used in evaluations or sta-
tistical studies and are not displayed in the computer printouts provided. 
Canada 
In Canada the case reports are not individually submitted to causality assessment. 
Sweden 
At the Swedish Pharamcovigilance Centre case reports are routinely assessed with regard to causality. There are two 
categories used: P, meaning probable or possible, and N, not assessable or remote These terms have not been de-
fined in more detail and there is no algorithm in use. 
2.1.3 Discussion 
When in 1981, during an international meeting in Morge organized by Ciba Geigy, a 
review was made of the current status of causality assessment, it was concluded that 
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nine questions were generally considered to be of major importance.'9' These 'Morge 
criteria' were: 
1. Drug given prior to event? 
2. Reaction at site of application? 
3. Drug/ADR interval compatible with the event? 
4. ADR immediately follows the drug and of acute onset? 
5. Rechallenge positive? 
6. Dechallenge positive? 
7. Were concomitant drugs stopped at the same time? 
8. Same ADR tot this drug before? 
9. ADR known with the suspected drug? 
In more general terms, four different basic considerations can be recognized in attri-
buting a clinical event to a drug: 
1. Associative connection, in time - including dechallenge and rechallenge - or place 
(e.g. contact dermatilis). 
2. Pharmacological explanation; blood levels; previous knowledge of the drug. 
3. Presence of characteristic clinical of pathological diagnostic criteria. 
4. Likelihood of exclusion of other possible causes. 
Furthermore, in a voluntary case reporting system the completeness and reliability of 
the data contained in the case reports is often an important limiting factor. Also, the 
relative contribution of a drug to the development of an adverse response in addition 
to other factors may be difficult to quantify (as is the case, for example, when an anti-
depressant is associated with a seizure in an epileptic patient). 
The standarized use of the various criteria in a generally applicable model is hampered 
by the situation that the relative importance of a criterion may differ considerably for 
different types of adverse reactions and under different conditions, and that a similar 
finding may be positive in one case and negative in the other. Deafness induced by ace-
tylsalicylic acid, for example, is essentially transient, whereas aminoglycoside-induced 
deafness is irreversible; a 'dechallenge' will therefore have opposite results. The time 
relation is decisive for acute hypersensitivity reactions, but is of little use in chronic 
effects. Also the purpose of raising the causality question - e.g. patient care, scientific 
study, regulation of juridical — may influence the outcome of the assessment. In the case 
of a hypersensitivity reaction in association with ampicillin, for example, even in one 
and the same patient, the connection may be clinically 'probable' (i.e. future use con-
traindicated), 'possible' in scientific respect and 'doubtful' in the legal point of view. 
A world-wide procedure for causality assessment of suspected adverse reactions to drugs 
has not yet been established. An important development seems to be that there is a 
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move from the concept of one single generally applicable algorithm for all reactions, 
towards a number of carefully structured systems for different organ-systems or reac-
tion types. The initiative of Bénichou has, with the support of the Council for 
International Organizations of Medical Sciences, already resulted in consensus with 
regard to special systems for the diagnosis and imputation of a variety of drug-induced 
disorders, including liver injury,'13' haemolytic anaemia'141 and other blood dyspa-
sias,'1''' renal failure,'16' interstitial pneumonia,'171 photosensitivity'18' and vascular pur-
pura.'19' Similar models for other system-organs are envisaged. These new systems are 
somewhat different from the official French national system of imputation. In fields in 
development, such as pharmacovigilance, drug regulation may have to be adapted in 
accordance with changing scientific views. Probably in the future a method may be 
developed, producing exact and consistent estimations of causality, which is based on 
a combination of the system-organ approach and the probabilistic model'20' and using 
computer assistance.'21' Accurate knowledge of the spontaneaus frequencies of adverse 
events in various conditions, and of the influence of factors such as polypharmacy and 
the age of the patient on the development of an effect, will be needed in such a system. 
As is obvious from table 1, national pharmacovigilance centres in the countries of the 
European Community have developed more or less different procedures for imputing 
adverse events and drugs. In Luxembourg a monitoring system is not operational, but 
this small country of the EC is technically associated with one of the regional centres 
in France; hence the total number of countries in table 1 is 11. The centre in Portugal 
has only been established in 1991. Three countries have four, five have five, two have 
six and one has seven causality categories. All countries but one have a category 'pro-
bable' and all countries have a category 'certain' of'definite'. Most but not all countries 
use the categories 'unlikely' or 'excluded' and 'unclassified' or 'unassessable'. Three 
countries have no explanations or definitions of the tetms used. Only two countries 
(France and Spain) use detailed and quantitative, but different, assessment systems. 
It's obvious that the classifications used in different countries refer to a continuum, 
extending between the extremes 'unrelated' and 'definitely related'. In borderline cases 
the selection of a causality term may therefore be somewhat artificial. 
On considering the various terms, definitions and approaches used in EC countries, 
there appear, despite superficial differences, to be strong and basic similarities. Several 
terms are already used in most or all countries and have largely the same meaning. 
That different approaches towards causality assessment are a world-wide phenomenon, 
is illustrated by the situations in the three non-EC countries studied (table 2). Australia 
has four categories with well described meanings. Characteristic of the Australian 
approach is that 'previous knowledge' is excluded as an argument with regard to a caus-
al relationship. In Sweden only two categories are used ('probable or possible' or 'not 
assessable or remote'), whereas in Canada a causality assessment of the case report is not 
routinely made. 
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A rapid change towards one single imputation system for all EC countries may never-
theless not be easy to achieve. In some countries (e.g. France, Germany) the existing 
procedure has a formal or legal basis, whereas in others the scientific committees may 
not be happy to change established procedures. Some differences may reflect different 
opinions and traditions in medicine or legislation. 
2.1.4 Causality classification and drug regulation in the European Community 
A sophisticated set of six or more causality terms may in many respects be a useful in-
strument, e.g. for data processing, stuctured signal generation and easy retrieval of rele-
vant case reports. An important aim of European drug regulation is the harmonization 
of drug policies in member countries to achieve similar decisions with regard to drug 
registration, data sheet texts and withdrawal. For the purpose of drug regulatory deci-
sion-making, a small number of only two or three categories, differentiation between 
'strong' and 'weak' cases, may well be enough. The first category provides information 
with regard to the nature of the reaction and the evidence of causality; the latter may 
be indicative of the extent of the problem and the urgency with wich measures should 
be taken. 
In this context two determinants are especially important: 
1. The documentation of a case report, i.e. the completeness and the quality of data 
available. 
2. The evidence (the amount of proof) in the available data with regard to the likeli-
hood of a causal role of the drug. 
In the existing imputation systems, three major causality categories can be recognized, 
which cover the vast majority of the various national terms and enable the exchange, 
compilation and comparison of the data collected in different countries, as needed for 
regulatory decision-making. These categories can be characterized as follows: 
Category A. Reports including good reasons and sufficient documentation to assume 
a causal relationship, in the sense of plausible, conceivable, likely, but not 
necessarily highly probable. 
Category B. Reports containing sufficient information to accept the possibility of a 
causal relationship, in the sense of not impossible and not unlikely, al-
though the connection is uncertain and may be even doubtful, e.g. 
because of missing data, insufficient evidence or the possibility of an-
other explanation. 
Category O. Reports where causality is, for one or another reason, not assessable, e.g. 
because of missing or conflicting data. 
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A number of other, numerically minor, causality terms are used in several countries. 
These can in most instances be easily allocated to one of these three (А, В or O) cate­
gories, without disturbing the integrity of the national system. 
Whenever these general descriptions would not be enough, one can always trace the 
original term used at the national level and its specific meaning. So long as the catego­
ry 'certain' is not in use in two large countries (Germany and UK), it will not be sensi­
ble to use it in the European system. 'Certain' reports from other countries may be 
included in category in A. Categories 'unlikely', 'deleted' and 'excluded' may be needed 
for national administration and may perhaps have some value with regard to signal 
generation, but are unlikely to play a role in international decision-making and are not 
needed for routine international data exchange in drug regulation. 
When the suspicion arises that a drug may be associated with a serious reaction, the first 
question is if the drug really can cause the reaction. Often the bulk of the evidence cau­
sally implicating the drug is produced by the A category reports. The second important 
question in risk management is how frequently the reaction occurs. When exact epide­
miologic data arc not available, as often is the case, the total number of А, В and О 
reports together gives an impression of the magnitude or social relevance of the pro­
blem. When a signal consists, for example, of 15 A-reports, 40 B-reports and 90 O-
reports, the preliminary conclusion can be made that the causal relationship is proba­
bly true, that the reaction occurs with a significant frequency, but that in many cases 
the evidence or documentation is limited and that further quantitative study is needed. 
In Denmark, Greece, The Netherlands, Portugal and Spain the national terms can al­
ready directly (and automatically) be converted into the categories А, В and O, almost 
without interfering with existing procedures. In each of the remaining countries 
(Belgium, France and Luxembourg, Germany, Ireland, Italy and UK) there is one 
national causality term which may, depending upon the content of the case reports 
concerned, be allocated to more than one (adjacent) of these new categories. In most 
cases this will be a simple decision (a choice between either 'unclassified and possible' 
or 'possible and probable', according to the descriptions of the EC terms). 
Alternatively, one may simply decide to select the term with the lowest probability 
value; this will enable automatical conversion of the causality terms, without falsely 
introducing more 'evidence' than is available in the original reports. When two or more 
drugs are simultaneously suspected, the role of each drug individually often remains 
inconclusive. Such reports will usually fit in the В category. A proposal of the 
Pharmacovigilance Working Party, to use three basic causality categories as a step 
towards harmonization in the Community, has recently been adopted by the 
Committee for Proprietary Medicinal Products.'22' The conversion of national terms 
into А, В and О categories is shown in table 3. 
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Table 3 — Review of causality terms used at National PharmacovigiUnce Centres in the 
European Community and the corresponding categories as described by the European 
Pharmacovigilance Working Party22 
Belgium 
- Certain 
- Probable 
- Possible 
— Unclassified 
- Unclassifiable 
A 
A 
В (or A*) 
0 
0 
(Unlikely and deleted excluded**) 
Denmark 
- Definite 
- Probable 
— Possible 
- Unclassified 
(Unlikely excluded**) 
France and I uxembourg 
- Very likely 14 
- likely 13 
- Plausible 12 
— Possible/dubious 11 
Unlikely (appears 
excluded, 10) excluded** 
Germany 
— Possible 
— Not evaluated 
- Unclassibiable 
(Unlikely excluded") 
Greece 
- Certain 
- Probable 
— Possible 
- Unclassified 
(Not possible or unlikely, 
and Unlikely excluded**) 
A 
A 
В 
0 
A 
A 
В 
0(or 
B(oi 
0 
0 
A 
A 
В 
0 
в-) 
:A*) 
Ireland 
— Certain 
- Probable 
- Possible 
— Unclassified 
- Unclassifiable 
(Unlikely excluded**) 
Italy 
- Certain 
- Probable 
- Possible 
(Doubtful excluded**) 
The NetherUnds 
— Certain 
- Probable 
- Possible 
— Unclassified 
Unclassifiable 
(Unlikely excluded") 
Portugal 
— Probable 
— Possible 
— Unclassified 
(Unlikely esclu 
Spain 
- Definite 
— Probable 
- Possible 
- С onditional 
ided") 
(Improbable excluded**) 
United Kingdom 
— Probable 
— Poswsible 
— Insuffiecient information 
- Unassessable 
(Unlikely excluded**) 
A 
A 
В (or A') 
0 
0 
A 
A 
В (or O*) 
A 
A 
В 
0 
0 
A 
В 
0 
A 
A 
В 
0 
A 
В (or A*) 
0 
0 
* In these cases the National Centre mav automatically select the 'lowest causality term, or may choose (on a 
case-by-ca.se basis) one of the rwo indicated categories 
** 'Unlikely' reports will be retained in the files of National Centres 
Categories in European causality classification 
A Reports including good reasons and sufficient documentation to assume a causal relationship, in the sense of 
plausible, conceivable, likely, but not necessarily highlj probable 
В Reports containing sufficient information to accept the possibility of a causal relationship, in the sense of not 
impossible and not unlikely, although the connection is uncertain and may be even doubtful, e g because of 
missing data, insufficient evidence or the possibility of another explanation 
О Reports where causality, is for one or another reason, not assessable, e g because of missing or conflicting data 
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2.1.5 Towards world wide consensus 
Pharmacovigilance and drug regulation are no longer a national but a world-wide in­
terest. Collaboration between governmental pharmacovigilance centres and with phar­
maceutical companies is increasing. Further standarization and harmonization of ter­
minologies, definitions and procedures are needed. For a decade the WHO 
Collaborating Centre for International Drug Monitoring has used six different terms 
for causality classification. Recently a set of definitions has been proposed to delineate 
the meaning of these terms.[25' These definitions are listed in table 4. It is envisaged that 
these terms and definitions — or perhaps modifications which may be deemed necessa­
ry when more experience with their use has been obtained — will be adopted in inter­
national pharmacovigilance. Six causality categories may be helpful in various respects, 
e.g. for early signal generation and selecting relevant reports for further study. This does 
not necessarily mean, however, that more than three categories as described above are 
needed for regulatory decision-making. 
Table 4 — Definitions of causality categories as recently proposed by the WHO 
Collaborating Centre for International Drug Monitoring' 
Certain 
A clinical event, including laboratory test abnormality, occurring in a plausible time relationship t^ o drug admini­
stration, and which cannot be explained by concurrent disease or other drugs or chemicals The response to with­
drawal of the drug (dechallenge) should be clinicall) plausible 1 he event must be definitive pharmacologically or 
phenomenologicallv, using a satisfactory rechallengc procedure if necessary 
Probable/Likely 
A clinical event, including laboratorytest abnormality, with a reasonable time sequence to administration of the 
drug, unlikely ю be attributed to concurrent disease or other drugs or chemicals, and which follows an clinically 
reasonable response on withdrawal (dechallenge) Rechallenge information is not required to fulfil this definition. 
Possible 
A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the 
drug, but which could also be explained by concurrent disease of other drugs or chemicals Information on drug 
withdrawal may be lacking or unclear 
Unlikely 
A clinical event, including laboratory test abnormality, with a temporal relationship to drug administration which 
makes a causal relationship improbable and in which other drugs, chemicals or underlying disease provide plausi­
ble explanations 
Conditional/Unclassified 
A clinical event, including laborator}' test abnormality, reported as an adverse reaction, about which more data is 
essential for a proper assessment or the additional data are under examination 
Unassessible/Undassifiable 
A report suggesting an adverse reaction which cannot be |udged because information is unsufficient or contradic­
tory, and which cannot be supplemented or verified 
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SUMMARY 
As with any other study method, spontaneous reporting' in pharmacovigilance is a process of 
data acquisition, assessment, presentation and interpretation. The provision of information 
(i.e. of interpreted data) concerning previously unknown, or otherwise important adverse 
drug reactions is a major goal. The assessment of case reports in spontaneous reporting takes 
pUce in 2 steps: first the assessment of each case individually, and secondly the interpretation 
of the aggregated data. The Utter step is only completed for a minority of case reports, such 
as when actions or measures are deemed necessary. 
Uncertainty in case reports regarding the involvement of the suspected drugs is an inherent 
drawback of spontaneous reporting. Standardised case-causality assessment has become a 
routine at pharmacovigiUnce centres around the world. It aims at a decrease in ambiguity 
of the data andpUys a role in data exchange and the prevention of erroneous conclusions. A 
variety of systems for standardised causality assessment have been developed, ranging from 
short questionnaires to comprehensive algorithms. Since none of the avaibble assessment sys-
tems has been validated (i.e. shown to consistently and reproducibly produce a fair approxi-
mation of the truth), causality assessment has only limited scientific value. Causality assess-
ment neither eliminates nor quantifies uncertainty but, at best, categorises it in a 
semiquantitative way. 
Routine causality assessment is usually part of the first step in case assessment, and is based 
on a general system that is intended for all reactions and all drugs. During the subsequent 
phase of aggregated assessment, causality assessment is likely to be repeated and the use of a 
specific aetiological-diagnostic system may be more appropriate. It may be recommended to 
restrict case-causality assessment to selected case reports that are likely to pUy an active role 
in pharmacovigiUnce and to use specific systems, adapted to the reaction or problem invol-
ved. It is an inherent limitation of spontaneous reporting that, with the exception of rare 
proof-positive case reports, conclusive evidence cannot usually be produced. Standardised 
causality assessment has not really changed this situation. 
As a rule, confirmation of the connection between a drug and an adverse reaction requires 
further analytical or experimental study. 
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All hail the imputologist... it runs 
So critical, so clever 
Who calcuhtes that 2 times 2 
Makes nothing whatsoever 
MNG Dukes, 1988 
2.2.1 Introduction 
Often, there is some uncertainty in a medical diagnosis. This is especially true in 
patients with diseases that are suspected to be drug-induced. Such diseases often resem-
ble disorders with other causes (e.g. viral infections) and there are usually no diagnos-
tic markers or laboratory tests demonstrating the role of the drug. Spontaneous repor-
ting (which, in many countries, is the national system for reporting of suspected 
adverse reactions to drugs) is currently the backbone of pharmacovigilance.'1' It is not 
a perfect method, however, and uncertainty with regard to the causal involvement of 
the drugs, together with underreporting, are major drawbacks. 
There are 2 different questions concerning causality in pharmacovigilance. First, is it 
possible that the drug can cause the adverse reaction? Second, has the drug actually 
caused the event (in a given patient)? These questions may be interdependent. The 
answer to the second question may be influenced by that to the first. If the first 
question remains inconclusive, as often is the case, it cannot usually be solved by the 
answers to the second question. 
The first question requires aggregated assessment of all available data from different 
sources and has been reviewed elsewhere.'21 The second question - the one involved in 
case-causality assessment or, more appropriately, drug-relationship assessment or impu-
tation'·1' - refers to the structured and standardised assessment, in individual patients or 
case reports of patients, of the likelihood of a causal relationship between suspected 
drugs and adverse medical events. Such judgements are based on knowledge and expe-
rience, and even among experts there is frequent disagreement.'4' 
In many countries, pharmacovigilance is part of governmental drug regulation. Drug 
regulation takes place at the meeting point of medical practice, science, ethics, market-
ing, and legislation. In legal decisions regarding changes in a marketing authorisation, 
facts may be more appropriate than suspicions. It is understandable that the uncertain 
nature of case reports may confuse the dialogue between regulators and pharmaceuti-
cal companies. 
In the early 1980s, in an attempt to reduce ambiguity in the evaluation of adverse drug 
reactions, a variety of standardised causality assessment systems were introduced at 
pharmacovigilance centres in many countries around the world.'1,5' In several coun-
tries, it has become mandatory for pharmaceutical companies to assess case causality in 
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case reports of adverse reactions to their own drugs. These developments may have con-
tributed to the general belief that such systems can establish or measure causality in 
individual patients and case reports, and solve the problems relating to uncertainty. In 
this article, wc review the usefulness of case-causality assessment and its future role in 
the vigilance of approved medicines. 
2.2.2 The Discovery of Adverse Drug Reactions 
The discovery of hitherto unknown adverse drug reactions, a main objective of phar-
macovigilance, often takes place only after the drug is marketed. '6' The process of sig-
nal detection, and the nature and sources of the data, have been reviewed in previous 
papers.12,7' The course of events leading to discovery frequently follows the shape of an 
S curve (see fig. 1), with 3 major phases: a latent period, during which (sooner or later) 
the first suspicion arises (signal generation), followed by the often sudden accumula-
tion of data (signal strengthening), and finally a (usually lengthy) phase of evaluation, 
during which the reaction is confirmed, explained and quantified (signal testing or fol-
low-up). 
Crucial in pharmacovigilance is the steep middle part of the curve, during which a 
weak hypothesis develops into a strong suspicion (signal). At the end of the phase of 
signal strengthening, a preliminary assessment of the data will be made, for example, 
for the preparation of a regulatory measure (amendment of data sheet or restrictive 
action) or a publication. 
Many 'known' adverse reactions, such as those included in Summaries of Product 
Characteristics (SPC) and textbooks, are still somewhere in the third phase. Knowledge 
generalion strengthening lollow-up 
Fig 1 — The discovery of an adverse drug effect 
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is often still incomplete, for example regarding frequency, mechanism and risk factors. 
The reactions are legally accepted, but are, nevertheless, still awaiting full scientific 
evaluation and proof. 
A characteristic problem in pharmacovigilance is that science and policy may not devel-
op at the same pace. Often, regulatory decisions must be made while the scientific ver-
dict is still pending. In such situations, the uncertainty in case reports may be a cause 
of confusion and an obstacle to legal measures, measures that may inflict permanent 
damage to the commercial value of the drug. The appropriate way of obtaining the 
necessary scientific proof is through further analytical or, if possible, experimental stud-
ies, and may take considerable time and money. 
2.2.3 The Assessment of Case Reports 
Spontaneous reporting is concerned with a great variety of different drugs and types of 
adverse reactions.'7'8' Case reports may be assessed for different purposes and in dif-
ferent ways. Major uses of the data are signal detection, drug regulation, and the 
distribution of information to healthcare professionals. 
In general, assessment takes place in 2 steps, which are: (i) the case-by-case assessment 
of individual reports, and (ii) aggregated assessment and interpretation of the data 
(table 1). The first step usually takes place on arrival of the report. The primary issue is 
the possible relevance of the observation: is the reaction unknown ('unlabelled'), 
serious, or otherwise of interest (e.g. in scientific or educational respects)? Next comes 
assessment of the quality of documentation of the observation, coding of drug and 
event, and causality. The second step is the aggregated assessment of all available data.'2' 
Obviously, case assessment is concerned with more than causality only. The assessment 
criteria mentioned in table I are not entirely independent; the details of one criterion 
may affect the assessment of the others. The quality of documentation, for example, 
determines whether a reasonable causality assessment can be made or not. Case reports 
are often concise and lacking in details. Follow-up may be needed to obtain missing 
data and new information, for instance, with regard to outcome, laboratory findings or 
underlying diseases. Case reports are spontaneously, and in many countries, voluntari-
ly submitted by healthcare practitioners, and there are limitations to the collection of 
additional information. Requests for follow-up information must be as limited in 
quantity and as easy to comply with as possible.1'3l Inevitably, there may be some dis-
crepancy between the data that are: (i) needed in practical medicine (and available in 
the report); (ii) scientifically relevant; and (iii) legally desirable or required. As long as 
pharmacovigilance has to rely on spontaneous case reports, it must be accepted that we 
will have to act on data that are not perfect and may even be incomplete. 
Aggregated assessment of the data usually takes place at the end of the phase of signal 
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strengthening (fig. 1 and table 1) and takes into account a number of different consid­
erations, such as quantitative strength of the association, consistency of the data, expo­
sure-response relationship, biological plausibility, pharmacological or pathological 
mechanism, and possible analogies with experience with other drugs.'2' Because of rea­
sons such as the uncertainty in case reports, this assessment usually results in a more or 
less provisional point of view. Only rarely does the presence of one or more proof-posi­
tive reports - for instance, in the case of a convincing recurrence on re-exposure to the 
drug ('positive rechallenge') - produce conclusive evidence with regard to the role of 
the drug. As a rule, spontaneous reporting cannot provide definitive answers. 
Table 1 — Assessment of case reports in pharmacovigiUnce 
I. Individual case assessment 
1. Relevance of the experience - for example: 
unknown adverse reaction3 
seriousnessb 
new drug 
high reporting frequency 
scientific or educational value 
2. Quality of documentation: 
completeness of datac 
verification and follow-up 
3. Coding of case report; with regard to: 
adverse evcntd 
suspected drug0 
4. Case-causality assessment (imputation/ 
II. Aggregated assessment of the data 
The systematic study and interpretation of series of case reports; e.g. for: 
signal detection 
regulatory measures 
publication 
a Not mentioned in the literature and not included in the approved product information ('unlabelled') 
b For example, as proposed by the Council for International Organisations of Medical Sciences " ' 
с For example, co-medication and outcome, according to the new documentation grading of the World Health 
Organization Monitoring Centre in Uppsala, Sweden ' 1 0 ' 
d For example, World Health Organiiation Adverse Reactions Terminology (WHOART) preferred term " " 
e For example, according to the Anatomical-Therapeutic-Chemical Classification n 
f Likelihood of a causal relationship with the drug 
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2.2.4 Methods of Causality Assessment 
2.2.4.1 The Literature 
In the early seventies, Professor Nelson Irey, on the basis of his experiences with the 
Registry of Tissue Reactions to Drugs at the Armed Forces Institute of Pathology 
(Washington, DC, USA), first addressed the principles underlying the attribution of 
diseases to drugs in individual patients. 'H ' Since then, other scientists have proposed a 
variety of methods for structured and standardised causality assessment in individual 
patients or case reports, ranging from simple sets of questions to complex algorithms 
or computerised questionnaires.'·1·1520' These were general methods, intended for all 
drugs and all types of medical event, irrespective of the clinical manifestations, the 
underlying mechanisms, the purpose of the assessment, or whether the reaction would 
be new or established. In these methods, characteristically, the general question of cau-
sation is divided into a number of subquestions. During an international meeting in 
Morges, Switzerland, in 1981, 9 points were concluded to be most important in cau-
sality assessment (table 2).'21· 
Usually, prefixed numerical scores are attached to the answers to the various sub-
questions and these scores result in a cumulative value, which is subsequently transla-
ted into a causality term or category, for instance, 'unlikely', 'possible', 'probable' or 
'certain'. The use of such systems was shown to decrease variations in judgements of 
various experts.'1''22"24' The subquestions approach increases logic and consistency in 
judgement, but also has some disadvantages. Dividing into a series of small sub-
questions does not really simplify the often difficult main question and may not replace 
expert knowledge. Often the subquestions must be answered in absolute terms (e.g. yes 
or no), whereas in the practical situation - especially with short or incomplete case 
Table 2 — The 9 points that were considered to be the most important in causality assess-
ment at the meeting in Morges, Switzerland in 1981'21' 
1. Drug given prior to event? 
2. Reaction at site of application? 
3. Dtug/adverse reaction interval compatible with the event? 
4. Adverse reaction immediately follows drug administration and is of acute onset? 
5. Rechallenge positive? 
6. Dechallenge positive? 
7. Were concomitant drugs stopped at the same time? 
8. Same adverse reaction to this drug before? 
9. Adverse reaction known with the suspected drug? 
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reports - the true answer would often be somewhere in between. Thus, knowledge may 
actually be replaced by pragmatism. 
The feasibility of a method depends upon whether the subquestions match the situ-
ations encountered in practice. For example, in the Karch and Lasagna decision 
table,1'5' 3 important questions are: (i) 'was there an appropriate interval between the 
agent and the event?'; (ii) 'was this a known reaction to the agent?'; and (iii) 'can the 
event be reasonably explained by the patients clinical state or other (nondrug) thera-
pies?'. Occasionally the time interval is very characteristic - for instance, in light of 
pharmacokinetic characteristics or pathological mechanisms - and there is a strong 
argument in favour of a relationship; more often, however, it is fairly indeterminate. 
Whether the interval is or is not 'appropriate' is obviously a somewhat subjective 
judgement. 
In this and many other systems, the fact that a reaction is not known substantially 
decreases the causality score. Such systems may be less appropriate for the purpose of 
signal detection (chapter 1.2). For many of the 'known' (i.e. accepted) adverse reac-
tions, even when listed in data sheets or text books, there is circumstantial evidence, but 
no definite proof. Moreover, with regard to the estimation of the likelihood of an event 
being drug-induced, the frequency of the reaction would be more appropriate than 
how well the reaction is known. Apart from the difficulties in deciding in a case report 
whether the event could be explained by the clinical state or other therapies (question 
3), the word 'reasonably' introduces an element of subjectiveness in the assessment. 
In many cases, regarding these 3 questions, the choice between yes or no may not be 
self-evident. More realistic answers might, for example, be: 'interval possible, but not 
characteristic', 'a few published case reports provide inconclusive evidence that the reac-
tion may occur with this drug', and 'the event may occasionally occur secondary to the 
clinical state of the patient'. The more subtle the answers to the subquestions are, howe-
ver, the less likely is the assessment to reduce the original uncertainty. The larger the 
number of different subquestions in a system, the more comprehensive and individual 
is the assessment,'25' but also the more laborious the task. In an attempt to accommo-
date the obvious heterogeneity of adverse reactions, Venulet and co-workers'25' recog-
nised in their elaborate system 10 different subsections: 
- dose-related 
- dose-unrelated 
- type I allergic 
- at the site of application 
- interaction 
- drug dependence 
- irreversible 
- withdrawal symptoms 
- fetal malformation 
- unclassified. 
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The detailed Yale algorithm'16' may be especially suitable for the diagnosis of drug-
related diseases in hospitalised patients. The data requested (e.g. blood drug concen­
trations) are easily available during hospitalisation, but case reports in pharmacovigi-
lance, for example those submitted by family practitioners, are often limited in length 
and detail (small reporting form). For the study of drug-related hospital admissions, 
Hallas et al.'26' proposed 4 causality categories (definite, probable, possible and unlikely/ 
unevaluable), based on similar criteria as used by Karch and Lasagna (page 97).'15' 
2.2.4.2 Probability Calcubtion 
Probability calculation may use a different approach to causality assessment, for exam­
ple, by using Bayes' theorem.'27,28 In general, Bayes' theorem expresses the relationship 
between the probability of a proposition before (prior) and after (posterior) the acqui­
sition of additional data. In other words: posterior odds = likelihood ratio χ prior 
odds.'29' Within the context of causality assessment, Bayes' theorem represents the rela­
tionship between the probability that a drug caused an event before and after the acqui­
sition of additional determinants (e.g. time relationship, patient characteristics, clinical 
data). The formula is (in odds form): 
Pr (DCE | AC) Pr (AC | DCE) Pr (DCE) 
= χ 
Pr (ОСЕ | AC) Pr (AC | ОСЕ) Pr (ОСЕ) 
in which Pr = probability, AC = additional characteristics, DCE = drug caused event, 
and ОСЕ = other cause event. 
To overcome the complex calculations involved, a computerised system - the Bayesian 
Adverse Reactions Diagnostic Instrument (BARDI - has been developed.'30' However, 
Bayes' theorem may not be the most appropriate model in causality assessment.''"' The 
prior probability that the drug caused the event (without knowledge of additional char­
acteristics) is not likely to be constant in different populations and settings, and varia­
bles used to calculate the likelihood ratio may not be independent. Moreover, data nee­
ded to calculate the likelihood ratio (such as the effects of gender, age, laboratory 
values, concomitant disease or rechallenge) are often not available. Therefore, the cal­
culations may result in quasi-accurate probabilities. Other statistical techniques using 
multivariate logistic regression analysis, as used in diagnostic reasoning,'31' may prove 
to be more appropriate. 
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2.2.4.3 Aetiological-Diagnostic Systems 
A major problem in causality assessment is the enormous diversity of adverse reactions 
and the limited possibilities for adjustment of the causality assessment systems for 
general use.'12'"' In this light, the original concept of one general method for the stan-
dardised assessment of all possible adverse drug reactions may not have been ideal. 
Bénichou's group1'141 designed a series of aetiological-diagnostic schemes that are espe-
cially adapted to specific and defined disorders known to be relatively frequently in-
duced by drugs. In these schemes, the requirements needed for a proper diagnosis are 
first identified. With the help of consensus meetings, comprehensive but practical 
assessment schemes were constructed, on the basis of: 
- disease definition (including the various forms of the disease) 
- clinical appearance and pathology 
- signs of severity 
- aetiology (various possible causes) and diagnosis 
- evidence implicating a drug 
- chronological criteria 
- management. 
Such comprehensive assessment schemes have, for example, been developed for liver 
injury, granulocytopenia, thrombocytopenia, haemolytic anaemia, aplastic anaemia, 
vascular purpura, photosensitivity reactions, acute renal failure and interstitial lung dis-
ease. P4' For some, but not all of these reactions, the likelihood of a relationship is 
expressed in a semiquantitative way, using 5 different categories (incompatible, incon-
clusive, compatible, suggestive or very suggestive). Another example of a specially 
designed approach for specific situations are the causality criteria that have been devel-
oped for adverse events occurring after vaccination.','i' 
Such special schemes enable a structured and well-founded case assessment in the per-
spective of the aetiological diagnosis, but do not result in a quantitative estimation of 
the likelihood of a relationship, and only rarely provide certainty. These schemes may 
contribute to, but not replace, aggregated assessment of the data. For many adverse 
reactions, no such systems are available. 
2.2.2.4 National Pharmacovigihnce Centres 
Since 1980, routine case-causality assessment systems have been introduced at nation-
al pharmacovigilance centres around the world.'1·51 As a rule, they are systems for gener-
al use, developed at each individual centre and often somewhat different to those ori-
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ginally described in the literature; however, there is no evidence that the national sys-
tems give better results. These systems vary from simple questionnaires to well struc-
tured assessment schemes.'5,36; The number of causality terms used in the European 
Union (EU) varies between 4 and 7 in the various member countries. 
The German system has only 1 positive category ('possible'), 1 negative ('unlikely') and 
2 indeterminate ('not evaluated' and 'unclassified'). There is no special algorithm for 
allocating these terms. The most sophisticated of national systems is that developed in 
France'3' It combines the evidence for causation from 3 different points of view: time 
relationship, differential diagnosis (these 2 forming the 'intrinsic imputation') and lite-
rature knowledge ('extrinsic imputation). It is worth mentioning that the system used 
for many years in The Netherlands was based on integrated assessment of causality and 
data documentation quality.137' It is noteworthy that in the UK routine causality assess-
ment has been abandoned.'16' 
Despite various différences, the national systems are generally based on:'5' (i) the time 
association between drug use and the start and course of the adverse event ('challenge, 
dechallenge and rechallenge') - sometimes the location association also is relevant, as 
in contact dermatitis; (ii) pharmacology (established knowledge of actions, kinetics, 
metabolites, and adverse effects); (iii) characteristic diagnostic features and combina-
tions (clinical, laboratory); (iv) likelihood or exclusion of other explanations. The tem-
poral association is often the reason for suspecting the drug and reporting the case in 
the first place. In many cases, the major factor is that the event occurred after starting 
the drug, merely indicating that a relationship is possible, or not impossible. Moreover, 
the other 3 criteria are often complex or ambiguous, and their assessment requires a 
thorough knowledge of clinical medicine, pharmacology and epidemiology. 
2.2.4.5 The European ABO System 
As a step towards harmonisation, the European Union Pharmacovigilancc Working 
Party has developed a system using 3 basic causality categories - named А, В and О -
to which the various national causality categories can be allocated (see table 3).'5' 
A category 'certain' could not be included, since it is not in use in several of the nation­
al systems. Neither was a category 'unlikely' included, because such reports are usually 
of little value in postmarketing regulatory decision-making. The ABO categories 
enable the cumulative presentation of case reports from all EU countries in an easy, 
automated and meaningful way, without the need to reassess the reports or to change 
existing national procedures. The categories combine causality with documentation 
quality. The distribution of report categories in a series of case reports gives an impres­
sion of the evidence contained in the data and of the possible extent of the problem. 
The ABO system is specifically intended for the purpose of drug regulation. 
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Table 3 — European Union ABO system causality categories 
Category Definition 
A Reports including good reasons and sufficient documentation to assume a 
causal relationship, in the sense of plausible, conceivable, likely, but not 
necessarily highly probable 
В Reports containing sufficient information to accept the possibility of a 
causal relationship, in the sense of not 
impossible and not unlikely, although the connection is uncertain and may 
be even doubtful, e.g. because of missing data, insufficient evidence or the 
possibility of another explanation 
О Reports where causality is, for one or another reason, not assessable, e.g. 
because of missing or conflicting data 
The original reports and classifications remain unaltered in the national files and can, 
whenever needed, be easily identified and retrieved at the national level. 
2.2.4.6 The United States 
The key factor in regulations pertaining to pharmacovigilance at the US Food and 
Drug Administration is that it is mandatory for pharmaceutical companies to report 
whenever there is a reasonable possibility that a drug caused an adverse experience. 
There is no official guideline or algorithm, however, for determining what is a 'reason­
able possibility'. In the approach proposed by Johnson,' 1 8 ' the 2 questions in pharma­
covigilance related to causality - whether the drug can or has caused the event - are 
combined (table 4). 
Table 4 — Causality assessment criteria in the US1^ 
Temporal relationship 
Similar problem with the same drug 
Similar problem with a related drug 
Confounding by drug 
Confounding by disease 
Clinical plausibility 
Dechallenge/rechallenge 
Quality of reports - need follow-up 
Discuss with clinical experts 
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2.2.4.7 WHO Causality Categories 
Pharmacovigilance is of global interest and, after consultation with all participating 
countries, the Uppsala Monitoring Centre of the World Health Organization has estab-
lished 6 defined causality categories.'39' As can be seen in a point-wise review of these 
categories in table 5, this approach is based on a combination of criteria regarding caus-
ality and documentation quality (including the availability of data). 
These WHO categories have only recently been introduced, and are mainly used in 
countries that have recently joined the international programme. 
2.2.5 Limitations 
Although the use of general standardised causality assessment systems decreases varia-
tions in judgement, varying degrees of interobserver disagreement continue to occur 
and different systems may produce different results.[24,32'33·4050' A decrease in interob-
server variation does not necessarily mean that the assessment is more accurate. It may 
possibly reflect, for example, that many observers made the same error. In a recent 
study,'49' using the attractive and well-known method of Naranjo et al.,'17' 2 experi-
enced assessors showed full agreement in only 35% of 106 case reports. Apparently, the 
power of the system to discriminate between adjacent categories such as 'possible' and 
'probable' is limited. 
None of the available causality assessment systems has been validated - in this context, 
validation refers to the action of proving that a procedure actually leads to the expec-
ted results.'51' As has been pointed out by Hutchinson and Lane,'24' the basic problem 
here is that the testing of an assessment system cannot succeed, since for most adverse 
reactions, no true 'gold standard' exists. 
Standardised causality assessment systems usually result in a reaction being placed in 
one or another causality term or category. They give an explicit outcome (e.g. 'not rela-
ted' or 'certain') in only a minority of cases, do not quantitatively measure the likeli-
hood of a relationship, and cannot usually separate valid from invalid reports. In other 
words, uncertainty is not reduced, but categorised (at best, in a semiquantitative way). 
The vast majority of case reports in pharmacovigilance are either 'probable', 'possible', 
'doubtful' or 'unclassified'. However, the meaning of such categories is often not sharp-
ly delineated and overlap may occur, leaving ample space for different views and per-
sonal preferences.'40' The reason for performing a causality assessment (e.g. patient 
care, science, judicial) may to some extent influence the answers to the subquestions 
and the assessment outcome. Also, reaction-specific aetiological-diagnostic systems 
(page 86) result in a causality category, or only rationalise the diagnosis, without pro-
viding a causality classification. Further evaluation of the workability and usefulness of 
these systems is needed. 
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Table 5 — WHO causality categories. All points in a category should be (reasonably) com-
plied with 
1. Certain 
Event or laboratory test abnormality, with plausible temporal relationship to drug intake 
Cannot be explained by disease or other drugs - response to withdrawal clinically plau-
sible (e.g. in terms of pharmacokinetics, and pathological pharmacological mecha-
nisms) 
Event definitive pharmacologically or phenomenologically (to distinguish it from 
vague events in many case reports) 
Rechallenge (if necessary) 
2. Probable 
Event or laboratory test abnormality, with reasonable temporal relationship to drug 
intake 
Unlikely to be attributed to disease or other drugs 
Response to withdrawal clinically reasonable 
Rechallenge not necessary 
3. Possible 
Event or laboratory test abnormality, with reasonable temporal relationship to drug 
intake 
Could also be explained by disease or other drugs 
Information on drug withdrawal lacking or unclear 
4. Unlikely 
Event or laboratory test abnormality, with a time to drug intake that makes a rela-
tionship improbable (but not impossible) 
Diseases or other drugs provide plausible explanations 
5. Conditional/unclassified 
Event or laboratory test abnormality 
More data for proper assessment needed 
Or additional data under examination 
6. Unassessable/unclassifiable 
A report suggesting an adverse reaction 
Cannot be judged because of insufficient or contradictory information 
Report cannot be supplemented or verified 
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Table 6 — Uses and limitations of causality assessment 
What it can do 
Decrease disagreement between assessors 
Classify uncertainty (semiquantitative) 
Mark individual case reports 
Improve the scientific basis or assessment (education) 
What it cannot do 
Give an accurate quantitative measurement of the likelihood of a relationship 
Distinguish valid from invalid cases 
Prove the connection between a drug and an event 
Quantify the contribution of a drug to the development of an adverse event 
Change uncertainty into certainty 
Case-causality assessment is provisional. When knowledge increases, the meaning of an 
apparently unusual or unexpected finding in a case report may change, and a negative 
argument may become a positive argument.'32' The original idea of one general system 
for standardised assessment of all adverse reactions and all drugs, is crossed by the pro-
found heterogeneity of adverse reactions, in clinical and mechanistic respects. Whereas 
the scores corresponding to the various answers to the subquestions are fixed, the 
impact of a given subquestion may vary profoundly for different adverse reactions. In 
the case of deafness with erythromycin, for example, a 'positive dechallenge' (prompt 
recovery after stopping) is an argument in favour of causation, but for gentamicin the 
same finding would argue against a connection, since the damage is known to be per-
manent. 
Probability calculation as a tool for (computerised) causality assessment is as yet in an 
experimental stage,'52' and its future role in pharmacovigilance is still uncertain. The 
uses and limitations of standardised causality assessment are summarised in tabic 6. 
2.2.6 A Positive Rechallenge 
A rechallenge, in the true sense of the word, is a planned prospective re-exposure expe-
riment. In the case of a subjective event, several blinded rechallenges may be needed to 
achieve a convincing result. For serious adverse effects, a rechallenge is rarely ethically 
acceptable. 
A well-documented positive rechallenge, intentional or incidental, may irrefutably 
prove the connection between a drug and an adverse reaction. Since certainty is noto-
riously rare in pharmacovigilance, such proof-positive observations (of previously un-
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known as well as of established adverse reactions) have great scientific value and their 
reporting is of utmost importance. In a rechallengc experiment, on the other hand, the 
conditions are often somewhat different from the original episode (e.g. a lower dosage 
or shorter duration of use). Likewise, a negative rechallenge may not necessarily exclude 
a relationship. In spontaneous reporting, a 'positive rechallengc' may refer to a variety 
of situations, ranging from a dubious similar episode in the past to a true prospective 
rechallenge; undoubtedly, the latter is a rare thing. The evidence from these various 
observations may differ considerably and is often difficult to specify in causality-assess-
ment systems. 
2.2.7 The Use of Causality Assessment in Pharmacovigilance 
In the aftermath of the thalidomide tragedy, spontaneous reporting was introduced as 
an early warning system for possible future drug-induced disasters. In an attempt to 
achieve maximal sensitivity, physicians were requested to report, in confidence, their 
earliest suspicions, however uncertain or incomplete. Important reports were envisaged 
to arrive among a stream of reports of less value. Important cases would be identified 
by a team of experts or a special adverse reactions committee. The accompanying 
stream of doubtful or irrelevant reports would remain silent in the confidential files; 
their uncertainty was not a problem. 
Nowadays spontaneous reporting is at the same time a scientific method, an instru-
ment of drug regulation, and a source of information for health professionals, scientists 
and (hesitantly but increasingly) for patients and consumer organisations. 
A spontaneous reporting database is influenced by bias and underreporting, and con-
tains a mixture of signals in various phases of development, probably true and proba-
bly false associations, and random associations that may have no meaning whatsoever. 
Heterogeneity and uncertainty of the data and the absence of appropriate consumption 
data may further complicate interpretation. Case-causality assessment is an attempt to 
decrease ambiguity of the data and to stimulate a sensible use of spontaneous reporting. 
In the remainder of this section, we discuss the role of causality assessment in the light 
of a number of important aspects of pharmacovigilance: signal detection, regulatory 
measures, scientific publications, communication routines and patient care. 
2.2.7.1 Signal Detection 
In spontaneous reporting, both new and established adverse reactions are reported. For 
hypothesis generation, the first assessment criterion of incoming reports is whether the 
adverse reaction is unknown or not. A signal usually consists of a series of case reports 
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of varying quality and likelihood. Often there is a core minority of well-documented 
'index cases' supported by a larger number of reports of lower quality ('feasible 
cases').'53' 
In causality assessment, knowledge concerning the adverse reaction - its characteristic 
features and mechanism - constitutes a major argument. For new adverse reactions, 
however, such knowledge is not yet available or still limited. Therefore, the assessment 
of causality is, in the case of a new and unexpected reaction, even more difficult and 
the assessment outcome likely to be lower, compared with known reactions. 
In many methods of causality assessment,'5' including those of Karch and Lasagna,'15' 
and Kramer et al.,"6' the fact that a reaction is unknown automatically decreases the 
score. As a result, cases with a low causality score may nevertheless be of special interest 
in early signal generation. In some countries (for example, Australia and France), on 
the other hand, national centres have deliberately excluded this question from their 
causality system;'3,5' with regard to signal detection, these systems would be preferable. 
Case reports of potentially important new adverse reactions may or may not receive a 
low causality score, depending on a variety of circumstances. In this phase in particu-
lar, individual causality scores may have little effect on the aggregated (but prelimina-
ry) evidence. In the one situation, a number of 5 or 10 'possible' case reports may con-
stitute a probable signal, whereas in the other situation, the connection may be 
unlikely, depending on factors such as time relationship, characteristics and backg-
round frequency. When evidence increases and the signal strengthens (see fig. 1), at 
some point, a position must be taken (e.g. for the preparation of a data sheet amend-
ment or of a publication). In this phase, aggregated assessment of all available data is 
needed, as is explained in section 2. 
As part of this, an aetiological-diagnostic assessment of the case reports may be made, 
using a system that is specific for the adverse reaction and, if possible, results in a cau-
sality estimation (page 86). If such a system is not available in the literature, it could be 
designed for the occasion. The assessment results may differ from, and are likely to 
overrule, those of the previous routine causality assessment using a general system. 
It is characteristic of spontaneous reporting that despite these efforts, there is usually 
no proof in this phase that the drug can cause the reaction, unless there are one or more 
proof-positive cases, for example, with a convincing relapse on re-exposure to the drug 
(positive rechallenge). As a rule, the final answer has to come from further analytical 
studies. 
2.2.7.2 ReguhtoryMeasures 
Once an adverse reaction is detected, appropriate measures will be taken. It is often suf-
ficient to include the reaction in the SPC and the package insert, if necessary with addi-
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tional warnings or changes to the recommendations for use. In more serious cases, re­
strictions of the indications for use may be needed or, in extreme situations, a with­
drawal of the marketing authorisation may be considered. Regulatory decision-making 
is a legal procedure, based on scientific findings. In this process, the uncertainty of case 
reports may be a cause of confusion or disagreement. 
In the weighing of the importance of an adverse reaction, both seriousness and fre­
quency count. Precise quantitative data, however, are often not available. Spontaneous 
reporting cannot usually measure the frequency of adverse reactions, because of factors 
such as underreporting and uncertainty of causation. A wcll-dcvelopcd system may 
nevertheless often give a reasonable impression as regards frequency. In the public 
health interest, the benefit of the doubt is obviously on the side of the patients. For 
companies and regulators, however, the issue may be more complex. Decisions have to 
be made within the framework and limitations of legislation pertaining to pharmaceu­
tical products, its specific function in regulating economically important products. In 
case of doubt, the burden of proof may rest with the regulating authority. 
The limitations of case-causality assessment systems, as reviewed in section 4, are espe­
cially noticeable in drug regulation. It may make a great difference to the position of 
the drug if a majority of the case reports involved could be laid aside as doubtful or unli­
kely. In their original paper, Kramer et al.'16' stated that incidence figures of adverse 
reactions should be restricted to cases qualifying as 'definite' or 'probable'. It is doubt­
ful, however, that in drug regulation, these reports may (as a rule) be disregarded. The 
exclusion of'possible' and 'unclassifiable' case reports is likely to underestimate the size 
of a problem. In many systems, the difference between the adjacent categories 'possi­
ble' and 'probable' is often not sharp; disagreement may occur. Case reports of new 
adverse reactions may qualify as 'possible' only because they are 'unknown' in the first 
place. Also the distinctions between other adjacent categories (such as 'possible', 
'doubtful', 'unclassifiable' or 'unlikely') may be fairly unclear. With only 2.8% of clas­
sified case reports in the database of the Uppsala Monitoring Centre, cases that quali­
fy as 'unlikely' appear to be rare in pharmacovigilance. 
In many countries, for example, the US and those of the EU, it is mandatory for phar­
maceutical companies to attach a causality assessment to case reports, but it is not 
explained how this should be done. For a long time, some countries have used a system 
that is adapted to the situation in that country and seems to be satisfactory (e.g. France 
and Germany). The causality classification developed by the European Union Pharma­
covigilance Working Party is especially intended for drug regulation. It is easy to use, 
and combines documentation quality with causality. In any series of case reports, the 
distribution of type А, В and О cases gives an impression of the amount of evidence 
contained in the data. When a signal consisting of 58 case reports contains, for exa­
mple, 13 type A, 21 type В and 24 type О reports, it would make a much stronger sig­
nal than if there were only 1 type A, 6 type В and 51 type О reports. There is no pu-
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bushed information available, however, regarding large-scale experiences with the 
above systems. 
Besides causality, other assessment aspects may be used in the rationalisation of drug 
regulation. An example are the guidelines for the appropriate use of critical preferred 
adverse reaction terms as developed by the Council for International Organisations of 
Medical Sciences.^ For a number of characteristic adverse reactions (e.g. agranulo-
cytosis, hepatitis, acute renal failure) specific aetiological diagnostic assessment systems 
have been defined (page 86). These may contribute to, but not replace, aggregated 
assessment of the data. For many other adverse reactions, no such systems are available. 
Science and drug regulation often do not keep pace. Decisions must be made, although 
the scientific evaluation is far from finished. Since it is known from the beginning that 
spontaneous reporting usually cannot provide certain and quantitative data, we should 
not try to force it to do so. As in signal detection, the final answers can, as a rule, only 
be provided by further studies. 
2.2.7.3 Data Exchange and Communication 
With regard to signal detection, the principles and procedures have now largely crystal-
lised.-2' In many other respects, spontaneous reporting is still in a phase of develop-
ment. It is increasingly seen as a 'multipurpose' database. Transparency has replaced 
confidentiality in many countries, and data are already distributed, exchanged and 
accumulated in various ways and for various purposes in the phases before conclusions 
are made or measures taken. 
National pharmacovigilance centres exchange data with pharmaceutical companies, 
national centres in other countries, the European Medicines Evaluation Agency, and 
the World Health Organization. In such routines of communication, categorisation of 
causality may be an indicator of the uncertainty contained in individual cases, and may 
play a role in early signal detection. 
When data shortage is the major reason for uncertainty and for classifying a case as only 
'possible' or 'unclassifiable', it may be more accurate (and easier) to categorise docu-
mentation quality as such. In addition to governmental agencies and pharmaceutical 
companies, data users may be scientific institutes, national drug bulletins, formulary 
committees, or consumer organisations and other nongovernmental organisations. 
Opinions based on spontaneous reporting may be influenced by factors such as preju-
dice or lack of expertise. 
The attachment of a causality classification to case reports is one of the possible efforts 
to stimulate the sensible use of the data. Also a proper understanding of the limitations 
of causality assessment and of the relativity of causality categoties is required. Causality 
assessment is provisional, and may be imprecise or even wrong. Already the word 'pos-
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sible' may, for example, cause misunderstanding. At pharmacovigilancc centres, it is a 
fairly low category, bordering on 'unlikely'. Cases that are declared 'possible' by a 
governmental agency, however, may easily become likely ones in the perception of jour-
nalists or action groups. As a piece of evidence in drug regulation, 'unlikely' reports are 
practically worthless. From the point of hypothesis generation, on the other hand, 
'unlikely' cases may sometimes be of special interest. 
In spontaneous reporting, data are submitted for a particular purpose; it is not a ran-
dom database. As a rule, case reports have their value only within the context of a clus-
ter or scries of reports, as pieces in a jigsaw puzzle. With the exception of proof-posi-
tive cases, individual cases have little or no function or value in their own right. 
Spontaneous reporting is still very much under development and new possibilities or 
new needs may change procedures in data utilisation. Likewise, the role of causality 
assessment may change. At this moment, however, the scientific value of routine case-
causality assessment seems small. 
It is a responsibility of pharmacovigilance centres to present balanced information, 
explaining what is known and what is unknown, and to prevent unnecessary misun-
derstandings as far as is possible. This may partly explain the popularity of routine cau-
sality assessment around the wotld, despite its limitations. More general ways of fos-
tering the responsible use of spontaneous reporting data are: (i) ensuring that 
pharmacovigilance centres have sufficient and qualified staff to provide data users with 
appropriate instructions and advice; and (ii) to establish rules for 'good practice' in 
pharmacovigilance, including a data-management code (specifying which data may be 
used, by whom and for what purposes).^" 
2.2.7-4 Science 
In addition to signal detection and risk management, spontaneous reporting can be 
used for predominantly scientific purposes. The national and international systems, for 
example, provide a unique opportunity to collect comparatively large numbers of rare 
adverse reactions. The systematic investigation of a series of (well-documented) case 
reports can increase the knowledge of such reactions (for example, with regard to cli-
nical and pathological characteristics), knowledge that may otherwise be very difficult 
to obtain. Examples of serial studies are liver injury induced by nitrofurantoin'56' or 
ketoconazole,157'181 and nomifensine-induced haemolytic anaemia.1591 
In such studies, standardised causality assessment using appropriate aetiological-dia-
gnostic systems can be helpful, for example, in identifying the features that are most 
likely to be characteristic of the reaction and, in turn, have diagnostic value in future 
patients. In this approach, proof-positive cases, however rare, play an extremely impor-
tant role because they reveal with certainty the microscopic features of the adverse reac-
tion concerned. 
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Case causality assessment may play a role in several other methods that are used in the 
study of approved medicines, such as population studies (e.g. in hospitalised patients), 
case-control surveillance and record linkage. In some studies, however, the study design 
may dictate the use of a general system, such as in a general survey of drug-related mor-
bidity. In a study of drug-related hospital admissions, Hallas et al.'26· developed a strat-
egy for the standardised assessment of adverse drug effects and of doserelated thera-
peutic failure, taking into account causal relationship (4 categories: definite, probable, 
possible and unlikely/unevaluable), significance in relation to the hospital admission (4 
categories: dominant, partly contributing, less important, not contributing) and avoid-
abiliry (4 categories: definitely avoidable, possibly avoidable, unavoidable, not évalu-
able). 
In studies in which causality is a major interest, or that are intended to demonstrate 
causality, it is through the study design itself that the problems relating to uncertainty 
need to be solved (i.e. analytical or experimental studies). 
2.2.7.5 Patient Care 
The assumption that a drug is or was the cause of an illness may have far-reaching con-
sequences for the current or future treatment of the patient. The decision to stop an 
effective drug, or the conclusion that a drug or group of drugs is contraindicated for 
future use, may disadvantage and even endanger patients. 
Structured assessment of the likelihood of a drug relationship and of the many 
questions involved, may obviously improve the individual diagnosis in patients with 
suspected adverse drug reactions. Often an unequivocal test is absent, however, and 
some degree of uncertainty is likely to persist. The validity of the current general assess-
ment methods has not been clearly demonstrated because, in many cases, the diagno-
sis cannot often be made with certainty (page 89). In individual patients, the outcome 
of an assessment algorithm may strengthen a conclusion, but should not replace the cli-
nical diagnosis. False outcomes may confuse a proper diagnosis and not be to the 
advantage of the patient. Since methods that have especially been designed for drug 
regulation or population studies do not take into account the interests of the patients, 
they may be less appropriate in clinical practice. 
2.2.8 Efficiency 
Causality assessment is only a tool, and not a purpose in its own right. Around the 
world, pharmacovigilance centres and pharmaceutical companies are routinely engaged 
in case-causality assessment. 
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Worldwide, the annual number of case reports is steadily increasing. The Uppsala 
Monitoring Centre now receives about 200 000 adverse reaction reports each year.160' 
However, only a minority of case reports will ever factually contribute to pharmacovi-
gilance and become involved in actions such as signal detection, regulatory measures or 
articles in scientific journals. It may be difficult to foresee which reports will play a role 
and which will not. In general, the aims of spontaneous reporting determine whether 
a case report is likely to be important or not. Major criteria, with regard to the relevance 
of a case report, are whether the reaction is unknown ('unlabelled'), serious or other-
wise of scientific interest (section 2). 
Staff numbers at pharmacovigilance centres are limited and their time is precious. Time 
has to be divided over routine data assessment, signal generation, the performance of 
special studies and several other activities. For efficiency reasons, a pharmacovigilance 
centre may concentrate assessment capacity on case reports that are likely to be of in-
terest.'6" Routine administrative requirements should not deter from intensive signal 
follow-up and the production of reports or publications of scientific quality (however 
time-consuming this may be). 
2.2.9 Conclusions 
There is a hierarchy in the assessment of case reports derived from spontaneous report-
ing, in which relevance and quality of data documentation come before case-causality 
assessment. Causality assessment cannot eliminate or quantify uncertainty, but can, at 
best, categorise it in a semiquantitative way. Since none of the available systems has 
been validated (i.e. been shown to consistently and reproducibly reveal a reasonable 
approximation of the truth), general case-causality assessment is of limited scientific 
value. 
In pharmacovigilance, case-causality assessment is routinely used in data exchange, 
international collaboration and the prevention of erroneous conclusions. For these pur-
poses, the causality categories developed by WHO have the advantage of being easy to 
use and internationally accepted. In the years to come, 'good practice' in pharmacovi-
gilance may be expected to foster the appropriate use of spontaneous reporting data in 
a more general way. 
Only a minority of case reports become factually involved in pharmacovigilance 
actions, such as regulatory measures or publications. For efficiency reasons, pharmaco-
vigilance centres may concentrate on the assessment of case reports of potential inter-
est. In such cases, specific aetiological diagnostic assessment systems arc to be preferred. 
It is an inherent limitation that spontaneous reporting often produces only circum-
stantial evidence. As a rule, further analytical or experimental studies are needed to con-
firm causality, measure frequency, identify risk factors and explain mechanisms. 
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Section 3 
Ethics and quality assurance: 
Good Pharmacovigilance Practice 
The procedures and practices described in the previous chapters are all based on obser-
vations in real patients. Pharmacovigilance could not exist without the participation of 
practising physicians, pharmacists, and their patients. A case report is a detailed medi-
cal history and the use of such data is subjected to regulations pertaining to medical 
and pharmaceutical secrecy and privacy protection. For reasons discussed in previous 
chapters, the data obtained from spontaneous reporting may be scientifically ambi-
guous and difficult to interprete. Spontaneous reporting nevertheless plays a central 
role in postmarketing drug regulation, and may be involved in decisions that will have 
profound medical (therapeutic), economic and, possibly, political consequences. There 
is a need for quality assurance in the process of data collection, assessment and use in 
pharmacovigilance. Chapter 3 contains recommendations for Good Practice in phar-
macovigilance. Good Pharmacovigilance Practice aims to ensure that an effective phar-
macovigilance system is in place in a country and that both the public health interest 
and the rights and responsibilities of individuals are guaranteed. 
101 

CHAPTER 3 
Good practice in 
the postmarketing surveillance of medicines 
R.H.B. MEYBOOM 
PHARMACY WORLD SCIENCE 1997;19:186-190 
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SUMMARY 
In addition to Good Clinical Trial Practice for the study of experimental drugs, reguUtions 
are also needed for good practice in the assessment of medicines after approval (Good PMS 
Practice, GPP). GPP has to protect the interests of public health at large as well as those of 
individual patients, investigators and pharmaceutical companies. GPP may be the natural 
way to solve threatening conflicts between privacy legisUtion and the public interest. 
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3.1 Introduction 
It is now generally recognised and accepted that there is a need for Good Clinical Trial 
Practice (GCP), to ensure that clinical drug trials are, in ethical and scientific respects, 
properly conducted.11 2' It has taken decades, however, until general agreement with 
regard to GCP was reached. A clinical trial concerns a medically very delicate situation: 
the use of an experimental treatment, simultaneously aiming at the cure (or diagnosis) 
of a patient and the demonstration of the efficacy and safery ofthat treatment. GCP is 
primarily concerned with the protection of the rights, interests and responsibilities of 
individuals, i.e. patients, investigators, and (often) the pharmaceutical company con-
cerned. Important interests of the patients are the informed consent procedure, justifi-
cation of predictable risks and inconveniences, scientific efficiency (i.e. the potential for 
reaching sound conclusions with the smallest amount of data), and appropriate meas-
ures with regard to treatment, insurance and compensation if a serious untoward effect 
occurs. Ethics committees ensure that trials are conducted according to GCP and to 
the Declaration of Helsinki (World Medical Association, June 1964). When a patient 
has consented to participate in a trial, all (anonymised) data relevant to his treatment 
are assumed to become the property of the investigator or sponsor of the study. The 
development of new medicines and the scientific quality of clinical trials are obviously 
of great importance to public health, but in GCP the public interest is only a seconda-
ry issue. 
When a new drug is approved there is sufficient knowledge available to enable approp-
riate decision making regarding the treatment of individual patients. Paradoxically but 
inevitably, however, there is at the same time often some uncertainty with regard to the 
possible side effects of the drug or its safety (and efficacy) in the long term use in the 
population at large. Much of our knowledge of medicines comes available only during 
the years after introduction. To illustrate this, in table 1 a review is given of aspects of 
marketed medicines that often need further study. The clinical trial is a well developed 
and understood instrument.13' The study of marketed medicines, on the other hand, is 
still in a developmental stage and many problems involved have only partly been 
solved. 
3.2 Postmarketing surveillance 
The Health Council in the Netherlands has defined postmarketing surveillance (PMS) 
as 'the systematic surveillance and scientific study of all intended and unintended 
effects of medicines on human health, after their release for marketing'.'4' It was added 
that 'its aim is to obtain data of scientific quality for the rational and safe use of medi-
cines'. In this definition and in the context of this paper PMS refers to pharmacovigi-
lance as well as to pharmacoepidemiology. 
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Table 1 — Review of subjects of interest in the postmarketing evaluation of medicines 
1. Fine-tuning of dosage recommendations 
2. Reappraisal of indications (extension or restriction) 
3. Drug use and drug users characteristics 
4. Assessment of long-term efficacy (e.g. in the case of surrogate endpoints) 
5. Assessment of side effects: 
5.1. Detection of unexpected side effects and interactions 
5.2. Identification of risk factors 
5.3. Quantitative measurement of (un)safety 
5.4. Long term safety/toxicity 
5.5. Study of potential risk groups (e.g. children, elderly, pregnancy) 
5.6. Detection of unexpected beneficial effects 
6. Further pharmacological and mechanistic studies 
7. Detection of pharmaceutical defects and counterfeit drugs 
8. Dangers of misuse (intentional and accidental intoxication, dependence) 
9. Quality of life and utility assessment 
10. Collection of data needed for cost assessment 
The term pharmacovigilance is often used more specifically for the detection and pre-
vention of adverse reactions'5', i.e. monitoring and early warning. PMS faces many dif-
ferent problems, of scientific, ethical, logistic, legal and financial nature. Through the 
years a variety of methods and systems have been developed, which can roughly be dis-
tinguished into 'spontaneous reporting' in all its different shapes, and the various epi-
demiological approaches (see table 2).'6"8- All have specific advantages and shortcom-
ings and new ways may be envisaged in the future. Spontaneous reporting, for example, 
is mainly effective in the detection of characteristic adverse reactions with a suggestive 
time relationship but is of limited use in estimating reaction frequency.'9' PMS is still 
Table 2 — Methods for studying marketed medicines16'^ 
1. Spontaneous reporting 
2. Intensive hospital monitoring 
3. Prescription event monitoring 
4. Case control studies and case control surveillance 
5. Follow-up studies (with or without control group) 
6. Record linkage and large linked data resources 
7. Drug use and users studies 
8. Studies using disease registers 
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under development and there is as yet some uncertainty into how much detail we will 
- scientifically, ethically and financially - be able to measure the balance of benefits and 
risks of medicines. For less affluent countries, the exact and costly measurement of the 
risks of efficacious drugs may even remain a luxury. 
3.3 Burden of proof 
At the moment when a medicine is approved by the competent authority many changes 
take place. The drug is no longer experimental but has (legally) become an established 
treatment. Its users no longer are experimental patients, monitored by the precautions 
of the trial and the provisions of GCP. Instead, the experiences with the drug are from 
now on more or less hidden from view because of medical and pharmaceutical secrecy. 
From the medical point of view, on the other hand, a new drug only slowly looses its 
experimental character during the years after introduction. 
Before the registration of a medicine, the company has to meet the requirements put 
forward by the regulatory authority and to provide any data requested. If the data are 
not satisfactory, additional evidence must be produced by the company. Once the drug 
is registered, however, in many countries the burden of proof moves from the compa-
ny to the registration authority. New in European Union legislation is that a marketing 
authorisation is valid for a period of five years.'10' The authorisation will be renewable 
for subsequent five years periods upon application by the company, accompanied by a 
dossier contain up-to-date information on pharmacovigilance in the form of periodic 
safety updates. It is not clear, however, if the European authority can demand the con-
duction of additional studies (e.g. for the testing of hypotheses regarding adverse reac-
tions). 
3.3.1 Differences between countries 
Since the pioneering WHO Technical Reports'11', the principles of spontaneous report-
ing have been reviewed in several articles and books.'6"8 u"17- Somewhat different pro-
cedures have, however, developed in different countries'7 18] and different views exist 
with regard to important issues such as causality assessment'19', confidentiality, freedom 
of information, and reporting obligations. The Dutch Health Council has published a 
special report on 'Privacy in Postmarketing Surveillance', in which the need for anony-
mity of case reports is emphasised.'201 In the draft European Guideline on adverse reac-
tion reporting, on the other hand, it is explicitly requested that case reports contain the 
surname and first names of the patients (although the provision eif available and accep-
table under national lawi is added).'21' New regulations in the European Union give 
107 
companies and governments obligations with regard to the reporting of suspected 
adverse reactions'21"23'. In many countries in and outside the European Union repor-
ting obligations do not exist, however, for physicians and pharmacists, i.e. those who 
actually observe patients with adverse reactions in practice. The number of countries, 
on the other hand, where adverse reactions reporting has become mandatory also to 
health care professionals is increasing. 
In many countries (anonymised) data obtained through spontaneous reporting are 
publicly available under the freedom of information act (e.g. Australia, Canada, Nordic 
countries, USA). In other countries (e.g. France, Germany, UK), on the other hand, 
the data are confidential, in common with the registration file. 
33.2 Problems 
After approval of a drug also the study environment and scientific principles change. In 
PMS the users population and study parameters are not defined and fixed (as in a clin-
ical trial) but, on the contrary, are unselected and open. PMS needs to be non-inter-
ventional, i.e. prescribers may not be influenced in their choice of a drug during data 
collection for PMS and a treatment may not be changed for the purpose of PMS. A 
characteristic feature of PMS is that, as compared with a clinical trial, often data on 
very large numbers of patients are needed (e.g. to detect rare adverse reactions). If two 
(or more) PMS activities take place simultaneously, the one could unwantedly influ-
ence or delay the other'24' and there may even be not enough patients in a country to 
assess all new drugs. 
In PMS often problems are complex and questions difficult to solve. The available 
information often is associated with some uncertainty or is even inconclusive. 
Interpretation may be influenced by differences in opinion and background. 
Sometimes different conclusions may with good reason be attached to one and the 
same set of data. Medicines are at the same time powerful health care instruments and 
profitable commercial products. The findings in PMS play a role in a complex envi-
ronment encompassing many different and potentially conflicting interests'25' (e.g. 
commercial profit versus medical value, economical freedom versus health expenditure 
containment, company property versus freedom of information). 
When evidence accumulates and knowledge increases a change in dose recommenda-
tion or indications for use may be needed, or additional safety measures may be re-
quired. The findings in PMS may impair the commercial value of a drug and in ex-
treme situations lead to withdrawal. Even a false alarm may cause permanent damage 
to the drug. In large countries, after approval the number of users of a new medicine 
may within a short period of time become very large. The higher the number of users 
of a drug is, the larger is its commercial value but also the possible number of victims 
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of an unforeseen adverse reaction. Pharmacovigilance experts in drug companies in 
European countries are being given a personal responsibility in ensuring that data on 
adverse effects are promptly reported to the drug regulatory authority.12'1 This respon-
sibility should not be overruled by instructions in the company. Appropriate organisa-
tional arrangements in the company and strict employment contract provisions may be 
necessary to safeguard job security of pharmacovigilance officers. 
The basic principle underlying the safe introduction of a new medicine is, that when-
ever a patient uses the drug he and his doctor and pharmacists must be prepared to 
(anonymously) participate in the national pharmacovigilance program. On the other 
hand, much importance is attached to the principle right of any patient to refuse the 
use of data originating from his or her medical history (except for insurance account-
ing purposes).'26' Proposed new legislation in Europe regarding privacy and the con-
fidentiality of personal health data is a real threat to future PMS.·27· My personal 
impression is, however, that modern patients think largely positively of postmarketing 
drug evaluation and arc well prepared to contribute, provided that commercial (and 
political) interests are excluded. Recent evidence is in support of this view.'28' It may be 
in the future that the public might demand effective and transparent surveillance of 
marketed drugs, in spite of current legislation regarding privacy, medical secrecy and 
drug regulation. 
3.4 Good Practice 
For reasons discussed above there is a need for Good Practice in PMS (GPP). Patients 
contributing data to PMS deserve a formal review of the protocol, with regard to 
appropriateness, relevance and ethics. GPP starts where GCP ends and should be a 
logical extension of the latter. Whereas GCP is predominantly concerned with the 
rights of individuals, GPP is primarily a matter of the public interest. The procedures 
in all activities in the field of PMS need to be as well-considered and clear as possible. 
In contrast to a clinical trial, in PMS it may be unusual (or impossible) to obtain in-
formed consent of the individual patients. GPP may be the natural way of solving 
threatening incompatibilities between current legislation and regulation and the proper 
performance of PMS. Major points of interest in GPP are: 
- Scientific principles (aims, methods, procedures, inclusion of patients) 
- Ethics and legislation (responsibilities, rights and interests, privacy and medical secre-
cy) 
- Accounting (protocols, standardisation, reporting of study results) 
- Review: approval of studies and systems (e.g. with regard to appropriateness, scien-
tific efficiency and ethics), and inspection 
- Setting priorities and allocation of funds. 
109 
3.1.5 Current developments 
Through the years the WI IO Collaborating Centre for International Drug Monitoring 
has contributed much to the development and harmonisation of the methodology in 
spontaneous reporting.'11 2 9 31' In a few countries, e.g. France and Japan, recently 
national documents on pharmacovigilance have been preparedf32 зэ'. In addition, 
various bodies are contributing to the improvement of the procedures and regulations 
in this field. The Council for International Organizations of Medical Sciences 
(CIOMS), for example, has advised pharmaceutical companies on the international 
reporting of adverse reactions and the production of Drug Safety Updates134 3 5 ' and is 
providing structured definitions of the WHO Critical Adverse Reaction Terms.'36'.The 
Pharmacovigilance Working Party of the European Commission has drafted a number 
of Guidelines for marketing authorisation holders, i.e. on adverse reactions report-
ing'37j, periodic drug safety update reports'38', company sponsored postmarketing safe­
ty studies'39', and ongoing pharmacovigilance evaluation during the postmarketing 
period[40'. The new MEDDRA terminology for adverse drug reactions (Medical 
Dictionary for Drug Regulatory Affairs'41') is under consideration for adoption in the 
global scheme of the WHO Collaborating Centre in Uppsala. Bénichou and co-work-
ers have developed a series of structured etiologic- diagnostic assessment schemes for 
important or frequent drug-induced disorders.'4243' Although primarily focused on the 
preregistration phase, parts of the work the Conference on International 
Harmonization (ICH) are also relevant to PMS.'44' The European Pharmacovigilance 
Research Group is working on a variety of mainly scientific issues in pharmacovigilan-
ce' 5'. In the United Kingdom a code of behaviour in company-sponsored drug safety 
studies has been laid down in collaboration with the Medicines Control Agency in the 
Safety Assessment of Marketed Medicines SAMM Guidelines.'46' More recently, an 
excellent framework for conducting pharmacoepidemiologic studies has been devel-
oped by the International Society for Pharmacoepidemiology ISPE in the Guidelines 
for Good Epidemiology Practices for Drug, Device and Vaccine Research in the United 
States.'33' These and other activities are already anticipating GPP. 
3.6 The next steps 
For the further development of GPP, the following points need to be addressed: 
1. To define the aims of PMS and to identify appropriate methods of data collection 
and assessment for the various aims and their specific advantages and limitations. 
2. To design, standardise and describe in detail the methods and procedures for the 
collection, assessment and distribution of data (spontaneous reporting and other). 
3. To identify the interests, rights and responsibilities of all parties involved: indivi-
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duals (patients, doctors, pharmacists, investigators) and institutions (companies, 
governmental bodies, patients as a group). 
4. To design protocols for the reporting (accounting) of data and findings, and to 
develop appropriate software for data processing. 
5. To prepare a guideline for a data management code, specifying which data are 
available to whom, for which purpose, and under which conditions, and also refer-
ring to confidentiality. 
6. To develop strategies for assessing quality and performance of PMS systems. 
7. To establish an authoritative forum for the statistical review of pharmacoepide-
miologic studies. 
8. To audit in PMS. 
9. To ensure professional autonomy (and job security) of pharmacovigilance officers. 
10. To establish national 'PMS Ethics Committees' (or regional in large countries), for 
the co-ordination and review of the activities pertaining to points 1-9, especially 
with regard to: 
- appropriateness of protocols and procedures, 
- allocation of funds and setting priorities (with regard to study subjects), 
- enforcement of GPP rules, 
- protection of public health interest. 
For spontaneous reporting systems the description in detail is needed of the appropriate 
procedures in the collection, processing, assessment and dissemination of data. The 
success of a spontaneous reporting system depends upon the quantity and quality of 
adverse reaction reporting, the organisation of the system, and the utilisation of the col-
lected data. With regard to the level of reporting (input) the following criteria may be 
used: 
— Reporting rate (e.g. number of case reports/106 inhabitants/year). 
- Reporting distribution, i.e. the percentage of physicians reporting and reporter 
characteristics (e.g. general practitioners, specialists, pharmacists). 
- Reporting quality (e.g. according to the new WHO documentation grading.I4a') 
— Reporting efficiency (the proportion of relevant case reports, e.g. concerning un-
known or serious reactions). 
Drug utilisation data are useful as a reference, e.g. while assessing reporting rates and 
differences or changes in reporting. Regarding the organisation of a pharmacovigilan-
ce centre it is of interest how the system for data acquisition is structured. The profes-
sional expertise oí assessors and the mean assessment time per case report (or the num-
ber of staff members per 1000 case reports) may be used as parameters of the quality of 
data assessment at a centre. The budget available for pharmacovigilance and the sour-
ces and continuity of funding indirectly give information regarding organisational 
development. 
I l l 
The yearly numbers and the content of publications and changes in data sheets refer­
ring to spontaneous reporting, may be used as indicators of the utilisation of pharma-
covigilance data (output). The frequency of data base searches is another possible para­
meter in this respect. Also a data management code can give information of data 
utilisation in a country. 
Similarly, concrete and detailed guidelines are needed for all other activities in PMS. 
For the - national and international - establishment of GPP collaboration is needed 
from medical and pharmaceutical associations, academia, regulators and pharmaceuti­
cal companies. The support of authoritative institutions such as the World Health 
Organization may improve international harmonisation and acceptance. The public 
health interest in effective PMS is obvious. Since the necessary data have to come from 
the drug-using population at large, the willingness of individual patients to contribute 
is crucial. Patients are at the same time the source and the ultimate destination of infor­
mation in PMS. Consumer and patient organisations should therefore also play a role 
in the development of GPP and the establishment of PMS Ethics Committees. As is 
always true in medicine, also in GPP the interest of the patients must come first. 
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Section 4 
The Future 
The course of drug development, regulation and distribution constitutes a complex 
and dynamic process. Pharmacovigilance and its various methods arc in continuous 
development, whether from the scientific, logistic, ethical or legal aspect. With the 
background from the chapters preceding, chapter 4 presents an attempt at making an 
orderly synthesis of the many different, and sometimes conflicting, components of 
pharmacovigilance. The world is rapidly changing, certainly as regards medical practi-
ce routines, computer technology and ethical standards. This is the perspective from 
which the final chapter considers the future shape of pharmacovigilance. 
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CHAPTER 4 
General discussion: 
pharmacovigilance in perspective 
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4.1 Introduction 
As is discussed in the Introduction, pharmacovigilance aims at the detection, assess-
ment and prevention of adverse effects and other problems related to the use of medi-
cines for human use.'1'2' Its ultimate goal is to foster the rational and safe use of medi-
cines. 
During the Sixties, in the aftermath of the thalidomide disaster, national pharmacovi-
gilance centres were established in a number of countries around the world. New cen-
tres continue to be established, now mainly in developing countries. Originally, spon-
taneous reporting - the country-wide system for the reporting of suspected adverse 
effects of drug - was the only conceivable early warning system for possible future drug-
induced disasters. It has since proved to be the main source of information for phar-
macovigilance and drug regulation, in addition to any findings published in the litera-
ture. Its principles and procedures (the 3d paragraph of the Introduction) are reviewed 
in a guideline soon to be published by the World Health Organisation.'2' 
National pharmacovigilance centres were usually established in connection with 
(equally new) drug regulatory agencies, responsible for granting marketing authorisa-
tions for medicinal products. Spontaneous reporting developed largely within the 
governmental legislative environment. 
Granting a marketing authorisation is an official decision, based on legal rules and cri-
teria, and secondary to the results of a series of scientific studies encompassing phar-
maceutical quality, experimental pharmacology and toxicology, and controlled clinical 
trials. After approval is granted for a medicine, the data provided by spontaneous 
reporting are direct - both scientific and legal - evidence in further regulatory decision 
making. These data may be difficult to interpret scientifically, however, and - since the 
involvement of the suspected drug in individual patients is usually uncertain - may not 
suffice as legal evidence. Through the years, doubt has been expressed on several occa-
sions regarding the validity of spontaneous reporting.'3"5' From the start, most coun-
tries often kept secret the data and arguments underlying postmarketing regulatory 
decisions. As a consequence, the contributions of spontaneous reporting to regulatory 
changes could pass unnoticed by scientists and health care providers, i.e. the potential 
reporters. In the Eighties a number of publications revealed, however, that spontaneous 
reporting had become a major routine in postmarketing drug regulation.'6"11' At the 
time, however, spontaneous reporting was mainly regarded as an instrument of drug 
policy. Many of the scientific and logistic problems inherent to its use had not yet been 
explored, or not fully so. 
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4.1.2 Recent developments 
The experience from many countries makes it clear that spontaneous reporting is a pro-
lific source of information.l12"16' It thus plays an important role in postmarketing drug 
regulation, even in arriving at difficult and extreme decisions such as withdrawal from 
the market."7' The principles and procedures, the strengths and weaknesses of sponta-
neous reporting are now taking shape. Current developments suggest that there is con-
solidation and professionalisation of spontaneous reporting, and are indicative of in-
creased governmental interest in pharmacovigilance. Worldwide reporting rates have 
increased steadily over the years. There are now several countries where the number of 
case reports per year exceeds 200 or even 300/106 inhabitants.'18,19' National centres are 
also expanding: several European countries have teams of 20-50 people working full-
time in pharmacovigilance, i.e. a ratio of 1-2 staff members/106 inhabitants. 
Documents recently issued by the European Commission now include pharmacovigi-
lance and spontaneous reporting as a formal part of the basis for drug legislation and 
regulation.'20,2" Several countries demand that pharmaceutical companies both report 
suspected adverse effects to the regulatory authority and to have qualified pharmacovi-
gilance staff. In addition, an increasing number of countries have made reporting of 
adverse drug effects mandatory for physicians and other health care providers,'18' al-
though there are usually no penalties for non-compliance. 
There are many variations on the theme of spontaneous reporting.'8' Reporting may be 
intensified, may concentrate on selected drugs or adverse effects (e.g. skin reactions, 
liver injury or eye disorders), and can be regional, national or international. All these 
forms are valuable enrichments of pharmacovigilance, provided they are linked to the 
national pharmacovigilance database. Undoubtedly, further improvements and refine-
ments of spontaneous reporting are foreseeable.'13' Structured collaboration between 
pharmacists and physicians may quantitatively and qualitatively improve the reporting 
of adverse reactions.'22' Direct reporting by patients themselves has been found to accel-
erate the detection of adverse effects.'23' 
In addition to spontaneous reporting, complementary methods such as prescription 
event monitoring, case control studies and exposure-outcome linkage databases are 
increasingly used in pharmacovigilance.'8,24' Pharmacoepidemiology units have now 
been established at many universities and special post-graduate courses in pharmacovi-
gilance are offered in an increasing number of countries. 
In several countries the introduction of freedom of information legislation has relaxed 
the tradition of secrecy in pharmacovigilance (see below). Recent initiatives in various 
countries announce the formulation of rules for Good Pharmacovigilance Practice, as 
has happened in the past with Good Clinical Trial Practice. Good Pharmacovigilance 
Practice aims at ensuring appropriate procedures for the collection, processing, assess-
ment and distribution of data, and at the protection of the interests of individual 
patients as well as of public health (see chapter 3).'25' 
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4.3 What spontaneous reporting can do 
Experience gained internationally shows that spontaneous reporting is effective to pro­
vide information about a wide range of different adverse effects and other drug-related 
problems.'12'6' In the Netherlands, a modest rate of reporting of only about 1000 cases 
per year (70 / 106 inhabitants) still could yield a continuous stream of useful informa­
tion.'13' When the number of reporting physicians increases, the quantity of informa­
tion (number of topics) and its quality (evidence per topic) are likely to improve. Since 
there is a critical minimum of case reports needed for a signal,'26' increased reporting 
by a greater proportion of physicians is also likely to accelerate the detection of rare (but 
serious) adverse effects (see chapter 1). In the light of international experience it is rea­
sonable for a developed system to aim at receiving a steady annual input of up to 300 
reports per 106 inhabitants, including 30% or more of the serious adverse effects occur­
ring in the country, coming from more than 10% of practitioners.'1819,27"29' When such 
levels are reached, the community may be reasonably confident that unexpected adver­
se effects will be detected within an acceptable period of time. 
As discussed in chapters 1.1 and 1.2, spontaneous reporting is mainly effective in the 
detection of type A and type В adverse effects, with a clue for the physician to recog­
nise the possible drug involvement (e.g. a characteristic event and a suggestive time 
relationship) (see table l)."3 '3n¡ 
Table 1 — Advantages of spontaneous reporting 
— Very wide spectrum of subjects: 
- Many different adverse effects (although mainly type A and B), interactions 
and other problems (e.g. pharmaceutical defects) 
- Countrywide (in principle coverage of all drugs and all patients) 
— Effective 
— Rapid 
— Continuous 
— Comparatively cheap 
On the other hand, spontaneous reporting is likely to be of little use for adverse effects 
with a relatively high background frequency and occurring without a suggestive time 
relationship, e.g. the heterogeneous group of type С effects (table 2).'13' Other limita­
tions follow from the uncertain causal relationship in individual case reports and the 
unknown but great and variable degree of underreporting. In addition to signal detec­
tion, spontaneous reporting may often produce - if there are a high and steady report-
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ing rate and adequate data on drug consumption available - a useful impression of the 
frequency of adverse drug effects. The exact measurement of effect frequencies, or the 
comparative assessment of the safety of different drugs, however, is usually not feasible. 
Table 2 — Limitations of spontaneous reporting 
- Causal relationship in case reports usually uncertain 
- Underreporting and reporting bias 
- No quantitative measurement (comparison of drugs is often difficult) 
- Insensitive to type С adverse effects 
The success of a spontaneous reporting system depends on, in addition to the report­
ing rate, the quality and relevance of case reports (see table 3)-[2:i1 
Table 3 — Determinants of the level of performance of a spontaneous reporting system 
- Reporting rate (e.g. number of case reports/106 inhabitants/year) 
- Reporting distribution, i.e. the proportion of physicians reporting, reporter charac­
teristics (e.g. general practitionets, specialists, pharmacists), geographic distribu­
tion, reporting rates in specific populations 
- Reporting quality 
- Reporting efficiency (the proportion of relevant case reports, e.g. concerning un­
known or serious adverse effects) 
A variety of other factors may influence the success of spontaneous reporting, e.g. the 
numbers of drug users, drug registration policy, training of physicians and other health 
care providers, and feedback and other services provided by the centre. Drug utilisation 
data are useful as a reference, for instance for assessment of reporting rates and differ­
ences or changes in reporting. The more drugs there arc on the market for a given indi­
cation, the smaller are the numbers of users of each individual drug, and the less effec­
tive monitoring will be. For small countries, international collaboration may be a 
means of obtaining data for large populations. An increase in reporting can only be 
expected to imptove the fruits of pharmacovigilance if it is associated with a propor­
tionate increase in assessment capacity (e.g. number and training of staff, quality of 
computer facilities). Pharmacovigilance is only likely to give good results if the system 
is well organised and is acceptable to the medical community. Sufficient staff is needed 
for intensive communication with practitioners and follow-up of cases. Important new 
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information is only likely to be harvested as part of a much larger (and therefore expen-
sive) bulk of data of less interest. Even when the reporting rate is high in general, some 
groups of drugs (e.g. anticancer drugs) may as a result of selective underreporting es-
cape from monitoring.'13' 
4.4 Progress in automation 
Case reports contain detailed information concerning patients, including a medical 
and a medication history. From the start, the administration, processing and utilisation 
of such complex data posed serious problems for pharmacovigilance centres, especially 
with regard to signal detection and to presentation of the aggregated data. Modern, 
powerful and flexible, computer systems have fortunately solved many of these diffi-
culties. 
The WHOART - preferred and high level - adverse reaction terminology was designed 
in the sixties as a fixed and hierarchical system of key words and diagnostic codes, con-
sistent with the state of computer technology at the time. New computer technology 
has meanwhile been developed and different approaches may now be tried. Entire 
event descriptions can be stored as free text, and case reports can be processed and 
retrieved by using plain words, parts of words, and combinations. The specific function 
of a preferred terminology (such as WHOART or MEDDRA) in spontaneous report-
ing may change in the future. 
In many countries, the introduction of automation into medical and pharmaceutical 
practice has drastically changed administrative routines in family practices, hospital 
wards and pharmacies. These changes open interesting possibilities for pharmacovigi-
lance. For example, in a computerised medical administration system, electronic 
reporting of suspected adverse drug effects may become an easy and routine activity. An 
improvement, both quantitatively and qualitatively, in national reporting will contri-
bute to improved international pharmacovigilance, for example by the Uppsala 
Monitoring Centre. The new Eudrawatch system of the European Medicines Evalua-
tion Agency will enable swift data transmission in drug regulation in the European 
Union. 
Further advances in computer technology will lead to further improvements of inter-
national collaboration. For example, free text could be included in case reports, the 
delay for data transmission may be lessened, and lack of harmonisation may become a 
soluble problem. 
To combine spontaneous reporting with drug utilisation data has long been a goal. 
Advancements in computer technology have spurred work on this issue. In the 
Netherlands, for example, there have been try-outs, using the GIP drug prescription 
database of the Ziekenfondsraad (Council of Sick Funds). On an international scale, 
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the Uppsala Monitoring Centre and International Medical Statistics IMS are collabo-
rating in the ADR Signal Analysis Project ASAP, which involves combining reporting 
and prescription data.'31' 
Many countries have made much progress with the introduction of computerised 
administration in medical and pharmaceutical care. Throughout the Netherlands -
where most patients deal with a single pharmacy — almost all pharmacies have comp-
rehensive computer facilities. The building up of data bases by linking individual com-
puters, and resolving of incompatibilities between different software systems, have now 
become technical problems, rather than the utopia of 10 years ago. The unbiased col-
lection of up-to-date data on drug prescribing and (subsequent) medical events in vast 
populations seems to be within reach. The barriers now, replacing insurmountable 
technical challenges, will probably be new legislation regarding privacy protection and 
medical ethics.'32' However, as pharmacovigilance is of the utmost importance for users 
of medicines, the question of privacy as a barrier can be expected to be solved.'26' 
4.5 A synthesis of spontaneous reporting and population studies? 
Each method in pharmacovigilance (e.g. spontaneous reporting, prescription event 
monitoring, record linkage, or case control surveillance) follows a more or less individ-
ual approach to signal generation. In spontaneous reporting, new adverse effects are 
often signalled through a fairly small number of eye-catching case reports.'1213' In pop-
ulation studies unexpected associations are traced through statistical disproportionali-
ty.l33,3'i' Promising results have occasionally followed the application of a technique 
from one method to another method, e.g. calculation of odds ratios in a spontaneous 
reporting data base.'35,36' Statistical techniques for signal generation are currently under 
development and are being tested in different situations. A computerised model now 
being designed in the Netherlands combines clinical, statistical, quality and legal crite-
ria. It is to be applicable to spontaneous reporting as well as to other databases.'34' 
When new, giant, databases will be set up to cover large parts of national populations 
- with powerful computers, flexible software, and scanning techniques - there will open 
unprecedented possibilities for statistical assessment in pharmacovigilance and phar-
macoepidemiology. The original idea of linking drug exposure and medical history 
records, conceived some decades ago by pioneers such as Doll, Skegg and Inman, is 
likely to become a major instrument in pharmacovigilance. Concepts about causality 
in medicine are changing.'37' As elsewhere in medicine,'38,39' novel statistical ap-
proaches will probably be followed for signal detection in giant comprehensive data 
resources.'40"'12' A scenario like this one, with integration of population exposure-event 
databases, spontaneous reporting and case control assessment, could result in a synthe-
sis of existing approaches. Pharmacovigilance could than perhaps be extended to type 
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С adverse effects. Statistical signal generation may overcome the Achilles' heel of spon­
taneous reporting: the physician's limited ability to recognise unknown and unexpec­
ted adverse effects. Uncertainty as regards the background frequency of various medi­
cal events — another notorious problem in pharmacovigilance - may also be dealt with 
(except for events that give no reason to consult a physician). 
This optimistic view is tempered somewhat by the fact that there remain expected and 
unexpected limitations and errors to be envisaged. Obviously a medical,history is much 
more than a diagnosis, an administrative note, or laboratory findings. Diagnostic codes 
may not be identical to the precise diagnostic descriptions. Self-medication is not usu­
ally stored in databases, is therefore excluded from vigilance, yet may be a major con-
founder. It may be difficult to translate statistical findings for populations in terms of 
risk estimation for individual patients. 
While, in the future, spontaneous reporting may be of less importance, it is expected 
to continue to serve as a direct and rapid monitoring system for urgent and serious pro­
blems, especially during the first few years following the introduction of a new drug. 
4.6 Is this all we need? 
Spontaneous reporting primarily serves the aim of early detection of serious and unex­
pected adverse effects of new drugs. Undoubtedly this was the cardinal issue in the early 
sixties. In future decades, however, there is expected more emphasis on the rational, safe 
and cost-conscious use of drugs, on the precise evaluation of the merits and on the 
appropriate use of established treatments. These purposes require a much wider spec­
trum of information (summarised in table 4) which, in turn, implies a variety of addi­
tional activities. Notwithstanding the importance of many of these topics, the phar­
macovigilance budget is only a modest part of the total expending on drug regulation 
and marketing. 
The 'real life' conditions of drug use after marketing are quite different from those 
during the trials before marketing. Indication, duration of use, and patient character­
istics may not be the same. Once a drug is on the market, exact quantitative knowledge 
is needed of both its short and long-term efficacy and safety in different situations, rela­
tive to other drugs and treatments, and to the untreated condition. Further informa­
tion is often needed, about dosage and pharmacokinetics in special populations and 
situations and about the parameters for therapeutic monitoring (e.g. blood levels, 
warning signs, risk factors). Methods for acquiring information are still under devel­
opment and face a number of scientific, ethical and logistic difficulties. In addition, 
there is uncertainty about both the appropriate ways of funding this research and of the 
size of the funds that will be needed. Ideally, systems should be developed that meas­
ure simultaneously quantitatively and comparably both the efficacy and the safety of 
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Tabk 4 — Topics of interest for the study of medical drugs after approval 
1. Fine-tuning of dosage recommendations. 
2. Reappraisal of indications (extension or restriction). 
3- Medical drug use and drug users characteristics. 
4. Assessment of long-term efficacy (e.g. in the case of surrogate endpoints). 
5. Assessment of side-effects: 
5-1. Detection of unexpected side-effects and interactions. 
5.2. Identification of risk factors. 
5.3. Quantitative measurement of (un)safety. 
5.4. Long term safety/toxicity. 
5.5. Study of potential risk groups (children, the elderly, pregnancy, etc.). 
5.6. Detection of unexpected beneficial effects. 
6. Further kinetic, pharmacological and mechanistic studies. 
7. Detection of pharmaceutical defects and counterfeit drugs 
8. Dangers of misuse (intentional and accidental intoxication, dependence). 
9. Quality of life and utility assessment. 
10. Collection of data needed for cost assessment. 
drugs, also when they are used chronically and in the case of surrogate endpoints. In 
the foreseeable future, however, there remain pressing issues, such as that of unravelling 
of the delayed and complex influence of oral contraceptives on carcinoma of the breast, 
as major challenges to postmarketing drug evaluation. 
4.7 Confidentiality and transparency 
The registration dossier is the best-informed data source for a drug. It is in its entirety 
the property of the company and may only be used by the competent authority for the 
purpose of registration of the drug. After approval, the only public part of a registra-
tion file is the Summary of Product Characteristics. In several countries, including the 
Netherlands, drug regulation is excluded from freedom of information legislation; in 
other countries it is not. 
In most countries, adverse reaction reporting started as a spontaneous, voluntary and 
confidential activity. Since a case report is essentially a medical history, it is subject to 
the constraints deriving from medical secrecy and privacy regulations (see chapter 3). 
A basic principle is the right of patients to refuse to allow the use against their wish of 
data originating from their medical histories (with the exception of designated conta-
gious diseases or insurance accounting purposes).'43' Originally, confidentiality con-
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cerned the report as a whole, including the drug-adverse event association involved. 
This was expected to decrease the reluctance of reporters to submit doubtful or incom-
plete observations. Often, the pharmacovigilance database was regarded as part of the 
drug's secret registration file. 
Through the years, in many countries the concept of confidentiality has become less 
strict, resulting in diversity in the availability of data (sec table 5). 
Table 5 — Parties having access to information in reports in 45 countries (reproducedfrom 
Olsson"8!) 
Category 
Health professionals 
Drug manufacturers 
Researchers 
General public 
Drug information centres 
Medical libraries 
In 8 countries case details are not 
On 
31 
29 
29 
10 
1 
made 
demand 
available to 
Periodic 
standard 
listing 
3 
11 
2 
1 
any outside party 
By on-line 
connection 
1 
4 
1 
It has now become usual that in many countries numerical data, and often case report 
summaries also, are available to health care professionals and frequently to the public 
also, with the restriction that any data possibly leading to the disclosure of the identi-
ties of persons or institutes involved must be removed. In some countries (e.g. France), 
on the other hand, access to the spontaneous reporting database is difficult or impos-
sible. 
Although it originally reported only to regulatory authorities, the Uppsala Monitoring 
Centre has, after consultation with participating countries, changed its policy and now 
releases numerical data to third parties on request. In addition, 30 countries have 
agreed to routinely disclose case details as stored in the international system. 
Pharmacovigilance is incontestably a general public health interest. The data acquired 
through spontaneous reporting are supplied voluntarily by real patients and should 
thus be regarded as the property of the community at large. All those involved with 
medicines benefit from accurate and timely information.'44' Ideally, all persons or par-
ties with an interest in medical drug use, drug information and drug policy should have 
access to the national spontaneous reporting database (with the exception of possible 
personal identifiers). The spontaneous reporting system is, however, based on the wil-
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lingness of patients and of health care professionals to contribute. If these groups, for 
one reason or another, no longer trusted the system, this system as a whole might col-
lapse. 
In spontaneous reporting, data are usually based on suspicions, and may be prelimina-
ry, ambiguous, doubtful or wrong (see chapter 2.2). Premature or erroneous conclu-
sions may be reached and lead to unbalanced'publicity, unnecessary anxiety, patient 
non-compliance, public mistrust and unwarranted decisions. It is the responsibility of 
a pharmacovigilance centre to give instructions for use of the data and to provide assi-
stance regarding its interpretation. A data management code, explaining which data 
may be used for which purpose, is desirable. 'Good communications practice', and not 
concealment of the data, will be the appropriate way of preventing unnecessary drug-
safety scares.'44' 
4.8 Science and policy do not keep pace 
New medicines are usually developed as the property of a pharmaceutical company. 
Once a medicine has become an established treatment, its efficacy, safety and cost are 
of interest to the community as a whole. The decision as to whether or not a new drug 
may be put on the market rests solely with the regulatory authority. After registration, 
however, drug policy is formulated by a variety of organisations: e.g. hospital or region-
al formulary committees, governmental and non-governmental medicines reimburse-
ment systems (insurance), professional medical and pharmaceutical associations, uni-
versity teachers and information officers, consumer and patient organisations, as well 
as scientific and educational journals and books. Ultimately, patients and prescribcrs 
set their own therapeutic policies, based on the information within their reach. 
Many adverse effects are detected or fully evaluated only after the introduction of the 
drug. As explained in chapters 1.2 and 2.2, the course of events leading to the disco-
very and understanding of an adverse drug effect frequently follows an S curve, with 
three major phases (see chapter 2.2, figure 1): a latent period during which a suspicion 
arises at some point, followed by the often sudden accumulation of data (signal 
strengthening), and finally, a usually lengthy phase of evaluation during which the 
adverse effect is confirmed (signal testing), explained and quantified. The steep middle 
part of the curve, during which a weak hypothesis changes into a strong suspicion (i.e. 
signal detection, see chapter 1.2) is crucial in pharmacovigilance. Many 'known' adver-
se effects, e.g. as included in Summaries of Product Characteristics and in textbooks, 
are still somewhere early in the third phase. Knowledge about the adverse effects is 
often incomplete, e.g. as it regards frequency, mechanism and risk factors. The exis-
tence of the effect is legally acknowledged but full evaluation and scientific proof are 
still missing. 
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Once marketing authorisation is granted, the company usually cannot be required to 
perform further study (see chapter 3). As a result, there may be a vacuum as regards the 
performance and the funding of the scientific study of approved medicines. The recent 
introduction in the European Union of a possibility for provisional approval of selec-
ted new drugs (e.g. for the treatment of HIV infection) seems to have changed this situ-
ation, but experience is still limited. Additional studies can be demanded, before 
approval of such drugs is made definitive. Also the new rule in the European Union, 
that a marketing authorisation needs to be renewed every 5 years, may be a stimulus in 
cases when further study is needed. Some countries are currently considering the intro-
duction of various categories of marketing authorisations, linked to different levels of 
monitoring activity. 
In chapters 1.2 and 2.2 it was explained that the detection and scientific evaluation of 
an adverse drug effect is a gradual process and may take a long time. Once a serious sus-
picion has arisen, however, a conclusion must be reached on the basis of the limited 
information available. For the protection of public health a decision must often be ar-
rived at and measures taken, while the scientific verdict is still pending. In other words, 
science and policy may not be developing at the same pace. Questions have to be an-
swered when they arise and decisions must often be arrived at ad hoc. Regulators and 
companies, educators and prescribers, and journalists and patients often cannot wait to 
make up their minds until the final truth has been established. As a consequence, in 
drug regulation a decision is often a compromise. Good data and reasonable arguments 
foster sensible compromises. Decisions are more likely to be accepted by the company 
and appreciated by the community when the arguments are reasonable and trans-
parent. 
Premature action — be it publicity or measure - may destroy a product commercially 
and lead to the undesirable disappearance of a valuable treatment. Delayed action, on 
the other hand, may lead to an unacceptable number of victims, compromise both 
government and company, and arouse public anxiety. Once a measure is applied, an 
indication dropped or the drug withdrawn, scientific evaluation may never be comple-
ted. A decision may often be considered to have been made both too early and too late, 
depending on the individual point of view. In such cases, there may be attempts to sift 
the available evidence. Public concern and undue publicity may urge stronger action 
than is scientifically justified. Commercial interests, on the other hand, may lead to 
attempts to minimise a problem. The natural solution would be to allow pharmacovi-
gilance the time, means and independence needed for the unbiased collection and veri-
fication of the necessary evidence. 
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4.9 New problems may arise 
The entire process — from drug development, production, promotion, to dispensing or 
buying - constitutes a very complex system. A change anywhere in this system, even a 
change in trend or policy, may — sometimes indirectly and unexpectedly— have conse-
quences for safety and pharmacovigilance. Some possible examples are discussed below. 
4.9.1 Self-medication 
In the European Union and other countries changes in regulations have eased the avail-
ability of'over-the-counter' (OTC) drugs (without prescription) and the advertising of 
these drugs. Five years after its introduction, a drug that would previously have been 
excluded from self-medication may now be considered for the OTC status.'^' 
Increased self-medication may have consequences with regard to pharmacovigilance. 
Experience has shown that many self-medication drugs can cause significant adverse 
effects.146' Release for self-medication may lead to heavy advertising and to a steep 
increase in the use of the drug. Such increases may not replace prescription drug use, 
but represent new additional, new, markets.147' Many O T C drug advertisements are of 
dubious informative value, and the increased use of O T C drugs may be far from ration-
al. Increased use proportionally increases the occurrence of adverse effects (in absolute 
numbers). Also, changed conditions of use may affect the risk of adverse experiences. 
O T C and prescription drugs containing the same active ingredient often bear different 
names and may have somewhat different data sheets. Patients may overlook the fact 
that the drug they take because it is promoted on television has the same active prin-
ciple as that prescribed by their physician and they therefore may unknowingly take too 
high a dose. 
For the above reasons, a drug that appeared reasonably safe when used on prescription, 
may not necessarily be safe after its release for self-medication. Unfortunately self-
medication drugs are mostly excluded from current pharmacovigilance. Health care 
professionals are often ill-informed with regard to O T C drug use by their patients. This 
is probably why adverse effects of O T C drugs are relatively rarely reported. In addition, 
unrecognised self-medication is a potentially serious confounder for practically all cur-
rent methods used in pharmacovigilance. Increased self-medication may require addi-
tional pharmacovigilance activities, under difficult conditions. 
4.1.9.2 Generics 
Also the increasing use of generic and 'parallel' products might have consequences for 
130 
pharmacovigilance. Generic drugs have the advantage of being cheap and are (in coun-
tries such as those of the European Union) of good quality. It is a rule of thumb in 
medicine not to make changes to a satisfactory treatment, unless there is a medical indi-
cation. A consequence of generic dispensing is that the same patient may receive differ-
ent preparations one after another, depending on a pharmacy's or a wholesaler's pur-
chasing policy. It is now common practice in the Netherlands, for example, that a 
treatment is started in hospital, using a given product, e.g. the patented preparation, 
which after discharge of the patient is routinely replaced by the generic used in the 
patient's local pharmacy. Different generic or parallel products may contain different 
colouring agents or other excipients that may elicit hypersensitivity reactions. For some 
drugs with a small therapeutic window even small differences in bioavailability could 
be clinically relevant. Also, manufacturing errors may occur and be more difficult to 
detect when many different products circulate. The information in the data sheets of 
generic products may not be the same. For these reasons, spontaneous reporting needs 
to pay more attention to the precise identity of the suspected drugs. However, report-
ing physicians are often not aware of the actual generic or parallel product the patient 
is taking. 
Patients recognise their drug by its size, shape, colour or some characteristics of the 
packaging. This may play a role in the prevention of medication error, especially in the 
case of polypharmacy, impaired vision or the elderly. A change of product may have 
emotional effects, e.g. decrease trust, induce placebo side-effects, and cause non-com-
pliance. Another possible disadvantage of generic dispensing concerns litigation for 
compensation in the case of a serious adverse effect. If a patient subsequently took dif-
ferent products, and the offending product and its manufacturer cannot be identified 
unambiguously, the patient's position may be weakened. Thanks to new legislation 
such problems will not occur in countries of the European Union, but this is less 
obvious in other parts of the world. 
4.9.3 Non-orthodox drugs 
The increased interest worldwide in the use of non-orthodox drugs (e.g. phytotherapy, 
herbal and traditional remedies) is associated with additional difficulties for pharma-
covigilance. Such products may contain large numbers of poorly or unidentified drugs, 
several of which may cause serious adverse effects, or be fortified with potent drugs such 
as corticosteroids or nonsteroidal antiinflammatory drugs. These products largely es-
cape the official system of approval and quality control. The coding of such products, 
analysis of their contents, and identification of toxic ingredients pose new and difficult 
problems. In the case of adverse effects, it may be very difficult to expose the causative 
agent. The Uppsala Monitoring Centre has started a special project to address the pro-
blems related to these drugs. 
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4.9.4 Globalisation of drug registration 
Through the years, new drugs were often registered at different times in different coun-
tries. A step-wise, country by country, increase in the use of a drug has the advantage 
that the total population exposed is only gradually increased and that experience gain-
ed in one country can be incorporated into the approval procedure in other countries. 
The creation of large supranational markets (for example the European Union), or even 
of a global market, may well effect pharmacovigilance. The greater the number of users 
of a new drug, the greater the number of victims of an unforeseen adverse effect will 
be. Intensive collaboration between national pharmacovigilance systems therefore 
becomes essential, possibly demanding a more intensive effort. 
4.10 Rational drug use and the information turmoil 
The ultimate goal of pharmacovigilance is the rational and safe use of medicines.'21 In 
other words, the findings are intended to influence physicians, pharmacists and 
patients in their choice of medicines (including self-medication) and of precautions to 
be taken. Prescribes are under assault in several ways and by different parties attempt-
ing to influence their preferences, e.g. by pharmaceutical companies, drug bulletins, 
formulary committees, health authorities and sick funds. The intentions and priorities 
of the various parties - for example rational prescribing, market share increase or cost-
containment — may differ, however, and even conflict (see the next paragraph). 
Unfortunately, rationality in prescribing may be a fairly subjective notion. Drug utili-
sation data are difficult to interpret. Overprescribing and underprescribing may both 
be disadvantageous. Seemingly simple questions, such as whether a promising new 
drug really is better than its predecessor, may pose problems, not answerable objective-
iy. 
Information produced by pharmacovigilance may change the position of a drug. The 
data so obtained are often preliminary and open to different interpretations, however, 
and different views and backgrounds may influence the judgements or decisions. The 
importance of an adverse effect depends upon its seriousness, frequency and preventa-
biliry, and must be seen in the context of the indications for use and efficacy of the 
drug. Therapeutic truth may be hard to extract from the turmoil of information. 
To assess safety, communicate about risk and influence prescribing are all difficult. 
Scientific assessment of the quality of prescribing and of the impact of pharmacovigi-
lance on the improvement of prescribing is an additional issue with its own methodo-
logy, difficulties and challenges. 
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4.11 A pharmacovigilance arena 
Medicines are both powerful health care instruments and profitable commercial 
products. This dualism applies throughout the process of drug regulation. Different 
parties in the community have an interest in pharmacovigilance and drug regulation; 
the bases for these interests may differ and be in conflict. 
Several ministries within a government are involved in drug policy in different ways. 
The pharmaceutical industry is an important economic factor, especially in drug 
exporting countries, where it yields employment and foreign currency. Ministries of 
economics ensures that there are no undue obstacles to the selling and exportation of 
medicinal products. Health authorities are committed to ensure the pharmaceutical 
quality, efficacy and safety of the drugs in the country concerned, and also to restrict 
the budgets spent on pharmaceuticals. Cheap drugs, however, may not necessarily be 
safe. One of the reasons for relaxation of the self-medication regime may be that this 
relieves the drug reimbursement budget. 
The regulatory authority plays a key role with regard to changes in the conditions of 
use and marketing of a medicine. The place of the regulatory authority within the 
ministry of health and names such as 'Committee on the Safety of Medicines' or 
'Medicines Evaluation Board' may suggest a wide interest in the promotion of ration-
al prescribing and the education of physicians. Usually, however, the primary responsi-
bility of the regulatory authority is coming to terms with pharmaceutical companies. 
This is to be achieved within the scope of the law, with regard to the marketing autho-
risations of drugs and to the approved indications for use and other informarion con-
tained in the Summary of Product Characteristics. Appeals to regulatory decisions can 
only be made by the company concerned and not, for example, by a health care fund 
or consumers' council. The economic function of drug regulation may be illustrated by 
the fact that the European Medicines Evaluation Agency EMEA is part of the directo-
rate of trade of the European Commission (Directorate 3). 
The quality of pharmacotherapeutic training of healthcare professionals is the respon-
sibility of the ministry of education. Those involved in training need to have up-to-date 
knowledge of the adverse effects of medicines. 
Health care insurers share with the government the interest in drug safety as well as in 
containment of the costs of drugs (especially of new expensive treatments of, for instan-
ce, cancer or HIV infection). 
For pharmaceutical companies, the involvement in pharmacovigilance is a complex 
matter. Greater safety is a major argument for the promotion of many new drugs. For 
a company it is of vital importance to know as much as possible about the adverse 
effects of its products. Sales managers and pharmacovigilance experts may disagree, 
however, with regard of the implications of a given adverse effect. Even the mere 
rumour of an adverse effect may endanger the commercial value of the drug and even 
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decrease the share value quoted for the company. Decline of one drug may be to the 
advantage of the competition. Except for the obligation of informing (in confidence) 
the authorities, companies often keep information on adverse effects secret. Medical 
secrecy and privacy protection are other reasons why data on adverse effects may remain 
secret. Proposed new legislation in Europe regarding privacy and the confidentiality of 
personal health data is a real threat to future pharmacovigilance.'32' 
Impartial information providers - such as national bulletins, university teachers and 
medical journalists — and pharmaceutical companies compete for the attention of the 
medico-pharmaceutical audience. Scientific journalists are committed to the provision 
of well-balanced information, while the popular press searches for sensation. The pre-
cise data and considerations underlying regulatory decisions are often not made public, 
other than as an eventual announcement or press release. National drug bulletins 
depend, apart from published articles, on what company and regulator are willing to 
show. 
Vast amounts of money are paid out to victims of adverse effects of drugs. In litigation 
cases (claims for compensation), the data collected through pharmacovigilance may 
play a crucial role and be of great interest to lawyers.148' 
International and national developments may interact. International trade agreements 
may interfere with national restrictive actions. The World Health Organization and 
Ministry ol'health Health care insurers 
Regulation and 
legislation 
Drug users: 
Patients, 
Organisations , 
Figure 1 — A Pharmacovigilance Arena 
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non-governmental organisations such as Health Action International pursue global 
transparency and harmonisation in drug policy, and promote the use of 'essential' 
drugs. Reinsurance companies may discourage pharmaceutical companies from selling 
drugs chat carry a high risk of litigation for compensation. 
Economic factors, scientific uncertainty of the data, secrecy in decision making, politi-
cal consequences of unsafe drugs, are all aspects that may mobilise lobbies and pressure 
groups. This complex of direct and indirect and more or less conflicting interests places 
pharmacovigilance at the centre of a sort of arena (see figure l).'49·50' 
Within this interplay of forces, lack of transparency or secrecy of data can lead to unbal-
anced conclusions, confusion of both patients and physicians, and public mistrust.'51' 
Herxheimer and others have recently criticised the undue secrecy prevalent in pharma-
covigilance and drug regulation.'51"54' 
4.12 Can pharmacovigilance be 'privatised'? 
In the past 25 years spontaneous reporting has become a mainstay of pharmacovigi-
lance. The various procedures and requirements for spontaneous reporting are well 
recognised and expected soon to be laid down in 'good practice' (see the 3rd paragraph 
of the Introduction and chapter 3).'226' The level of performance of a national sponta-
neous reporting system can be evaluated by using international experiences as a stan-
dard (e.g. as regards the number, quality and source of case reports). The primary 
governmental responsibility is to ensure that an appropriate pharmacovigilance system 
is in place in the country, providing the regulatory agency with the necessary infor-
mation. It may be disputed, however, whether a national pharmacovigilance organisa-
tion should itself be a government agency. What is needed in the first place is that phar-
macovigilance should be able to thrive in an environment of independence and be 
somewhat protected from possible influences relating to the interests discussed earlier 
in this chapter. Some distance between the pharmacovigilance system and the govern-
ment may favourably influence the problem of underreporting. 
In the United Kingdom prescription event monitoring - as an additional countrywide 
pharmacovigilance system - has been developed as a private initiative, in the form of a 
trust.'55' In the Netherlands the national spontaneous reporting system has recently 
been contracted out to an autonomous foundation (the Netherlands Pharma-
covigilance Foundation, LAREB), subsidised by the government.·56' With these exam-
ples in mind, and in line with current political views, it may be deemed appropriate to 
delegate the processes of collection, assessment and distribution of pharmacovigilance 
data to a separate organisation, e.g. a foundation or a trust. This could foster both the 
advancement of pharmacovigilance and its integration in the health care community. 
Whatever the case may be, scientific independence and continuity of financial resour-
ces must be guaranteed. 
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4.13 Implications 
In the early sixties, in the aftermath of the thalidomide tragedy, spontaneous reporting 
was the only conceivable early warning system for possible new drug-induced disasters. 
In spite of early scepticism, spontaneous reporting has proved to be a continuing source 
of useful information on adverse effects and other drug related problems. The princip­
les, procedures, strengths and weaknesses of spontaneous reporting have by now large­
ly taken shape. Professionalisation and formalisation, both as a scientific method and 
as an instrument in drug regulation, are currently taking place. 
In addition to spontaneous reporting, population studies are in increasing use in phar-
macovigilance, e.g. prescription event monitoring, case control surveillance and large 
linked data resources. The introduction of automation into medical and pharmaceuti­
cal practice administration and progress in computing technology are likely to lead to 
drastic changes in the routines of pharmacovigilance. The setting up of databases 
encompassing very large populations may allow the integration of different methods 
and synthesis of signal detection strategies. 
In coming years some issues may become of special interest in the development of phar­
macovigilance: 
4.13.1 Spontaneous reporting 
Improvement of the national spontaneous reporting system through: 
- An increase in the proportion of medical practitioners participating in spontaneous 
reporting. 
- The development of software for electronic reporting in automated medical and 
pharmaceutical administration systems. 
- The development of automated signal generation. 
- The establishment of rules for 'good practice' in spontaneous reporting, with spe­
cial reference to: 
- Ethical and legal basis of reporting. 
- Improvement of data availability and transparency in pharmacovigilance. 
- Development of criteria for the assessment of the performance of a pharmacovi­
gilance centre. 
4.13.2 Type С adverse effects 
The development or improvement of additional methods in phatmacovigilance, espe­
cially with regard to the study of type С adverse drug effects. 
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4.13.3 Risk/benefit evaluation 
Intensification of the scientific study of medicines after approval, e.g. for signai testing, 
frequency estimation of adverse reactions, identification of risk determinants, and elu-
cidation of reaction mechanisms. Such studies are needed for careful and integrated 
assessment of the benefits and risks of drugs, which, in turn, is the basis of well-consid-
ered drug regulation (for example, the periodic renewal of marketing authorisations) 
and, more generally, rational drug use. 
4.13.4 Independence and transparency 
In the midst of different and possibly conflicting interests, pharmacovigilance needs a 
climate of independence, whether scientific, political or financial, to allow for due col-
lection and assessment of the data. On the other hand, the system must be as transpa-
rent as possible, to ensure public confidence. Also, information must be readily availa-
ble and distributed. However, the possibility that preliminary or ambiguous data may 
lead to erroneous conclusions, drug scares and commercial damage poses a dilemma. 
'Good practice' in pharmacovigilance and in communications may be an appropriate 
solution. 
4.13.5 From pharmacovigifance to pharmacotherapy 
The ultimate aim of pharmacovigilance is that new information be rapidly and effec-
tively incorporated into therapeutic decision making, by physicians, pharmacists and 
patients, by drug information professionals and formulary committees, by regulators 
and pharmaceutical companies. More comprehensive and efficient pharmacovigilance 
should further improve the safe introduction of new medicines and foster rational 
pharmacotherapy. 
REFERENCES 
1. International drug monitoring: the role of national centres. Wld Hlth Org techn Rep Scr, No 498, Geneva, 
1972. 
2. Safer)' Monitoring of Medic-al Drugs. Guidelines for setting up and running of a Pharmacovigilance Centre. 
World Health Organi/arion, Geneva, 1998. 
3. Doller)' CT, Rawlins MD. Monitoring adverse reactions to drugs. Brit Med J 1977;1:96-7. 
4. New strategies for drug monitoring. Bnr Med J 1977;1:861-2. 
5. Venning CìR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. 
Brit Med J 1982,284-249-251. 
6. Griffin JP, Weber JCP. Voluntary systems of adverse reation reporting. Part 1. Adv Drug React Ac Pois Rev 
1985,4.213-30. 
137 
7 Griffin JP, Weber JCP Voluntary systems of adverse reation reporting Part 2 Adv Drug React Ac Pois Rev 
1986,5 23-55 
8 Inman W H W (Ed) Monitoring for Drug Safer)' MTP Press, Lancaster, 1986 
9 Mann RD The yellow card data the nature and scale of the adverse drug reactions problem In Mann RD 
(Ed) Adverse drug reactions Parthenon Publishing, Carnforth, 1987 (pp 5-66) 
10 Rawlins M D Spontaneous reporting of adverse drug reactions Brit J Clin Pharmacol 1988 26 1 11 
11 Drug monitoring in the Nordic countries An evaluation of similarities and differences Nordic Council on 
Medicines, Uppsala, 1989 
12 Mann RD Drug safety alerts - a review of'Current Problems' Pharmacoepidemiology and Drug Safety 
1992,1 269-79 
13 Meyboom RHB, Gnbnau FW], Hekster YA, De Koning GHP, Egberts ACG Characteristics of topics in 
pharmacovigilance in the Netherlands Clin Dtug Invest 1996,4 207-19 
14 XIII Journées Françaises de Pharmacovigilance Thérapie 1992,47(5) 359-453 
15 European Society of Pharmacovigilance ESOP 4th Annual Meeting, Lisbon, September 18-20, 1996 
16 Fucik H, Edwards, IR Impact and credibility of the W H O adverse reaction signals Drug Information 
Journal 1996,30 461-4 
17 Spnet-Pourra C, Auriche M Drug withdrawal from sale an analysis of the phenomenon and its implications 
PJB Publications, Richmond, 1988 
18 OlssonS(Ed) National pharmacovigilance systems Country profiles and overview I he Uppsala Monitoring 
Centre, S-75103 Uppsala, Sweden, 1997 
19 Belton, KJ European Pharmacovigilance Research Group Oral Communication Meeting 21 March, 
Amsterdam-Schiphol Hilton Hotel 
20 Notice to applicants for marketing authorisations for medicinal products for human use in the Furopean 
(Draft) Chapter V, Pharmacovigilance of medicinal products for human use Commission of the European 
Communities Community Ш/5944/94 (December 1994) 
21 Procedures for competent authorities on the undertaking of pharmacovigilance activities European Agency 
for the Evaluation of Medicinal Products F M F \ , CPMP/175/95, Iondon 1995 
22 Koning GPII A regionalized spontaneous surveillance program for adverse drug reactions as a tool to 
improve pharmacothetapy Academic thesis Utrecht University, Faculty of Pharmaceutical Sciences, 1993 
23 Egberts I CG, Smulders M, De Koning FHP, Meyboom RHB, Leufkens H G M Can adverse drug reactions 
be detected earlier' A comparison of reports by patients and professionals Brit Med J 1996,313 530-1 
24 Strom BI (Ed) Pharmacoepidemiology John Wiley, Chichester, 1994 (2d Edition) 
25 Meyboom RHB Good Practice in the Postmarketing Surveillance of Medicines Pharmacy World Science 
1997,19 187-90 
26 Edwards R, Lindquist M, Wiholm BE, Napke e, et al Quality entena for earlv signals of possible adverse drug 
reactions lancet 1990,336 156-8 
27 Yellow card reporting by doctors Current Problems in Pharmacvigilance 1997,23 6 Medicines Control 
Agency, Market lowers, 1 Nine Flms Lane, I ondon SW8 5 N Q 
28 Botiger LE, Westerholm В Drug-induced blood dvscrasias in Sweden Brit Med J 1973,3 339-43 
29 I umley CE, Walker SR, Hall G C . Staunton N, Grob PR The under-reporting of adverse drug reactions in 
general practice Pharmaccut Med 1986,1 205-12 
30 Meyboom RHB, Egberts ACG, Edwards IR, Gnbnau FWJ, Hekster YA, De Koning GHP Principles of sig­
nal detection in pharmacovigilance Drug Safety 1997,16 355-65 
31 Uppsala Reports, Issue 4, May 1997, page 3 
32 Mann RD Databases, privacy, and confidentiality - the effect of proposed new legislation on pharmacoepi­
demiology and drug safety monitoring In Aronson JK, Van Boxtel CJ (Eds) Side Effects of Drugs Annual 
18, Flsevier, Amsterdam, 1995 (xxi-xxxv) 
33 Finney DJ Statistical logic in the monitoring of reactions to therapeutic drugs In Inman W H W (Ed) 
Monitoring for Drug Safety M 1Ρ Press, Lancaster, 1986 (pp 423-4433-442) 
34 Egberts ACG, Van der Hofstede JW, Meyboom RHB De Koning GHP, Bakker A, Leufkens H G M 
Iransformation of a data base of spontaneously reported suspected adverse drug reactions and its use as tool 
in signal detection In Egberts ACG Pharmacoepidemiologic approaches to the evaluation of antidepressant 
drugs (112-124) Utrecht Universiry, Taculty of Pharmacy (PhD Thesis), Utrecht, 1997, ISBN 90 393-1771-
2 
35 Strieker BHCh Tijssen JGP Scrum sickness-like reactions to cefaclor J Clin Fpidemiol 1992,45 1177-84 
36 Egberts AC G, Meyboom RHB, De Koning ΓΗΡ, Bakker A, Leufkens H G M Non puerperal lactation asso­
ciated with antidepressant drug use Br J Clin Pharmacol 1997,44 (in press) 
37 Charlton BG Attribution of causation in epidemiology chain or mosaic' J Clin Fpidemiol 1996,49 105-7 
38 Goldberger AI Non-linear dvnamics for clinicians chaos theory, fractals, and complexity at the bedside 
I-ancer 1996,347 1312-4 
138 
39 Cross SS, Harrison Rh Kennedy RL Introduction co neural networks Lancet 1995346 1075-9 
40 AlvagcrT, Smith Γ], Vijai F Neural-network applications for analysis of adverse drug reactions Biomedical 
Instrumentation & Iechnology 199? 27 408-11 
41 Linsner A, Hoist A A higher order Bayesian neural network with spiking units International Journal of 
Neural Systems 1996,7 115-28 
42 Rikken F, Kiers H A I , Vos R Mapping the dynamics of adverse drug reactions in subsequent time periods 
using INDSC AL Scientometncs 1995,33 367-80 
43 Roscam Abbing H D C Informatie en toestemming in de gezondheidszorg, recente ontwikkelingen Ned 
Indschr Geneeskd 1994,138 2561-4 
44 Editorial Time to act to avoid drug-safety scares Lancet 1997,350 1041 
45 Wijziging Besluit U R geneesmiddelen Staatscourant 107, 10 juni 1993 
46 Meyboom RHB Side effects of self-medication drugs In Fryklof LE, Westerling R Sclf-Mcdication 
Journal of Social and Administrative Pharmacy, Suppl 1984 1 Swedish Pharmaceutical Press, Stockholm, 
1984 
47 Temin Ρ Costs, benefits, and politics in switching drugs from prescription to over-the-counter in the 
United States In Fryklof I b, Westerling R Self-Medication Journal of Social and Administrative 
Phatmacy, Suppl 1984 1 Swedish Pharmaceutical Press, Stockholm, 1984 (pp 189-200) 
48 Dukes MNG, Swartz В Responsibility for drug-induced injury A reference book for lawyers, the health 
professions and manufacturers Flsevicr Science Publishers, Amsterdam, 1988 
49 Me) boom RFIB Observations with regard to pharmacovigilancc in the Netherlands and in the European 
Community RAD AR Meeting, I ondon, 1 March 1991 
50 McNamce D Speaking about pharmacovigilancc Lancet 1996,348 908 
51 Mcdawar С Sccrecv and medicines Int J Risk Safety Med 1996,9 133-41 
52 Dukes M N G Drug regulation and the tradition of secrecy Int J Risk Safety Med 1996,9 143 9 
53 Herxheimer A Side effects freedom of information and the communication of doubt Int J Risk Safety 
Med 1996,9 201-10 
54 Statement or the International Working Group on transparency and accountability in drug regulation Int J 
Risk Safety Med 1996,9 211-7 
55 Inman W H W 30 Years in postmarketing surveillance A personal perspective Pharmacoepidemiology and 
Drug Safety 1993,2 239 58 
56 Brockmans AW, Lekkerkerker JFF, De Koning GHP, Vree PH Nieuwe regels voor het melden \an bijwer­
kingen in Nederland na 1995 Ned 1 ijdschr Geneeskd 1996,140 1166-7 
139 

Summary 
Introduction 
/ Why pharmacovigilance? 
Medical drugs are thoroughly tested - first in animals and subsequently in human vol-
unteers and patients - prior to their release onto the market. Nevertheless, studies must 
continue after introduction and special vigilance is needed to complement available 
knowledge of the various adverse effects and other features of the drug. The reasons are 
given in this chapter. 
2 Objective and outline of this thesis 
The aim of this thesis is to try to evaluate expetiences with pharmacovigilance in the 
Netherlands and to provide information useful for understanding the scientific basis of 
pharmacovigilance and for further development and improvement of the pharmacovi-
gilance system in this country. The thesis consists of an Introduction and four subse-
quent sections. Section 1 is concerned with the detection of (unknown and unexpect-
ed) adverse drug reactions and the principles and mechanisms involved. In section 2 
case-causality assessment (imputation) is reviewed. Ethical issues and 'good practice' in 
pharmacovigilance are addressed in section 3. Finally, in section 4 pharmacovigilance 
is discussed in the perspective of pharmacotherapy, drug regulation and possible future 
developments. 
3 Spontaneaous reporting 
In addition to the information derived from the medical and pharmaceutical literature, 
spontaneous reporting - the country-wide system for reporting of suspected adverse 
effects of drugs - is currently the most important source of information routinely used 
in pharmacovigilance around the world. This paragraph provides details regarding the 
principles, procedures and functioning of a spontaneous reporting system. 
Chapter 1.1 Characteristics of topics in pharmacovigilance in The Netherlands 
A retrospective analysis was made of the nature and composition of 107 consecutive 
topics ptesented in publications by or in collaboration with the national pharmacovi-
gilance centre in The Netherlands, containing data obtained through 'spontaneous 
reporting'. These topics were written about in various national and international jour-
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nais, special bulletins or as 'dear doctor letters'. The topics comprise a wide variety of 
events and disorders. There is, however, a predominance of concrete, characteristic and 
often serious diseases, notably specific hypersensitivity reactions (43%, e.g. anaphy­
laxis, blood dyscrasias and liver injury), toxic manifestations or syndromes (30%, espe­
cially involving the nervous system), and drug interactions (13%). Most reports pre­
sented predominantly qualitative information. Sixty two percent of the topics 
concerned type B, 33% type A and 3% type С adverse effects. (Type A adverse effects 
are related to the pharmacological effect of the drug and are dosage-related; type В 
effects are often allergic or idiosyncratic reactions; type С effects are related to an in­
creased frequency of 'spontaneous' disease.) Examples of other sources of signals in 
pharmacovigilance are prescription event monitoring, large automated data resources 
concerning morbidity and drug use (including record linkage), case-control surveil­
lance and follow-up studies. The topics often involved small numbers of case reports: 
10 or less in 70% of the 107 topics. Of the topics 46% discussed new information. 
There was some predominance of established (56%) over new drugs. Five pharmaco-
therapeutic groups accounted for 74% of topics. Of the 72 approved drugs or drug 
groups, 12 (17%) have since been removed from the market. 
The study results led to the following observations, which may contribute to the fur­
ther improvement of the methods and strategies in pharmacovigilance. 
1. Pharmacovigilance must keep an open mind regarding the new, the unusual and 
the unexpected. The routines involved should allow for the precise recording of 
case histories and not lead to simplification or distortion of adverse events. 
2. Spontaneous reporting is particularly useful in the detection of type В adverse 
effects and of type A effects that were not identified during clinical testing (includ­
ing drug interactions), but it is of less value in the study of type С effects. 
3. A limited number of adverse effects account for most of the more serious problems 
encountered in pharmacovigilance. Pharmacovigilance may be improved by inten­
sified monitoring of these effects. 
4. Information derived from even small numbers of case reports may provide valuable 
information and lead to the detection of new adverse effects. 
5. The provision of first reports (i.e. on new adverse effects) is a major role of phar­
macovigilance. 
6. In addition, dissemination to health care practitioners of all sorts of information 
relevant to the knowledge of adverse effects and to the appropriate use of medicines 
(including reminders of previously reported adverse effects) is an important func­
tion of pharmacovigilance. 
7. Pharmacovigilance should cover all drugs on the market, whether new or esta­
blished, approved or unorthodox. 
8. Pharmacovigilance topics often concern predominantly qualitative information. 
Precise quantitative information (frequency) often demands additional studies. 
142 
9. Signal detection speed is directly dependent on the size of the monitored popula­
tion of drug users and therefore on the proportion of physicians contributing to 
the reporting system. Underreporting delays the detection of rare adverse effects. 
In addition, the capacity of spontaneous reporting to provide clues with regard to 
the frequency of adverse effects (important for regulatory decision-making) also 
depends on the proportion of reporting physicians. 
10. Integration of national and international pharmacovigilance requires further devel­
opment. 
Chapter 1.2 Principles of signal detection in pharmacovigilance 
Adverse drug effects are manifold and heterogeneous. Several situations may hamper 
the signalling (i.e. the detection of early warning signs) of adverse effects and new sig­
nals often differ from previous ones. 
Signals have qualitative and quantitative aspects. Different categories of adverse effects 
need different methods for detection. Current pharmacovigilance is predominantly 
based on spontaneous reporting and is mainly helpful for detection of type В effects 
(effects that are often allergic or idiosyncratic reactions, characteristically occurring in 
only a minority of patients and usually unrelated to dosage, and that are serious, unex­
pected and unpredictable) and unusual type A effects (effects that are related to the 
pharmacological effect of the drug and are dosage-related). Examples of other sources 
of signals are prescription event monitoring, large automated data resources on morbi­
dity and drug use (including record linkage), case-control surveillance and follow-up 
studies. Type С effects (effects related to an increased frequency of'spontaneous' dis­
ease) are difficult to study, however, and continue to pose a pharmacoepidcmiologic 
challenge. 
Seven basic considerations can be identified that determine the evidence contained in 
a signal: quantitative strength of the association, consistency of the data, exposure 
response relationship, biological plausibility, experimental findings, possible analogies, 
and the nature and quality of the data. A proposal is made for a standard signal manage­
ment procedure at pharmacovigilance centres, including the following steps: signal 
delineation, literature search, preliminary inventory of data, collection of additional 
information, consultation with the World Health Organization Centre for 
International Drug Monitoring (Uppsala) and the relevant drug companies, aggrega­
ted data assessment and a written report. 
Thus, different adverse effects need different methods of detection. Signals in pharma­
covigilance originate from a variety of sources. Pharmacovigilance must not rely upon 
one single method but needs a strategy of complementary activities. Signals arc essen­
tially suspicions. The testing of signals demands further analytical and experimental 
studies. 
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A better understanding of the conditions and mechanisms underlying the detection of 
adverse drug effects may allow further improvements in pharmacovigilance. 
Chapter 2.1 Causality assessment at pharmacovigilance centres 
in the European Community 
The assessment and classification of the likelihood of a causal relationship between a 
drug and a suspected adverse reaction, also referred to as imputation, has received much 
attention in pharmacovigilance. Comparison of the procedures in use at national phar­
macovigilance centres in the countries of the European Union (EU) and in three coun­
tries outside the community (Sweden, Australia and Canada) showed that causality 
assessment has developed somewhat differently in different countries. In spite of the 
differences, the procedures in most EU countries have much in common and three 
basic causality categories — named А, В and О - could be recognised, covering the vast 
majority of case reports from different countries. As a step towards harmonisation in 
the EU, and in order to facilitate international data processing and drug regulation, the 
Committee for Proprietary Medicinal Products (CPMP) adopted the use of these three 
categories. 
The scientific basis of pharmacovigilance is still in development and the strategies for 
causality assessment may change in the future. The establishment of European drug 
regulation, and the increase in worldwide collaboration require further harmonisation 
of causality assessment and other procedures in pharmacovigilance. 
Chapter 2.2. Causal or casual? The role of causality assessment in pharmacovigilance 
Like any other study method, spontaneous reporting is a process of data acquisition, 
assessment, presentation and interpretation. The provision of information - i.e. of 
interpreted data - concerning previously unknown or otherwise important adverse 
reactions is a major goal. The assessment of case reports takes place in two steps: first 
the assessment of each case individually, and second the interpretation of the aggrega­
ted data. The latter step is only completed for a minority of case reports, e.g. when 
actions or measures are deemed necessary. 
Uncertainty in case reports as regards the involvement of the suspected drugs is an 
inherent drawback of spontaneous reporting. Standardised case causality assessment 
has become routine at pharmacovigilance centres around the world. It aims at a de­
crease in ambiguity of the data and plays a role in data exchange and the avoidance of 
erroneous conclusions. A variety of systems for standardised causality assessment have 
been developed, ranging from short questionnaires to comprehensive algorithms. Since 
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none of the available assessment systems has been validated, i.e. shown to consistently 
and reproducibly reveal a fair approximation of the truth, causality assessment has only 
limited scientific value. Causality assessment neither eliminates nor quantifies uncer-
tainty but, at best, categorises it semiquantitatively. 
Routine causality assessment is usually part of the first step in case assessment and is 
based on a general system, i.e. intended for all reactions and all drugs. During the sub-
sequent phase of aggregated assessment, causality assessment is likely to be repeated and 
the use of a specific etiologic-diagnostic system may be more appropriate. It is recom-
mended that case causality assessment be restricted to selected case reports that are like-
ly to play an active role in pharmacovigilance and to use specific systems, adapted to 
the reaction or problem involved. 
It is an inherent limitation of spontaneous reporting that, with the exception of rare 
proof-positive case reports, conclusive evidence cannot usually be produced. Standard-
ised causality assessment has not really changed this situation. As a rule, confirmation 
of the connection between a drug and an adverse reaction requires further analytic or 
experimental study. 
Chapter 3 Good practice in the post-marketing surveillance of medicines 
In addition to Good Clinical Trial Practice for the study of experimental drugs, regu-
lations are also needed for good practice in the assessment of medicines after approval 
(Good PMS Practice, GPP). GPP has to protect the interests of public health at large 
as well as those of individual patients, investigators and pharmaceutical companies. 
GPP may be the natural way to solve looming conflicts between privacy legislation and 
the public interest. 
Chapter 4 Pharmacovigilance in perspective 
In the early sixties, in the aftermath of the thalidomide tragedy, spontaneous reporting 
was the only conceivable early warning system for possible new drug-induced disasters. 
In spite of early scepticism, spontaneous reporting has proved to be a continuous source 
of useful information on adverse effects and other drug-related problems. The princi-
ples and procedures, the strengths and weaknesses of spontaneous reporting have by 
now largely taken shape. Professionalisation and formalisation of pharmacovigilance, 
both as a scientific method and as an instrument in drug regulation, are currently 
taking place. 
In addition to spontaneous reporting, population studies are increasingly used in 
pharmacovigilance, e.g. prescription event monitoring, case control surveillance and 
large linked data resources. The introduction of automation into medical and phar-
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maceutical practice administration and progress in computing technology are likely to 
drastically change routines in pharmacovigilance. The setting up of databases encom­
passing very large populations may enable the integration of different methods and syn­
thesis of signal detection strategies. 
In the next few years the following issues may be of special interest in the development 
of pharmacovigilance: 
Spontaneous reporting 
Improvement of the national spontaneous reporting system, through: 
- Increase in the proportion of medical practitioners participating in spontaneous 
reporting. 
- Development of software for electronic reporting in automated medical and phar­
maceutical administration systems. 
- Development of automated signal generation. 
- Establishment of rules for 'good practice' in spontaneous reporting, with special 
reference to: 
- Ethical and legal basis of reporting. 
- Improvement of data availability and transparency in pharmacovigilance. 
Development of criteria for assessment of the performance of a 
pharmacovigilance centre. 
Type С adverse effects 
The development or improvement of additional methods in pharmacovigilance, espe­
cially with regard to the study of type С adverse drug effects. 
Risk/benefit evaluation 
Intensification of the scientific study of medicines after approval, e.g. for signal testing, 
frequency estimation of adverse reactions, identification of risk determinants, and elu­
cidation of reaction mechanisms. Such studies are needed for careful and integrated 
assessment of the benefits and risks of drugs, which, in turn, is the basis of well-consid­
ered drug regulation (for example, the periodic renewal of marketing authorisations) 
and, more in general, a rational drug use. 
Independence and transparency 
In the midst of different and possibly conflicting interests, pharmacovigilance needs a 
climate of independence, in scientific, political and financial respects, for due collec­
tion and assessment of the data. O n the other hand, the system must be as transparent 
as possible, to ensure public confidence. Also, information must be readily available 
and distributed. A dilemma is that preliminary or ambiguous data may lead to errone­
ous conclusions, drug scares and commercial damage. 'Good practice', in pharmacovi­
gilance and in communications, may be the appropriate solution. 
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Front pharmacovigiL·nce to pharmacotherapy 
The ultimate aim of pharmacovigilance is that new information is rapidly and effec-
tively incorporated in therapeutic decision making, by physicians, pharmacists and 
patients, by drug information professionals and formulary committees, by regulators 
and pharmaceutical companies. More comprehensive and efficient pharmacovigilance 
should further improve the safe introduction of new medicines and foster rational 
pharmacotherapy. 
147 

Samenvatting 
Inleiding 
1 Waarom farmacovigibnce? 
De epidemie van invaliderende aangeboren misvormingen door het slaapmiddel thal-
idomide (Softenon), in het begin van de zestiger jaren, heeft velen de ogen geopend 
voor het feit dat veilig geachte geneesmiddelen soms oorzaak kunnen zijn van ernstige 
bijwerkingen. Deze gebeurtenis stond bovendien niet op zichzelf, maar was één in een 
langere rij van uiteenlopende ervaringen die met elkaar gemeen hadden dat het om 
onverwachte en ernstige bijwerkingen ging van, vaak veel-gebruikte, gewone genees-
middelen. Voordien waren er bijvoorbeeld agranulocytose (afbraak van de witte bloed-
lichaampjes) door aminofenazon, remming van de bloedaanmaak (aplastische anemie) 
door chlooramfenicol, chronische niervergiftiging door pijnstillers zoals Saridon en 
kwaadaardige gezwellen ten gevolge van het zo gemakkelijk toe te passen röntgencon-
trastmiddel thoriumdioxide. Later volgden de tot verlamming en blindheid leidende 
'subacute myelo-optic neuropathy' door clioquinol (toen beter bekend als Entero-
vioform of Mexaform), leverontsteking door erythromycine-estolaat, ontsteking en 
vergroeiing van het buikvlies en het bindvlies (van het oog) door practolol en, opnieuw, 
een epidemie van vaak ernstige aangeboren schade, nu door diëthylstilbestrol, de eens 
zo populaire remedie ter bescherming van de zwangerschap. 
Blijkbaar zijn ten tijde van de toelating van een nieuw geneesmiddel, ondanks al het 
onderzoek dat hieraan is voorafgegaan, nog niet alle bijwerkingen bekend. Het gebrui-
kelijke klinische geneesmiddelenonderzoek (clinical trial) is in de eerste plaats geschikt 
voor het aantonen van de geneeskundige werking van het geneesmiddel. Wat de bestu-
dering van bijwerkingen betreft, met name als deze weinig frequent zijn, zijn de aan-
tallen patiënten in het onderzoek aan de kleine kant. Ook de duur van het onderzoek 
is beperkt, waardoor bijwerkingen die pas na verloop van tijd ontstaan kunnen worden 
gemist. Clinical trial-patiënten zijn voor het onderzoek uitgekozen. Zij zijn relatief 
gezond en gebruiken weinig of geen andere geneesmiddelen. Bepaalde groepen, zoals 
ouderen, kinderen en zwangere vrouwen, worden vaak van dergelijk onderzoek uitge-
zonderd. Na de toelating wordt het geneesmiddel vaak door meer gevarieerde patiën-
tengroepen en onder uiteenlopende omstandigheden gebruikt en kunnen onverwachts 
bijwerkingen en interacties met andere geneesmiddelen aan het licht komen. 
De bovengenoemde gebeurtenissen leidden omstreeks 1970 in veel landen tot het tot 
stand brengen van een landelijk meldpunt voor vermoede bijwerkingen. Als alle artsen 
voortaan hun vermoedens over mogelijke bijwerkingen centraal zouden melden, dacht 
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men, zouden nieuwe bijwerkingen in de kortst mogelijke tijd worden opgespoord. 
Hoewel sindsdien is gebleken dat het snel en betrouwbaar opsporen van bijwerkingen 
van geneesmiddelen niet zo gemakkelijk is als het leek, heeft een kwart eeuw ervaring 
in binnen- en buitenland laten zien dat het meldingssysteem een waardevolle bijdrage 
levert aan het onderzoek van geneesmiddelen na de toelating. Het is, naast de infor-
matie die incidenteel in de internationale vakpers verschijnt, een belangrijke bron van 
informatie geworden voor wat men tegenwoordig wel geneesmiddelenbewaking of 
'farmacovigilance' noemt. Farmacovigilance is overigens nog volop in ontwikkeling en 
verbeteringen zijn nodig. 
2 Doel en opbouw van hetproefichrifi 
Dit proefschrift wil een bijdrage leveren aan de principes en de uitvoering van het 
wetenschappelijk onderzoek van geneesmiddelen na de toelating, toegespitst op de 
doelstellingen van farmacovigilance. Nagegaan wordt of uit de ervaringen in ons land 
tot nu toe - hoe het systeem heeft gefunctioneerd, de onderwerpen die aan de orde zijn 
geweest, en de problemen die zich hebben voorgedaan - lering kan worden getrokken 
die van nut is voor de verdere ontwikkeling en verbetering van farmacovigilance. 
In de inleiding wordt ingegaan op de probleemstelling, de opbouw van het proefschrift 
toegelicht en aandacht besteed aan de methodiek van het landelijke meldingssysteem. 
Hierna volgen vier secties. Sectie 1 bestaat uit twee hoofdstukken en gaat in op de prin-
cipes en processen die ten grondslag liggen aan 'signaal detectie in farmacovigilance: het 
op het spoor komen van mogelijke of waarschijnlijke bijwerkingen. In hoofdstuk 1.1 
worden de ervaringen van het voormalige Bureau Bijwerkingen Geneesmiddelen 
geanalyseerd, met betrekking tot de onderwerpen die in de aandacht hebben gestaan 
(de aard van de bijwerkingen en de identiteit van de betrokken geneesmiddelen) en de 
samenstelling van de informatie. Naar aanleiding hiervan worden een aantal concrete 
aanbevelingen gedaan voor de toekomstige ontwikkeling van farmacovigilance, zoals 
dit in ons land thans door de stichting LAREB wordt gerealiseerd. In hoofdstuk 1.2 
wordt in algemene zin aandacht besteed aan de wetenschappelijke achtergrond van sig-
naaldetectie, en ingegaan op vragen zoals wat een signaal is, waar signalen kunnen wor-
den gevonden, hoe zij in elkaar zitten en hoe ermee moet worden omgegaan. 
Sectie 2 is gewijd aan een element van farmacovigilance dat in de afgelopen 15 jaar in 
het centrum van de belangstelling heeft gestaan: de beoordeling van het verband tus-
sen geneesmiddelen en vermoede bijwerkingen in individuele patiënten of meldingen. 
In hoofdstuk 2.1 is een overzicht gegeven van de diverse methoden voor causaliteitsbe-
oordeling die in de literatuur en door de nationale farmacovigilance centra in een aan-
tal landen binnen en buiten de Europese Unie zijn ontwikkeld en is het systeem toege-
licht dat door de Pharmacovigilance Working Party van de Europese Commissie werd 
uitgewerkt ten behoeve van harmonisatie in de EU. In het volgende hoofdstuk 2.2 is 
meer in het algemeen ingegaan op de wetenschappelijke achtergrond van causaliteits-
beoordcling, wordt een afweging gemaakt van het nut en de beperkingen ervan en wor-
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den aanbevelingen gedaan voor de toekomstige rol van causaliteitsbeoordeling in far-
macovigilance. 
Hoewel de omstandigheden verschillen heeft farmacovigilance met klinisch genees-
middelenonderzoek gemeen dat het is gebaseerd op waarneming bij werkelijke patiën-
ten. Aan het gebruik van patiëntengegevens zijn beperkingen en verplichtingen ver-
bonden, die voortvloeien uit ethiek, medisch/farmaceutisch beroepsgeheim en 
regelgeving ten aanzien van de medische behandelingsovereenkomst en bescherming 
van de persoonlijke levenssfeer. 
Sectie 3 heeft betrekking op het waarborgen van de ethische kanten van farmacovigi-
lance, de kwaliteit van de gegevens en het juiste gebruik van de gegevens. Hierbij is de 
aandacht geconcentreerd op het tot ontwikkeling brengen van 'good practice' in far-
macovigilance (zoals in het verleden voor klinisch geneesmiddelenonderzoek heeft 
plaatsgevonden). 
In de afsluitende sectie 4 wordt de balans opgemaakt van wat met farmacovigilance op 
dit moment mogelijk is en wat niet, ingegaan op de plaats ervan in het ingewikkelde 
complex van geneesmiddelenontwikkeling, -beleid en -gebruik, en gepreludeerd op de 
mogelijke ontwikkelingen in de toekomst. In de Nederlandse samenvatting is bewust 
meer uitgebreid op het onderwerp van het proefschrift ingegaan dan in de Engelse 
samenvatting. 
3 Het landelijke meldingssysteem 
Het landelijke meldingssysteem is een gestructureerde manier om gegevens uit de prak-
tijk te verzamelen over ervaringen van patiënten met vermoede bijwerkingen en ande-
re mogelijke problemen met geneesmiddelen. Meldingen zijn bij voorkeur afkomstig 
van praktizerende artsen, apothekers en tandartsen. Het melden is spontaan (er is geen 
verzoek uitgegaan om een specifieke geneesmiddel-bijwerking combinatie te rapporte-
ren), vrijwillig (geen wettelijke verplichtingen voor artsen of apothekers) en vertrou-
welijk (gegevens die herleidbaar zijn tot individuele personen en instellingen blijven 
geheim). Sinds de introductie in diverse landen, zo'n kwart eeuw geleden, heeft het 
meldingssysteem zich ontwikkeld tot een specifieke methode, met eigen principes en 
procedures, met sterke en zwakke kanten. Het is tot de dag van vandaag de hoeksteen 
van farmacovigilance. De voornaamste doelstellingen zijn: 
1. Het snel ontdekken van onverwachte, nog onbekende bijwerkingen. 
2. Het signaleren van een eventuele toename van de frequentie van een bijwerking. 
3. Het op het spoor komen van risicofactoren en mechanismen van bijwerkingen. 
4. Kwantitatieve evaluatie van bijwerkingen. 
5. Het interpreteren van gegevens en verspreiden van informatie. 
Het uiteindelijke doel van farmacovigilance is het bevorderen van rationeel en veilig 
geneesmiddclengebruik. 
De eerste taak van het meldingssysteem is het signaleren van ongewone en relatief zeld-
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zame bijwerkingen zoals overgevoeligheidsreacties. Onderrapportagc en onzekerheid 
over de causale rol van de verdachte geneesmiddelen zijn oorzaak van beperkingen. Het 
systeem is minder geschikt voor het vaststellen van de frequentie van bijwerkingen. 
Voor het definitieve bewijs dat een geneesmiddel een bepaalde bijwerking kan veroor-
zaken is vaak verder onderzoek nodig. Het welslagen van het meldingssysteem hangt 
vooral af van de mate waarin artsen - in kwaliteit en kwantiteit - daadwerkelijk mede-
werking verlenen aan deze landelijke organisatie. 
Hoofdstuk 1.1 Kenmerken van publicaties waarin resultaten van het Nederlandse 
meldingssysteem zijn gebruikt 
In de periode 1973-1990 zijn in totaal 107 berichten gepubliceerd waarin gegevens van 
het Bureau Bijwerkingen Geneesmiddelen waren verwerkt. Deze berichten werden op 
uiteenlopende manier in de bekendheid gebracht: in landelijke vakbladen zoals 
Nederlands Tijdschrift voor Geneeskunde, Pharmaceutisch Weekblad, Genees-
middelenbulletin, gedurende enige tijd in een speciaal Bulletin Bijwerkingen en enke-
le malen in een brief rechtstreeks aan artsen en apothekers, en daarnaast ook in inter-
nationale wetenschappelijke tijdschriften. De berichten hadden betrekking op een 
opmerkelijk grote diversiteit van onderwerpen. Desondanks was een bepaald patroon 
te herkennen: het ging in veel gevallen om serieuze ziekten, vaak met karakteristieke en 
ernstige verschijnselen. Op de voorgrond traden specifieke overgevoeligheidsreacties 
zoals anafylaxie, bloeddyscrasieën en hepatitis (tezamen 43%), toxische effecten op 
bepaalde organen (in het bijzonder het centrale zenuwstelsel; in totaal 30%), en inter-
acties (13%). De meeste berichten gaven kwalitatieve informatie over bijwerkingen; 
slechts in enkele gevallen werd ook de kwantitatieve kant belicht. 
'Bijwerkingen' zijn een bonte verzameling klachten, verschijnselen en ziekten, die met 
elkaar gemeen hebben dat geneesmiddelen bij het ontstaan ervan een rol hebben 
gespeeld. Een gangbare maar ruwe indeling is die in type А, В en С bijwerkingen. 
Onder type A bijwerkingen verstaat men dosisafhankelijke effecten waarbij de far­
macologische werking van het geneesmiddel op de voorgrond staat. Type В bijwerkin­
gen zijn meestal immunologische of idiosyncratische reacties, die niet of nauwelijks 
dosisafhankelijk zijn en slechts bij een klein deel van de patiënten optreden (maar vaak 
wel ernstig zijn). De aanduiding type С bijwerking slaat op de situatie dat een genees­
middel de kans op een - op zich niet zeldzame - ziekte vergroot, zonder dat er een in 
het oog springende tijdsrelatie met het geneesmiddel is. In 33% van de berichten ging 
het om type A, in 62% om type В en in maar 3% op type С bijwerkingen. De berich­
ten hadden vaak betrekking op een opmerkelijk klein aantal meldingen: minder dan 10 
in 70% van de gevallen. De berichten hadden iets vaker betrekking op oude genees­
middelen (56%) - gedefinieerd als langer dan 6 jaar op de markt — dan nieuwe genees-
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middelen. Vijf farmacotherapeutische geneesmiddelengroepen waren verantwoordelijk 
voor 74% van de berichten, namelijk geneesmiddelen die het centrale zenuwstelsel 
beïnvloeden, geneesmiddelen tegen infectieziekten, analgetica en antirheumatica, anti-
coagulantia en cardiovasculaire geneesmiddelen. 12 van de 72 betrokken geregistreer-
de geneesmiddelen zijn nadien uit de handel genomen. Of de betrokken bijwerkingen 
hierbij van invloed zijn geweest kon niet worden nagegaan. 
Uit het onderzoek kwamen de volgende punten naar voren die behulpzaam kunnen 
zijn bij het verder ontwikkelen en verbeteren van farmacovigilance: 
Men moet er voortdurend op bedacht zijn dat nieuwe bijwerkingen onverwachre en 
ongewone fenomenen kunnen zijn. Het landelijke meldingssysteem is vooral effectief 
voor het detecteren van type В bijwerkingen en type A bijwerkingen (waaronder inter­
acties tussen geneesmiddelen), die niet in het klinisch onderzoek aan het licht waren 
gekomen. Aan type С bijwerkingen - die voor de volksgezondheid van veel betekenis 
kunnen zijn - werd maar enkele malen aandachr besteed. 
Een beperkt aantal ziekten (bijvoorbeeld anafylaxie, hepatitis, bloeddyscrasieën) komt 
relatief vaak als bijwerking van geneesmiddelen voor. Intensieve bewaking van deze 
ziekten kan op een efficiënte manier de doelmatigheid van farmacovigilance vergroten. 
Het signaleren van nieuwe bijwerkingen is een belangrijke functie van farmacovigilan-
ce. Vaak is dit gebaseerd op maar een klein aantal meldingen. Daarnaast levert het mel-
dingssysteem een schat aan informatie op die van nut is voor het verstandig gebruik van 
geneesmiddelen, zonder dat het over een nieuw-ontdekte bijwerking gaat, bijvoorbeeld 
als attendering op een 'bekende' bijwerking die onderschat wordt. 
Farmacovigilance moet aandacht geven aan alle geneesmiddelen, nieuwe en oude, pre-
scriptie en zelfmedicatie, en ook aan de vele "onorthodoxe" producten zoals exotische 
kruidenpreparatcn die tegenwoordig veel gebruikt worden. 
De snelheid waarmee een zeldzame bijwerking kan worden ontdekt hangt mede af van 
de grootte van de onderzoekspopulatie, dat wil zeggen de proportie van de artsen die 
meewerkt aan het meldingssysteem. Met andere woorden, de opsporing van bijwer-
kingen wordt vertraagd naarmate de onderrapportage groter is. 
De bevinding dat slechts 14% van de berichten internationale gegevens bevatten, doet 
verondersrellen dat de internationale samenwerking op het gebied van farmacovigilan-
ce kan worden verbeterd. 
Hoofdstuk 1.2 Principes van signaaldetectie in farmacovigilance 
Zoals ook in hoofdstuk 1.1 was te zien, vormen bijwerkingen een zeer heterogene ver-
scheidenheid van ziekten en ziekteverschijnselen, die slechts met elkaar gemeen hebben 
dat een geneesmiddel bij het ontstaan ervan op de een of andere manier een rol heeft 
gespeeld. Nieuwe bijwerkingen van goedgekeurde geneesmiddelen zijn vaak onver-
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wacht en onvoorspelbaar, en het ontstaansmechanisme is vaak onduidelijk. Het ont­
dekken van dergelijke bijwerkingen kan door velerlei factoren worden bemoeilijkt of 
vertraagd. Goed beschouwd heeft iedere bijwerking zijn eigen geschiedenis. Er is niet 
een enkele methode waarmee alle bijwerkingen kunnen worden opgespoord. Signalen 
over mogelijke bijwerkingen kunnen een zeer verschillend herkomst hebben, waaron­
der clinical trials, meldingssystemen en epidemiologische gegevensbestanden. Voor ver­
schillende soorten bijwerkingen zijn verschillende opsporingsmethoden nodig. 
Uitgaande van de, overigens vrij grove, indeling in type А, В en С bijwerkingen, kan 
men concluderen dat spontane rapportage aan de landelijke centra of in de vaklitera­
tuur, vooral effectief is voor de detectie van type В bijwerkingen. Voor type A bijwer­
kingen is de clinical trial (fase III en fase IV) het onderzoeksinstrument van eerste 
keuze. Het meldingssysteem kan hierbij een waardevolle aanvulling zijn wanneer type 
A bijwerkingen ten tijde van de toelating nog niet aan het licht zijn gekomen, bijvoor­
beeld omdat zij weinig frequent zijn of alleen onder ongewone omstandigheden tot 
ontwikkeling komen. De detectie en evaluatie van type С bijwerkingen blijft een grote 
uitdaging voor de farmaco-epidemiologie. Recente resultaten met bijvoorbeeld case 
control-surveillance en gegevenskoppeling (record linkage) zijn in dit verband veelbe­
lovend, maar benadrukken tevens dat er nog een lange weg te gaan is voordat de veel­
heid van vragen en problemen op het gebied van de veiligheid van geneesmiddelen die 
op ons afkomen snel, betaalbaar en doeltreffend kunnen worden opgelost. 
Bij het ontdekken van een bijwerking kunnen drie fasen worden onderscheiden: sig­
naal generatie, signaal versterking en signaal bevestiging. Signaal detectie slaat op sig­
naal generatie en versterking tezamen. Zoals is geschetst in figuur 1 in hoofdstuk 2.1 
heeft tegen het einde van de tweede fase een afweging plaats van de beschikbare gege­
vens teneinde een voorlopig standpunt in te kunnen nemen over het verband tussen het 
geneesmiddel en de vermoede bijwerking, met het oog op de advisering van de 
medisch-farmaceutische gemeenschap en het beleid van het College ter beoordeling 
van geneesmiddelen en fabrikant of importeur. Pas tijdens de derde fase, waarin de 
hypothese in analytisch of experimenteel onderzoek wordt getoetst, worden de defini­
tieve antwoorden gegeven op de vraag of het oorzakelijk verband vaststaat, hoe frequent 
de bijwerking is, wat de risicofactoren zijn en welk mechanisme eraan ten grondslag 
ligt. Bij de voorlopige beoordeling van een signaal worden alle beschikbare gegevens 
betrokken en in onderlinge samenhang geïnterpreteerd. Er is een aantal kwalitatieve en 
kwantitatieve argumenten aan te geven dat hierbij vaak van invloed is: 
1. De sterkte van het signaal: bijvoorbeeld het aantal meldingen of de statistische dis-
proportionaliteit van een correlatie. 
2. Consistentie van de gegevens: de constante aanwezigheid van een bepaald symp-
toom of patroon. 
3. De aanwezigheid van een expositie-respons relatie: plaats van toediening, tijdsrela-
tie, dosisafhankelijkheid. 
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4. Biologische plausibiliteit van de hypothese: het vermoedelijke farmacologisch-
pathologische mechanisme. 
5. Experimentele bevindingen: bijvoorbeeld een recidive na herhaald gebruik, demon-
stratie van een afwijkend metabolisme of van geneesmiddelafhankelijke antilicha-
men. 
6. Analogie: bijvoorbeeld overeenkomstige ervaringen met een verwant geneesmiddel. 
7. Aard en kwaliteit van de gegevens: bijvoorbeeld objectiviteit van de observaties, 
exactheid van de documentatie, causaliteitsbeoordeling. 
Bij farmacovigilance centra, van overheid of farmaceutische industrie, passeert voort-
durend een diversiteit van meer of minder geloofwaardige signalen de revue. Hoewel 
het moeilijk kan zijn om kaf en koren te scheiden, moet voortdurend een inschatting 
worden gemaakt van de eventuele consequenties die aan de signalen moeten worden 
verbonden. Bij de bestudering van een signaal wordt aanbevolen de volgende gang van 
zaken aan te houden: 
1. Selectie van de relevante gegevens (meldingen) en voorlopige afbakening van het sig-
naal (hypothese). 
2. Literatuuronderzoek met betrekking tot de hypothese. 
3. In kaart brengen van de beschikbare gegevens over de betrokken observaties (mel-
dingen) en inventarisatie van ontbrekende gegevens (bijvoorbeeld afloop, laborato-
riumuitslagen, co-medicatie). 
4. Zoveel mogelijk verzamelen van nog ontbrekende gegevens (navraag bij melders) 
5. Raadplegen van de database van het Uppsala Monitoring Centre van de Wereld-
gezondheidsorganisatie. 
6. Overleg met de producent van het geneesmiddel (bijvoorbeeld over ongepubliceer-
de gegevens van farmacologische en klinische studies in het registratiedossier en voor 
een vergelijking met meldingen die door de producent internationaal zijn verza-
meld). 
7. Beoordeling van alle verkregen gegevens in onderlinge samenhang, met inachtne-
ming van de bovengenoemde overwegingen. 
8. Het neerleggen van bevindingen en interpretaties onder punt 7. in een schriftelijk 
verslag, dat de volgende onderdelen heeft: samenvattende beschrijving van het sig-
naal, presentatie van de gegevens, bespreking van eventuele relevante additionele 
gegevens (bijvoorbeeld in de literatuur), voorlopige beoordeling van het materiaal 
(signal assessment) met een specificatie van argumenten voor en tegen de hypothe-
se, een conclusie of standpuntbepaling en suggesties voor eventueel verder onder-
zoek om op hoofdpunten zekerheid te verschaffen. 
Dit verslag kan als basis dienen voor de besluitvorming door de registratie autoritei-
ten en de producent en voor een bekendmaking aan artsen en apothekers. 
Een signaal is in principe een vermoeden. Fabrikant en overheid, patiënt en behande-
laar staan vaak voor het blok om een standpunt te vormen, terwijl het nog niet onom-
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stotelijk is bewezen dat het geneesmiddel de bijwerking kan veroorzaken en het nog 
onzeker is hoe frequent of hoe zeldzaam de bijwerking is. Een vaak voorkomend dilem-
ma in farmacovigilance is dat het definitieve antwoord op deze vragen pas in de laatste 
fase van de ontdekking van een bijwerkingen kan worden gegeven. 
Hoofdstuk 2.1 Causaliteitsbeoordeling door farmacovigilance centra in de 
Europese Unie 
Het landelijke meldingssysteem voor bijwerkingen van geneesmiddelen is gebaseerd op 
meldingen van vermoede bijwerkingen. Hoewel inherent aan de methode, staat onze-
kerheid in de meldingen over de oorzakelijke betrokkenheid van de verdachte genees-
middelen vaak een eenduidige conclusie in de weg. Om te proberen dit probleem het 
hoofd te bieden, zijn diverse systemen ontwikkeld voor gestandaardiseerde causaliteits-
beoordeling bij (meldingen over) patiënten met vermoede bijwerkingen van genees-
middelen. 
In ons onderzoek naar de gang van zaken bij nationale farmacovigilance centra kwam 
naar voren dat causaliteitsbeoordeling routine is in alle landen van de Europese Unie 
en in twee van de drie onderzochte landen buiten de Unie. De gebruikte methode voor 
causaliteitsbeoordeling was echter min of meer verschillend in alle landen. Alleen al het 
aantal gehanteerde causaliteitstermen varieerde van 4 tot 7. Ondanks deze verschillen 
vertonen de benaderingen veel overeenkomst. Ten behoeve van harmonisering van het 
geneesmiddelenbeleid in de EU ontwikkelde de Pharmacovigilance Working Party drie 
basale categorieën, А, В en O genaamd, waarover de diverse nationale beoordeling 
automatisch kunnen worden verdeeld, zonder dat veranderingen of herbcoordeling 
nodig zijn. Deze ABO categorieën berusten op een gecombineerde beoordeling van 
causaliteit en van de kwaliteit van de documentatie van de meldingen. 
Hoofdstuk 2.2 De rol van causaliteitsbeoordeling in farmacovigilance 
Zoals iedere onderzoeksmethode bestaat het bijwerkingenmeldingssysteem uit een pro-
ces van gegevensverzameling, beoordeling en interpretatie. De bedoeling ervan is het 
produceren van informatie, dat wil zeggen van geïnterpreteerde gegevens. De beoorde-
ling van de gegevens vindt plaats in twee stappen. Eerst de beoordeling van de meldin-
gen afzonderlijk, gevolgd door beoordeling van series meldingen in onderlinge samen-
hang. Slechts bij een minderheid van de meldingen vindt deze tweede stap, beoordeling 
in onderlinge samenhang, daadwerkelijk plaats. Bijvoorbeeld ten behoeve van een 
wetenschappelijke publicatie of een beleidsmaatregel. Dat bij veel meldingen onzeker-
heid bestaat over de causale samenhang tussen verdachte geneesmiddelen en vermoede 
bijwerkingen is inherent aan de methode van het meldingssysteem. 
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Gestandaardiseerde causaliteitsbeoordeling van meldingen behoort tot de routines van 
farmacovigilance centra in alle streken van de wereld. De bedoeling is om dubbelzin-
nigheid van de gegevens te verminderen en om te voorkomen dat aan de meldingen 
onjuiste conclusies zouden worden verbonden. Een scala van systemen voor causali-
teitsbeoordeling is ontwikkeld, variërend van eenvoudige vragenlijstjes tot complexe 
algoritmen. Omdat geen van deze systemen is gevalideerd, dat wil zeggen dat niet is 
aangetoond dat de uitkomsten - consistent en reproduceerbaar — een goede weergave 
van de werkelijkheid geven, is de wetenschappelijke waarde ervan beperkt. 
Causaliteitsbeoordeling kan geen onzekerheid in zekerheid veranderen en kan vaak 
geen onderscheid maken tussen de meldingen die wèl en die niet meetellen. 
Causaliteitsbeoordeling drukt onzekerheid niet uit in een exacte maat of percentage, 
maar geeft slechts een semikwantitatieve schatting ervan, meestal in de vorm van een 
meer of minder duidelijk gedefinieerde categorie, zoals 'mogelijk' of 'waarschijnlijk'. 
Extremen zoals 'zeker' en 'onwaarschijnlijk' zijn in de minderheid. 
Routine causaliteitsbeoordeling maakt gewoonlijk deel uit van de eerste stap, de beoor-
deling van de meldingen afzonderlijk, waarbij gebruik wordt gemaakt van een alge-
meen systeem dat bedoeld is voor alle soorten bijwerkingen en geneesmiddelen. 
Wanneer een verzameling meldingen in onderlinge samenhang wordt bestudeerd, kan 
opnieuw causaliteits- beoordeling aangewezen zijn, maar nu met gebruikmaking van 
een meer specifiek benadering die speciaal is afgestemd op de betrokken bijwerking en 
vraagstelling. 
Het meldingssysteem is vooral een hypothese-genererende methode en kan vaak geen 
zekerheid geven. Meldingen waarin het verband proefondervindelijk is vastgesteld, bij-
voorbeeld door reëxpositie, zijn een uitzondering. Als regel is voortgezet (experimen-
teel of analytisch) onderzoek nodig om het definitieve bewijs te kunnen leveren. 
Hoofdstuk 3 'Good practice' in farmacovigilance 
Bij klinisch geneesmiddelenonderzoek zijn de rechten en plichten van patiënten en 
onderzoekers vastgelegd in 'good clinical trial practice' (GCP). Farmacovigilance heeft 
met klinisch geneesmiddelenonderzoek gemeen dat het is gebaseerd op waarneming bij 
patiënten. Omdat bij het gebruik van goedgekeurde geneesmiddelen de bescherming 
van GCP en het 'informed consent' niet langer gelden, is er behoefte een en ander vast 
te leggen aangaande de ethische kanten van farmacovigilance en het melden van bij-
werkingen. Aan het gebruik van patiëntengegevens zijn immers beperkingen en ver-
plichtingen verbonden die voortvloeien uit het medisch en farmaceutisch beroepsge-
heim en de regelgeving ten aanzien van de medische behandelingsovereenkomst en 
bescherming van de persoonlijke levenssfeer. Toekomstige 'good practice' in farmaco-
vigilance zal aandacht moeten besteden aan: 
157 
- Beoordeling van de wetenschappelijke kwaliteit en doelmatigheid van de systemen en 
activiteiten op het gebied van farmacovigilance in ons land. 
- Rechten en plichten van betrokken personen en instellingen, met name patiënten, 
melders en onderzoekers, en afstemming op de regelgeving ten aanzien van medisch 
geheim en bescherming van de persoonlijke levenssfeer. 
- Verslaglegging (protocollering, standaardisering, rapportage). 
- Toezicht op de uitvoering; toegankelijkheid van de gegevens. 
- Wetenschappelijke en financiële onafhankelijkheid. 
- Bepalen van prioriteiten bij de besteding van de voor farmacovigilance beschikbare 
gelden. 
Good practice in farmacovigilance moet garanderen dat steeds het algemeen belang op 
de eerste plaats komt, met inachtneming van de rechten van het individu. Good prac-
tice lijkt de aangewezen weg om een oplossing te vinden voor de barrière die door nieu-
we regelgeving (bescherming van de persoonlijke levenssfeer, medische behandelings-
overeenkomst) tegen farmacovigilance dreigt te worden opgeworpen. 
Hoofdstuk 4 Discussie: farmacovigilance in perspectief 
In het begin van de zestiger jaren, in de nasleep van het drama door thalidomide, was 
een landelijk meldingssysteem de enig denkbare mogelijkheid voor een snelle attende-
ring op eventuele toekomstige onverwachte en ernstige bijwerkingen. Ondanks aan-
vankelijke scepsis, is in de loop der jaren gebleken dat het meldingssysteem een voort-
durende bron is van nuttige en belangrijke informatie over bijwerkingen en andere 
mogelijke problemen met geneesmiddelen. In de praktijk heeft het meldingssysteem 
zich ontwikkeld tot een volwaardige methode, met zijn eigen principes and procedu-
res, zijn sterke en zijn zwakke kanten, die niet meer weg te denken is bij het onderzoek 
van geneesmiddelen na de toelating. In de laatste jaren vindt dit zijn weerslag in pro-
fessionalisering van het systeem en formalisering ervan in nieuwe regelgeving, zoals in 
de Europese Unie. 
Naast het meldingssysteem wordt internationaal in farmacovigilance in toenemende 
mate gebruik gemaakt van populatie-onderzoek voor het signaleren van bijwerkingen, 
zoals case control surveillance, prescription event monitoring en het koppelen van 
grootschalige gegevensbestanden, bijvoorbeeld van ziektekostenverzekeraars. 
Dankzij grote vooruitgang in automatisering van de medische en farmaceutische prak-
tijkvoering en ook van de beschikbare automatiseringstechnieken dienen zich moge-
lijkheden aan voor farmacovigilance, die korte tijd geleden nog volstrekt onuitvoerbaar 
waren. De verdere ontwikkeling van farmacovigilance zal in de komende jaren vooral 
in het teken staan van het volgende: 
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Landelijke meldingssysteem 
Verdere verbetering van het landelijke meldingssysteem, door: 
- Vergroting van het aantal participerende artsen, onder andere door het gebruik van 
moderne communicatiemedia. 
- Ontwikkeling van software in de geautomatiseerde medische administratiesystemen 
voor automatische bijwerkingen rapportage en, zo mogelijk, koppeling aan far­
maceutische administratie voor gegevenscompletering. 
- Ontwikkeling van geautomatiseerde signaaldetectie. 
- Vaststellen van regels voor 'good practice' in farmacovigilancc, met onder andere 
aandacht voor 
- het verder ontwikkelen van een gezondheidsrechtelijke basis voor het melden van 
de benodigde gegevens, 
- bevorderen van toegankelijkheid en verantwoord gebruik van farmacovigilance 
gegevens, 
- criteria voor het beoordelen van de kwaliteit van het functioneren van het lande­
lijke meldingssysteem. 
Type С bijwerkingen 
Het verder ontwikkelen van andere methoden voor farmacovigilance en het zoeken 
naar nieuwe wegen, in het bijzonder ten behoeve van het onderzoek van type С bij­
werkingen. 
Risk-benefit evaluatie 
Het verder tot ontwikkeling brengen van wetenschappelijk onderzoek van toegelaten 
geneesmiddelen, met name voor het toetsen van signalen, het bepalen van frequenties 
van bijwerkingen, de identificatie van risicofactoren, het ophelderen van de ontstaans-
mechanismen van bijwerkingen. Het uiteindelijk doel is dat een exacte kwantitatieve 
vaststelling van zowel baat als schadelijkheid van geneesmiddelen mogelijk wordt. Deze 
kennis is nodig zowel ten behoeve van goede individuele farmacotherapie, ter onder­
bouwing van een weloverwogen therapiebeleid en als grondslag voor de besluitvorming 
door het College ter beoordeling van geneesmiddelen (bijvoorbeeld de periodieke her-
registtatie van geneesmiddelen). 
Onafhankelijkheid en transparantie in het verzamelen en verspreiden van gegevens 
Om in een wereld vol tegenstrijdige belangen goed te kunnen gedijen, heeft farmaco­
vigilance behoefte aan een klimaat van onafhankelijkheid - in wetenschappelijk, finan­
cieel en politiek opzicht - ten einde de informatie te produceren die nodig is voor een 
objectieve meningsvorming over de veiligheid van geneesmiddelen. Anderzijds is trans­
parantie van het systeem nodig, om het vertrouwen van de samenleving te behouden. 
Gegevens moeten gemakkelijk beschikbaar zijn en optimaal benut kunnen worden. 
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'Good practice' in farmacovigilance en ook op het terrein van communicatie lijkt de 
juiste weg om eventueel verkeerd gebruik van de gegevens te voorkómen. 
Van farmacovigibnee naar farmacotherapie 
De uiteindelijke betekenis van farmacovigilance voor de gezondheidszorg valt of staat 
met het nemen van de laatste stap: het bewerkstelligen dat nieuwe informatie snel en 
effectief doorwerkt in individuele farmacotherapie. Goede farmacovigilance vergroot 
de veiligheid waarmee de introductie van nieuwe geneesmiddelen is omkleed en bevor-
dert de oordeelsvorming die ten grondslag ligt aan rationele farmacotherapie. 
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1. Het onderzoek dat aan de toelating van een geneesmiddel voorafgaat is aan 
beperkingen onderhevig. Dit brengt met zich mee dat de kennis van een 
geneesmiddel als regel onvolledig is, in het bijzonder met betrekking tot bij-
werkingen en tot gebruik dat afwijkt van de omstandigheden waaronder het 
klinisch onderzoek werd uitgevoerd. 
2. In de loop der jaren hebben wereldwijd systemen voor spontane rapportage 
van vermoede bijwerkingen van geneesmiddelen ('spontaneous reporting'), 
enigszins tegen de verwachtingen in, een ware schat aan informatie opgeleverd. 
3. Het centrale meldingspunt voor vermoede bijwerkingen van geneesmiddelen 
in een land - het landelijke farmacovigilance centrum - is de beheerder van de 
in de meldingen besloten gegevens en niet de eigenaar. Deze gegevens moeten 
goed beschikbaar zijn voor wetenschappelijke onderzoeks- en onderwijsinstel-
lingen op het gebied van farmacologie en farmacotherapie en bovendien toe-
gankelijk zijn voor 'public audit'. 
4. Er is wereldwijd grote en variabele onderrapportage van vermoede bijwerkin-
gen. Hierdoor kan het ontdekken van zeldzame bijwerkingen worden ver-
traagd en de frequentie van bijwerkingen te laag worden ingeschat, met als 
mogelijk gevolg dat er een onnodig groot aantal slachtoffers valt. 
5. Er zijn sterke aanwijzingen dat gestructureerde bestudering van (telefonische) 
vragen en klachten van geneesmiddelgebruikers, zoals geregistreerd door de 
Medicijnlijn (Consumentenbond, 1989) en de Geneesmiddeleninformatielijn 
(KNMP), voor farmacovigilance nuttige informatie kan opleveren. 
6. Geautomatiseerde statistische signaaldetectie in grote gecomputeriseerde 
bestanden van patiëntengegevens is een belangrijk aandachtsgebied voor far-
macovigilance in de komende jaren. 
7. Het is mogelijk dat het resultaat van vergelijkend 'dose finding' onderzoek ten 
gevolge van een sterk placebo-effect (in de controle groep) tot een hoger dose-
ringsadvies van een geneesmiddel aanleiding geeft dan voor een bevredigend 
therapeutisch resultaat nodig is. 
8. Van registratie-autoriteiten, zoals in Nederland het College ter beoordeling van 
geneesmiddelen, wordt vaak verwacht dat over geregistreerde geneesmiddelen 
beleidsbeslissingen of maatregelen worden genomen op een moment dat de 
benodigde wetenschappelijke gegevens nog niet beschikbaar zijn. 
9. Of het mogelijk is om de werkzaamheid en schadelijkheid van een geneesmid-
del in één en dezelfde maat uit te drukken en zodoende een exacte balans op 
te maken, is nog onzeker. 
10. Naarmate het farmacovigilance systeem in een land effectiever is, kan een 
nieuw geneesmiddel sneller - dat wil zeggen op geleide van minder vooraf-
gaand onderzoek - op verantwoorde wijze in gebruik worden genomen. 
11. Met zijn boek De Musica Antiqua uit 1652 is Marcus Meibomius een pionier 
geweest op het gebied van het wetenschappelijk onderzoek naar de muziek van 
het klassieke Griekenland. 
J. Chailley. La Musique Grecque Antique. Société d'Édition 'Les Belles Lettres', 
Paris, 1979. ISBN 2 251 32512 3. 
12. Het is terecht dat de diagnose meibomitis (International Classification of 
Diseases, 9e editie, code 373.12) niet in WHOART, de bijwerkingentermino-
logie van de Wereldgezond-heidsorganisatie, is opgenomen. 
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